UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended ~~June~~September 30, 2021


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission File Number: 000-55775

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

(Exact name of registrant as specified in its charter)


Maryland						47-2887436
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

18191 Von Karman Avenue, Suite 300 Irvine, California						92612
(Address of principal executive offices)						(Zip Code)

(949) 270-9200

(Registrant’s telephone number, including area code)

~~Not Applicable~~Griffin-American Healthcare REIT IV, Inc.

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☐

Emerging growth company

☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of ~~August 6,~~November 12, 2021, there were ~~76,069,129~~77,005,833 shares of Class T common stock and ~~5,662,132~~185,578,806 shares of Class I common stock of ~~Griffin-American~~American Healthcare REIT, ~~IV,~~ Inc. outstanding.

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

(A Maryland Corporation)

TABLE OF CONTENTS


			Page
PART I — FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)			3
Condensed Consolidated Balance Sheets as of JSept ~~une~~ember 3 0 ,30, 2021 and December 31, 2020			3
Condensed Consolidated Statements of Operations for the Three and Nine ~~and Six~~ Months Ended ~~June~~September 3 0 ,30, 2021 and 2020			5
Condensed Consolidated Statements of Equity for the Three and ~~and Six~~ Nine Months Ended Ju neSeptember 3 0 ,30, 2021 and 2020			6
Condensed Consolidated Statements of Cash Flows for the ~~Six~~Nine Months Ended ~~June~~September 3 0 ,30, 2021 and 2020			8
Notes to Condensed Consolidated Financial Statements			10
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			3336
Item 3. Quantitative and Qualitative Disclosures About Market Risk			5053
Item 4. Controls and Procedures			5154

PART II — OTHER INFORMATION

Item 1. Legal Proceedings			5255
Item 1A. Risk Factors			5255
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			5559
Item 3. Defaults Upon Senior Securities			5559
Item 4. Mine Safety Disclosures			5559
Item 5. Other Information			5559
Item 6. Exhibits			5660
Signatures			5762

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

As of ~~June~~September 30, 2021 and December 31, 2020

(Unaudited)


		June 30, 2021		December 31, 2020			September 30, 2021		December 31, 2020
ASSETS	ASSETS					ASSETS
Real estate investments, net	Real estate investments, net	$	912,467,000	$	921,580,000	Real estate investments, net	$	907,103,000	$	921,580,000
Cash and cash equivalents	Cash and cash equivalents	21,336,000		17,411,000		Cash and cash equivalents	16,183,000		17,411,000
Restricted cash	Restricted cash	1,176,000		714,000		Restricted cash	986,000		714,000
Accounts and other receivables, net	Accounts and other receivables, net	1,768,000		2,635,000		Accounts and other receivables, net	2,086,000		2,635,000
Identified intangible assets, net	Identified intangible assets, net	57,251,000		64,101,000		Identified intangible assets, net	54,752,000		64,101,000
Operating lease right-of-use assets, net	Operating lease right-of-use assets, net	14,073,000		14,133,000		Operating lease right-of-use assets, net	14,043,000		14,133,000
Other assets, net	Other assets, net	67,710,000		72,199,000		Other assets, net	68,743,000		72,199,000
Total assets	Total assets	$	1,075,781,000	$	1,092,773,000	Total assets	$	1,063,896,000	$	1,092,773,000

LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY	LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY					LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY
Liabilities:	Liabilities:					Liabilities:
Mortgage loans payable, net(1)	Mortgage loans payable, net(1)	$	17,572,000	$	17,827,000	Mortgage loans payable, net(1)	$	17,409,000	$	17,827,000
Line of credit and term loans(1)	Line of credit and term loans(1)	482,900,000		476,900,000		Line of credit and term loans(1)	488,900,000		476,900,000
Accounts payable and accrued liabilities(1)	Accounts payable and accrued liabilities(1)	22,929,000		23,057,000		Accounts payable and accrued liabilities(1)	21,897,000		23,057,000
Accounts payable due to affiliates(1)	Accounts payable due to affiliates(1)	1,029,000		1,046,000		Accounts payable due to affiliates(1)	324,000		1,046,000
Identified intangible liabilities, net	Identified intangible liabilities, net	1,174,000		1,295,000		Identified intangible liabilities, net	1,115,000		1,295,000
Operating lease liabilities(1)	Operating lease liabilities(1)	9,971,000		9,904,000		Operating lease liabilities(1)	10,021,000		9,904,000
Security deposits, prepaid rent and other liabilities(1)	Security deposits, prepaid rent and other liabilities(1)	8,151,000		10,387,000		Security deposits, prepaid rent and other liabilities(1)	6,300,000		10,387,000
Total liabilities	Total liabilities	543,726,000		540,416,000		Total liabilities	545,966,000		540,416,000

Commitments and contingencies (Note 10)	Commitments and contingencies (Note 10)	0		0		Commitments and contingencies (Note 10)	0		0

Redeemable noncontrolling interests (Note 11)	Redeemable noncontrolling interests (Note 11)	2,593,000		2,618,000		Redeemable noncontrolling interests (Note 11)	2,592,000		2,618,000

Equity:	Equity:					Equity:
Stockholders’ equity:	Stockholders’ equity:					Stockholders’ equity:
Preferred stock, $0.01 par value per share; 200,000,000 shares authorized; 0ne issued and outstanding		0		0
Class T common stock, $0.01 par value per share; 900,000,000 shares authorized; 76,069,129 and 75,690,838 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively		760,000		756,000
Class I common stock, $0.01 par value per share; 100,000,000 shares authorized; 5,662,132 and 5,648,499 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively		57,000		57,000
Preferred stock, $0.01 par value per share; 200,000,000 shares authorized; none issued and outstanding						Preferred stock, $0.01 par value per share; 200,000,000 shares authorized; none issued and outstanding	—		—
Class T common stock, $0.01 par value per share; 900,000,000 shares authorized; 76,069,129 and 75,690,838 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively						Class T common stock, $0.01 par value per share; 900,000,000 shares authorized; 76,069,129 and 75,690,838 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	760,000		756,000
Class I common stock, $0.01 par value per share; 100,000,000 shares authorized; 5,662,132 and 5,648,499 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively						Class I common stock, $0.01 par value per share; 100,000,000 shares authorized; 5,662,132 and 5,648,499 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	57,000		57,000
Additional paid-in capital	Additional paid-in capital	736,827,000		733,192,000		Additional paid-in capital	736,756,000		733,192,000
Accumulated deficit	Accumulated deficit	(208,759,000)		(185,047,000)		Accumulated deficit	(222,775,000)		(185,047,000)
Total stockholders’ equity	Total stockholders’ equity	528,885,000		548,958,000		Total stockholders’ equity	514,798,000		548,958,000
Noncontrolling interest (Note 12)	Noncontrolling interest (Note 12)	577,000		781,000		Noncontrolling interest (Note 12)	540,000		781,000
Total equity	Total equity	529,462,000		549,739,000		Total equity	515,338,000		549,739,000
Total liabilities, redeemable noncontrolling interests and equity	Total liabilities, redeemable noncontrolling interests and equity	$	1,075,781,000	$	1,092,773,000	Total liabilities, redeemable noncontrolling interests and equity	$	1,063,896,000	$	1,092,773,000

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued)

As of ~~June~~September 30, 2021 and December 31, 2020

(Unaudited)

___________

(1)Such liabilities of American Healthcare REIT, Inc., (formerly known as Griffin-American Healthcare REIT IV, Inc.), as of ~~June~~September 30, 2021 and December 31, 2020 represented liabilities of ~~Griffin American~~Griffin-American Healthcare REIT IV Holdings, LP or its consolidated subsidiaries. Griffin-American Healthcare REIT IV Holdings, LP iswas a variable interest entity, or VIE, and a consolidated subsidiary of ~~Griffin-American~~American Healthcare REIT, ~~IV,~~ Inc. The creditors of Griffin-American Healthcare REIT IV Holdings, LP or its consolidated subsidiaries do not have recourse against ~~Griffin-American~~American Healthcare REIT, ~~IV,~~ Inc., except for the 2018 Credit Facility, as defined in Note 7, held by Griffin-American Healthcare REIT IV Holdings, LP in the amount of ~~$482,900,000~~$488,900,000 and $476,900,000 as of ~~June~~September 30, 2021 and December 31, 2020, respectively, which is guaranteed by ~~Griffin-American~~American Healthcare REIT, ~~IV,~~ Inc.

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2021 and 2020

(Unaudited)


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			2021		2020		2021		2020
Revenues:
Revenues and grant income:										Revenues and grant income:
Real estate revenue	Real estate revenue	$	21,988,000	$	21,842,000	$	43,934,000	$	43,305,000	Real estate revenue	$	22,120,000	$	21,519,000	$	66,054,000	$	64,824,000
Resident fees and services	Resident fees and services	15,194,000		16,834,000		31,089,000		32,915,000		Resident fees and services	15,090,000		18,948,000		46,179,000		51,863,000
Total revenues		37,182,000		38,676,000		75,023,000		76,220,000
Grant income										Grant income	—		864,000		—		864,000
Total revenues and grant income										Total revenues and grant income	37,210,000		41,331,000		112,233,000		117,551,000
Expenses:	Expenses:									Expenses:
Rental expenses	Rental expenses	6,129,000		5,996,000		12,153,000		11,818,000		Rental expenses	6,389,000		5,905,000		18,542,000		17,723,000
Property operating expenses	Property operating expenses	14,445,000		14,442,000		29,639,000		27,459,000		Property operating expenses	14,540,000		17,397,000		44,179,000		44,856,000
General and administrative	General and administrative	3,659,000		3,840,000		7,406,000		8,288,000		General and administrative	4,304,000		3,672,000		11,710,000		11,960,000
Business acquisition expenses	Business acquisition expenses	2,438,000		8,000		2,752,000		17,000		Business acquisition expenses	3,800,000		57,000		6,552,000		74,000
Depreciation and amortization	Depreciation and amortization	10,597,000		12,720,000		22,999,000		25,250,000		Depreciation and amortization	10,746,000		12,669,000		33,745,000		37,919,000
Total expenses	Total expenses	37,268,000		37,006,000		74,949,000		72,832,000		Total expenses	39,779,000		39,700,000		114,728,000		112,532,000
Other income (expense):	Other income (expense):									Other income (expense):
Interest expense:	Interest expense:									Interest expense:
Interest expense (including amortization of deferred financing costs and debt discount/premium)	Interest expense (including amortization of deferred financing costs and debt discount/premium)	(4,869,000)		(4,974,000)		(9,595,000)		(10,284,000)		Interest expense (including amortization of deferred financing costs and debt discount/premium)	(4,961,000)		(4,839,000)		(14,556,000)		(15,123,000)
Gain (loss) in fair value of derivative financial instruments	Gain (loss) in fair value of derivative financial instruments	1,462,000		853,000		2,917,000		(3,752,000)		Gain (loss) in fair value of derivative financial instruments	1,514,000		1,450,000		4,431,000		(2,302,000)
Loss on disposition of real estate investments		(199,000)		0		(199,000)		0
(Loss) income from unconsolidated entity		(193,000)		1,074,000		(1,097,000)		1,329,000
Impairment of real estate investments										Impairment of real estate investments	—		(3,064,000)		—		(3,064,000)
Gain (loss) on disposition of real estate investments										Gain (loss) on disposition of real estate investments	15,000		—		(184,000)		—
Income (loss) from unconsolidated entity										Income (loss) from unconsolidated entity	70,000		(377,000)		(1,027,000)		952,000
Other income	Other income	9,000		261,000		16,000		270,000		Other income	33,000		8,000		49,000		278,000
Total net other expense	Total net other expense	(3,790,000)		(2,786,000)		(7,958,000)		(12,437,000)		Total net other expense	(3,329,000)		(6,822,000)		(11,287,000)		(19,259,000)
Loss before income taxes	Loss before income taxes	(3,876,000)		(1,116,000)		(7,884,000)		(9,049,000)		Loss before income taxes	(5,898,000)		(5,191,000)		(13,782,000)		(14,240,000)
Income tax expense		0		(39,000)		0		(39,000)
Income tax benefit										Income tax benefit	—		39,000		—		—
Net loss	Net loss	(3,876,000)		(1,155,000)		(7,884,000)		(9,088,000)		Net loss	(5,898,000)		(5,152,000)		(13,782,000)		(14,240,000)
Less: net loss attributable to noncontrolling interests	Less: net loss attributable to noncontrolling interests	104,000		209,000		368,000		376,000		Less: net loss attributable to noncontrolling interests	121,000		232,000		489,000		608,000
Net loss attributable to controlling interest	Net loss attributable to controlling interest	$	(3,772,000)	$	(946,000)	$	(7,516,000)	$	(8,712,000)	Net loss attributable to controlling interest	$	(5,777,000)	$	(4,920,000)	$	(13,293,000)	$	(13,632,000)
Net loss per Class T and Class I common share attributable to controlling interest — basic and diluted	Net loss per Class T and Class I common share attributable to controlling interest — basic and diluted	$	(0.05)	$	(0.01)	$	(0.09)	$	(0.11)	Net loss per Class T and Class I common share attributable to controlling interest — basic and diluted	$	(0.07)	$	(0.06)	$	(0.16)	$	(0.17)
Weighted average number of Class T and Class I common shares outstanding — basic and diluted	Weighted average number of Class T and Class I common shares outstanding — basic and diluted	81,687,564		80,402,887		81,599,875		80,352,269		Weighted average number of Class T and Class I common shares outstanding — basic and diluted	81,704,261		80,788,359		81,635,053		80,498,693

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

For the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2021 and 2020

(Unaudited)


		Three Months Ended June 30, 2021															Three Months Ended September 30, 2021
		Stockholders’ Equity															Stockholders’ Equity
		Class T and Class I Common Stock															Class T and Class I Common Stock
		Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Total Stockholders’ Equity		Noncontrolling Interest		Total Equity				Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Total Stockholders’ Equity		Noncontrolling Interest		Total Equity
BALANCE — March 31, 2021		81,697,347	$	817,000	$	736,486,000	$	(196,835,000)	$	540,468,000	$	633,000	$	541,101,000
Offering costs — common stock		—	—		2,000		—		2,000		—		2,000
Issuance of common stock under the DRIP		151,142	1,000		1,392,000		—		1,393,000		—		1,393,000
BALANCE — June 30, 2021																BALANCE — June 30, 2021	81,731,261	$	817,000	$	736,827,000	$	(208,759,000)	$	528,885,000	$	577,000	$	529,462,000
Amortization of nonvested common stock compensation	Amortization of nonvested common stock compensation	—	—		41,000		—		41,000		—		41,000			Amortization of nonvested common stock compensation	—	—		21,000		—		21,000		—		21,000
Repurchase of common stock		(117,228)	(1,000)		(1,159,000)		—		(1,160,000)		—		(1,160,000)
Distributions to noncontrolling interest	Distributions to noncontrolling interest	—	—		—		—		—		(31,000)		(31,000)			Distributions to noncontrolling interest	—	—		—		—		—		(7,000)		(7,000)
Adjustment to value of redeemable noncontrolling interests	Adjustment to value of redeemable noncontrolling interests	—	—		65,000		—		65,000		—		65,000			Adjustment to value of redeemable noncontrolling interests	—	—		(92,000)		—		(92,000)		—		(92,000)
Distributions declared ($0.10 per share)	Distributions declared ($0.10 per share)	—	—		—		(8,152,000)		(8,152,000)		—		(8,152,000)			Distributions declared ($0.10 per share)	—	—		—		(8,239,000)		(8,239,000)		—		(8,239,000)
Net loss	Net loss	—	—		—		(3,772,000)		(3,772,000)		(25,000)		(3,797,000)		(1)	Net loss	—	—		—		(5,777,000)		(5,777,000)		(30,000)		(5,807,000)		(1)
BALANCE — June 30, 2021		81,731,261	$	817,000	$	736,827,000	$	(208,759,000)	$	528,885,000	$	577,000	$	529,462,000
BALANCE — September 30, 2021																BALANCE — September 30, 2021	81,731,261	$	817,000	$	736,756,000	$	(222,775,000)	$	514,798,000	$	540,000	$	515,338,000


		Three Months Ended June 30, 2020															Three Months Ended September 30, 2020
		Stockholders’ Equity															Stockholders’ Equity
		Class T and Class I Common Stock															Class T and Class I Common Stock
		Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Total Stockholders’ Equity		Noncontrolling Interest		Total Equity				Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Total Stockholders’ Equity		Noncontrolling Interest		Total Equity
BALANCE — March 31, 2020		80,574,630	$	805,000	$	726,258,000	$	(150,398,000)	$	576,665,000	$	1,166,000	$	577,831,000
BALANCE — June 30, 2020																BALANCE — June 30, 2020	80,599,306	$	805,000	$	726,516,000	$	(159,366,000)	$	567,955,000	$	1,047,000	$	569,002,000
Offering costs — common stock	Offering costs — common stock	—	—		63,000		—		63,000		—		63,000			Offering costs — common stock	—	—		5,000		—		5,000		—		5,000
Issuance of common stock under the DRIP	Issuance of common stock under the DRIP	523,736	5,000		4,992,000		—		4,997,000		—		4,997,000			Issuance of common stock under the DRIP	445,239	4,000		4,243,000		—		4,247,000		—		4,247,000
Issuance of vested and nonvested restricted common stock	Issuance of vested and nonvested restricted common stock	7,500	—		14,000		—		14,000		—		14,000			Issuance of vested and nonvested restricted common stock	15,000	—		29,000		—		29,000		—		29,000
Amortization of nonvested common stock compensation	Amortization of nonvested common stock compensation	—	—		41,000		—		41,000		—		41,000			Amortization of nonvested common stock compensation	—	—		44,000		—		44,000		—		44,000
Repurchase of common stock	Repurchase of common stock	(506,560)	(5,000)		(4,638,000)		—		(4,643,000)		—		(4,643,000)			Repurchase of common stock	(71,551)	—		(706,000)		—		(706,000)		—		(706,000)
Distributions to noncontrolling interest	Distributions to noncontrolling interest	—	—		—		—		—		(32,000)		(32,000)			Distributions to noncontrolling interest	—	—		—		—		—		(22,000)		(22,000)
Adjustment to value of redeemable noncontrolling interests	Adjustment to value of redeemable noncontrolling interests	—	—		(214,000)		—		(214,000)		—		(214,000)			Adjustment to value of redeemable noncontrolling interests	—	—		(208,000)		—		(208,000)		—		(208,000)
Distributions declared ($0.10 per share)	Distributions declared ($0.10 per share)	—	—		—		(8,022,000)		(8,022,000)		—		(8,022,000)			Distributions declared ($0.10 per share)	—	—		—		(8,150,000)		(8,150,000)		—		(8,150,000)
Net loss	Net loss	—	—		—		(946,000)		(946,000)		(87,000)		(1,033,000)		(1)	Net loss	—	—		—		(4,920,000)		(4,920,000)		(105,000)		(5,025,000)		(1)
BALANCE — June 30, 2020		80,599,306	$	805,000	$	726,516,000	$	(159,366,000)	$	567,955,000	$	1,047,000	$	569,002,000
BALANCE — September 30, 2020																BALANCE — September 30, 2020	80,987,994	$	809,000	$	729,923,000	$	(172,436,000)	$	558,296,000	$	920,000	$	559,216,000

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY — (Continued)

For the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2021 and 2020

(Unaudited)


		Six Months Ended June 30, 2021															Nine Months Ended September 30, 2021
		Stockholders’ Equity															Stockholders’ Equity
		Class T and Class I Common Stock															Class T and Class I Common Stock
		Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Total Stockholders’ Equity		Noncontrolling Interest		Total Equity				Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Total Stockholders’ Equity		Noncontrolling Interest		Total Equity
BALANCE — December 31, 2020	BALANCE — December 31, 2020	81,339,337	$	813,000	$	733,192,000	$	(185,047,000)	$	548,958,000	$	781,000	$	549,739,000		BALANCE — December 31, 2020	81,339,337	$	813,000	$	733,192,000	$	(185,047,000)	$	548,958,000	$	781,000	$	549,739,000
Offering costs — common stock	Offering costs — common stock	—	—		5,000		—		5,000		—		5,000			Offering costs — common stock	—	—		5,000		—		5,000		—		5,000
Issuance of common stock under the DRIP	Issuance of common stock under the DRIP	581,491	6,000		5,493,000		—		5,499,000		—		5,499,000			Issuance of common stock under the DRIP	581,491	6,000		5,493,000		—		5,499,000		—		5,499,000
Amortization of nonvested common stock compensation	Amortization of nonvested common stock compensation	—	—		84,000		—		84,000		—		84,000			Amortization of nonvested common stock compensation	—	—		105,000		—		105,000		—		105,000
Repurchase of common stock	Repurchase of common stock	(189,567)	(2,000)		(1,872,000)		—		(1,874,000)		—		(1,874,000)			Repurchase of common stock	(189,567)	(2,000)		(1,872,000)		—		(1,874,000)		—		(1,874,000)
Distributions to noncontrolling interest	Distributions to noncontrolling interest	—	—		—		—		—		(55,000)		(55,000)			Distributions to noncontrolling interest	—	—		—		—		—		(62,000)		(62,000)
Adjustment to value of redeemable noncontrolling interests	Adjustment to value of redeemable noncontrolling interests	—	—		(75,000)		—		(75,000)		—		(75,000)			Adjustment to value of redeemable noncontrolling interests	—	—		(167,000)		—		(167,000)		—		(167,000)
Distributions declared ($0.20 per share)		—	—		—		(16,196,000)		(16,196,000)		—		(16,196,000)
Distributions declared ($0.30 per share)																Distributions declared ($0.30 per share)	—	—		—		(24,435,000)		(24,435,000)		—		(24,435,000)
Net loss	Net loss	—	—		—		(7,516,000)		(7,516,000)		(149,000)		(7,665,000)		(1)	Net loss	—	—		—		(13,293,000)		(13,293,000)		(179,000)		(13,472,000)		(1)
BALANCE — June 30, 2021		81,731,261	$	817,000	$	736,827,000	$	(208,759,000)	$	528,885,000	$	577,000	$	529,462,000
BALANCE — September 30, 2021																BALANCE — September 30, 2021	81,731,261	$	817,000	$	736,756,000	$	(222,775,000)	$	514,798,000	$	540,000	$	515,338,000


		Six Months Ended June 30, 2020													Nine Months Ended September 30, 2020
		Stockholders’ Equity													Stockholders’ Equity
		Class T and Class I Common Stock																Class T and Class I Common Stock
		Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Total Stockholders’ Equity		Noncontrolling Interest		Total Equity					Number of Shares	Amount		Additional Paid-In Capital		Accumulated Deficit		Total Stockholders’ Equity		Noncontrolling Interest		Total Equity
BALANCE — December 31, 2019	BALANCE — December 31, 2019	79,899,874	$	798,000	$	719,894,000	$	(130,613,000)	$	590,079,000	$	0	$	590,079,000			BALANCE — December 31, 2019	79,899,874	$	798,000	$	719,894,000	$	(130,613,000)	$	590,079,000	$	—	$	590,079,000
Offering costs — common stock	Offering costs — common stock	—	—		62,000		—		62,000		—		62,000				Offering costs — common stock	—	—		67,000		—		67,000		—		67,000
Issuance of common stock under the DRIP	Issuance of common stock under the DRIP	1,198,492	12,000		11,422,000		—		11,434,000		—		11,434,000				Issuance of common stock under the DRIP	1,643,731	16,000		15,665,000		—		15,681,000		—		15,681,000
Issuance of vested and nonvested restricted common stock	Issuance of vested and nonvested restricted common stock	7,500	—		14,000		—		14,000		—		14,000				Issuance of vested and nonvested restricted common stock	22,500	—		43,000		—		43,000		—		43,000
Amortization of nonvested common stock compensation	Amortization of nonvested common stock compensation	—	—		84,000		—		84,000		—		84,000				Amortization of nonvested common stock compensation	—	—		128,000		—		128,000		—		128,000
Repurchase of common stock	Repurchase of common stock	(506,560)	(5,000)		(4,638,000)		—		(4,643,000)		—		(4,643,000)				Repurchase of common stock	(578,111)	(5,000)		(5,344,000)		—		(5,349,000)		—		(5,349,000)
Contribution from noncontrolling interest	Contribution from noncontrolling interest	—	—		—		—		—		1,250,000		1,250,000				Contribution from noncontrolling interest	—	—		—		—		—		1,250,000		1,250,000
Distributions to noncontrolling interest	Distributions to noncontrolling interest	—	—		—		—		—		(32,000)		(32,000)				Distributions to noncontrolling interest	—	—		—		—		—		(54,000)		(54,000)
Adjustment to value of redeemable noncontrolling interests	Adjustment to value of redeemable noncontrolling interests	—	—		(322,000)		—		(322,000)		—		(322,000)				Adjustment to value of redeemable noncontrolling interests	—	—		(530,000)		—		(530,000)		—		(530,000)
Distributions declared ($0.25 per share)		—	—		—		(20,041,000)		(20,041,000)		—		(20,041,000)
Distributions declared ($0.35 per share)																	Distributions declared ($0.35 per share)	—	—		—		(28,191,000)		(28,191,000)		—		(28,191,000)
Net loss	Net loss	—	—		—		(8,712,000)		(8,712,000)		(171,000)		(8,883,000)			(1)	Net loss	—	—		—		(13,632,000)		(13,632,000)		(276,000)		(13,908,000)		(1)
BALANCE — June 30, 2020		80,599,306	$	805,000	$	726,516,000	$	(159,366,000)	$	567,955,000	$	1,047,000	$	569,002,000
BALANCE — September 30, 2020																	BALANCE — September 30, 2020	80,987,994	$	809,000	$	729,923,000	$	(172,436,000)	$	558,296,000	$	920,000	$	559,216,000

___________

(1)Amount excludes ~~$79,000~~$91,000 and ~~$122,000~~$127,000 for the three months ended ~~June~~September 30, 2021 and 2020, respectively, and ~~$219,000~~$310,000 and ~~$205,000~~$332,000 for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, respectively, of net loss attributable to redeemable noncontrolling interests. See Note 11, Redeemable Noncontrolling Interests, for a further discussion.

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the ~~Six~~Nine Months Ended ~~June~~September 30, 2021 and 2020

(Unaudited)


		Six Months Ended June 30,					Nine Months Ended September 30,
		2021		2020			2021		2020
CASH FLOWS FROM OPERATING ACTIVITIES	CASH FLOWS FROM OPERATING ACTIVITIES					CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	Net loss	$	(7,884,000)	$	(9,088,000)	Net loss	$	(13,782,000)	$	(14,240,000)
Adjustments to reconcile net loss to net cash provided by operating activities:	Adjustments to reconcile net loss to net cash provided by operating activities:					Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	Depreciation and amortization	22,999,000		25,250,000		Depreciation and amortization	33,745,000		37,919,000
Other amortization	Other amortization	1,399,000		1,392,000		Other amortization	2,099,000		2,084,000
Deferred rent	Deferred rent	(2,104,000)		(2,351,000)		Deferred rent	(2,707,000)		(3,440,000)
Stock based compensation	Stock based compensation	84,000		98,000		Stock based compensation	105,000		171,000
Loss on disposition of real estate investments	Loss on disposition of real estate investments	199,000		0		Loss on disposition of real estate investments	184,000		—
Loss (income) from unconsolidated entity	Loss (income) from unconsolidated entity	1,097,000		(1,329,000)		Loss (income) from unconsolidated entity	1,027,000		(952,000)
Change in fair value of derivative financial instruments	Change in fair value of derivative financial instruments	(2,917,000)		3,752,000		Change in fair value of derivative financial instruments	(4,431,000)		2,302,000

Impairment of real estate investments						Impairment of real estate investments	—		3,064,000
Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Accounts and other receivables	Accounts and other receivables	851,000		1,286,000		Accounts and other receivables	533,000		1,347,000
Other assets	Other assets	(1,677,000)		(1,419,000)		Other assets	(2,829,000)		(1,654,000)
Accounts payable and accrued liabilities	Accounts payable and accrued liabilities	1,660,000		2,078,000		Accounts payable and accrued liabilities	3,805,000		3,436,000
Accounts payable due to affiliates	Accounts payable due to affiliates	(47,000)		41,000		Accounts payable due to affiliates	(921,000)		27,000
Operating lease liabilities	Operating lease liabilities	(217,000)		(215,000)		Operating lease liabilities	(309,000)		(306,000)
Security deposits, prepaid rent and other liabilities	Security deposits, prepaid rent and other liabilities	443,000		(448,000)		Security deposits, prepaid rent and other liabilities	37,000		185,000
Net cash provided by operating activities	Net cash provided by operating activities	13,886,000		19,047,000		Net cash provided by operating activities	16,556,000		29,943,000
CASH FLOWS FROM INVESTING ACTIVITIES	CASH FLOWS FROM INVESTING ACTIVITIES					CASH FLOWS FROM INVESTING ACTIVITIES
Acquisitions of real estate investments	Acquisitions of real estate investments	(3,375,000)		(67,932,000)		Acquisitions of real estate investments	(3,385,000)		(68,032,000)
Proceeds from disposition of real estate investments	Proceeds from disposition of real estate investments	6,184,000		0		Proceeds from disposition of real estate investments	6,196,000		—
Capital expenditures	Capital expenditures	(2,334,000)		(4,616,000)		Capital expenditures	(4,384,000)		(6,729,000)
Net cash provided by (used in) investing activities		475,000		(72,548,000)
Net cash used in investing activities						Net cash used in investing activities	(1,573,000)		(74,761,000)
CASH FLOWS FROM FINANCING ACTIVITIES	CASH FLOWS FROM FINANCING ACTIVITIES					CASH FLOWS FROM FINANCING ACTIVITIES
Payments on mortgage loans payable	Payments on mortgage loans payable	(293,000)		(8,017,000)		Payments on mortgage loans payable	(475,000)		(8,166,000)
Borrowings under the line of credit and term loans	Borrowings under the line of credit and term loans	11,000,000		137,800,000		Borrowings under the line of credit and term loans	17,000,000		140,800,000
Payments on the line of credit and term loans	Payments on the line of credit and term loans	(5,000,000)		(55,100,000)		Payments on the line of credit and term loans	(5,000,000)		(58,100,000)
Deferred financing costs	Deferred financing costs	(382,000)		(43,000)		Deferred financing costs	—		(43,000)
Payment of offering costs	Payment of offering costs	(2,705,000)		(3,278,000)		Payment of offering costs	(3,940,000)		(4,876,000)
Distributions paid to common stockholders	Distributions paid to common stockholders	(10,772,000)		(10,042,000)		Distributions paid to common stockholders	(21,700,000)		(13,932,000)
Repurchase of common stock	Repurchase of common stock	(1,874,000)		(4,643,000)		Repurchase of common stock	(1,874,000)		(5,349,000)
Contribution from noncontrolling interest	Contribution from noncontrolling interest	0		1,250,000		Contribution from noncontrolling interest	—		1,250,000
Distributions to noncontrolling interest	Distributions to noncontrolling interest	(55,000)		(32,000)		Distributions to noncontrolling interest	(62,000)		(54,000)
Contributions from redeemable noncontrolling interest	Contributions from redeemable noncontrolling interest	126,000		1,118,000		Contributions from redeemable noncontrolling interest	125,000		1,118,000
Distributions to redeemable noncontrolling interests	Distributions to redeemable noncontrolling interests	(7,000)		(72,000)		Distributions to redeemable noncontrolling interests	(8,000)		(81,000)
Security deposits	Security deposits	(12,000)		6,000		Security deposits	(5,000)		(199,000)
Net cash (used in) provided by financing activities	Net cash (used in) provided by financing activities	(9,974,000)		58,947,000		Net cash (used in) provided by financing activities	(15,939,000)		52,368,000
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	4,387,000		5,446,000		NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(956,000)		7,550,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period	CASH, CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period	18,125,000		15,846,000		CASH, CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period	18,125,000		15,846,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — End of period	CASH, CASH EQUIVALENTS AND RESTRICTED CASH — End of period	$	22,512,000	$	21,292,000	CASH, CASH EQUIVALENTS AND RESTRICTED CASH — End of period	$	17,169,000	$	23,396,000

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued)

For the ~~Six~~Nine Months Ended ~~June~~September 30, 2021 and 2020

(Unaudited)


		Six Months Ended June 30,					Nine Months Ended September 30,
		2021		2020			2021		2020
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH	RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH					RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Beginning of period:	Beginning of period:					Beginning of period:
Cash and cash equivalents	Cash and cash equivalents	$	17,411,000	$	15,290,000	Cash and cash equivalents	$	17,411,000	$	15,290,000
Restricted cash	Restricted cash	714,000		556,000		Restricted cash	714,000		556,000
Cash, cash equivalents and restricted cash	Cash, cash equivalents and restricted cash	$	18,125,000	$	15,846,000	Cash, cash equivalents and restricted cash	$	18,125,000	$	15,846,000
End of period:	End of period:					End of period:
Cash and cash equivalents	Cash and cash equivalents	$	21,336,000	$	20,585,000	Cash and cash equivalents	$	16,183,000	$	22,690,000
Restricted cash	Restricted cash	1,176,000		707,000		Restricted cash	986,000		706,000
Cash, cash equivalents and restricted cash	Cash, cash equivalents and restricted cash	$	22,512,000	$	21,292,000	Cash, cash equivalents and restricted cash	$	17,169,000	$	23,396,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION					SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Cash paid for:	Cash paid for:					Cash paid for:
Interest	Interest	$	8,556,000	$	9,428,000	Interest	$	13,116,000	$	13,777,000
Income taxes	Income taxes	$	44,000	$	18,000	Income taxes	$	51,000	$	88,000
SUPPLEMENTAL DISCLOSURE OF NONCASH ACTIVITIES	SUPPLEMENTAL DISCLOSURE OF NONCASH ACTIVITIES					SUPPLEMENTAL DISCLOSURE OF NONCASH ACTIVITIES
Investing Activities:	Investing Activities:					Investing Activities:
Accrued capital expenditures	Accrued capital expenditures	$	3,016,000	$	2,309,000	Accrued capital expenditures	$	3,720,000	$	2,182,000
Tenant improvement overage	Tenant improvement overage	$	240,000	$	625,000	Tenant improvement overage	$	303,000	$	636,000
The following represents the increase (decrease) in certain assets and liabilities in connection with our acquisitions and disposition of real estate investments:	The following represents the increase (decrease) in certain assets and liabilities in connection with our acquisitions and disposition of real estate investments:					The following represents the increase (decrease) in certain assets and liabilities in connection with our acquisitions and disposition of real estate investments:
Other assets	Other assets	$	(16,000)	$	196,000	Other assets	$	(16,000)	$	196,000
Accounts payable and accrued liabilities	Accounts payable and accrued liabilities	$	(48,000)	$	201,000	Accounts payable and accrued liabilities	$	(50,000)	$	201,000
Prepaid rent	Prepaid rent	$	10,000	$	11,000	Prepaid rent	$	10,000	$	11,000
Financing Activities:	Financing Activities:					Financing Activities:
Issuance of common stock under the DRIP	Issuance of common stock under the DRIP	$	5,499,000	$	11,434,000	Issuance of common stock under the DRIP	$	5,499,000	$	15,681,000
Distributions declared but not paid to common stockholders	Distributions declared but not paid to common stockholders	$	2,689,000	$	2,651,000	Distributions declared but not paid to common stockholders	$	—	$	2,664,000
Accrued stockholder servicing fee	Accrued stockholder servicing fee	$	3,392,000	$	9,270,000	Accrued stockholder servicing fee	$	2,157,000	$	7,667,000

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

For the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2021 and 2020

1. Organization and Description of Business

American Healthcare REIT, Inc. (formerly known as Griffin-American Healthcare REIT IV, Inc.), a Maryland corporation, invests in a diversified portfolio of healthcare real estate properties, focusing primarily on medical office buildings, skilled nursing facilities and senior housing facilities that produce current income. We also operate healthcare-related facilities utilizing the structure permitted by the REIT Investment Diversification and Empowerment Act of 2007, which is commonly referred to as a “RIDEA” structure (the provisions of the Internal Revenue Code of 1986, as amended, or the Code, authorizing the RIDEA structure were enacted as part of the Housing and Economic Recovery Act of 2008). We qualified to be taxed as a real estate investment trust, or REIT, under the Code for federal income tax purposes beginning with our taxable year ended December 31, 2016, and we intend to continue to qualify to be taxed as a REIT.

We raised $754,118,000 through a best efforts initial public offering, or our initial offering, that commenced on February 16, 2016, and issued 75,639,681 aggregate shares of our Class T and Class I common stock. In addition, during our initial offering, we issued 3,253,535 aggregate shares of our Class T and Class I common stock pursuant to our distribution reinvestment plan, as amended, or the DRIP, for a total of $31,021,000 in distributions reinvested. Following the termination of our initial offering on February 15, 2019, we continued issuing shares of our common stock pursuant to the DRIP through a subsequent offering, or the 2019 DRIP Offering, which commenced on March 1, 2019. On March 18, 2021, our board of directors, or our board, authorized the suspension of the DRIP, effective as of April 1, 2021. As of ~~June~~September 30, 2021, a total of $46,970,000 in distributions were reinvested that resulted in 4,923,550 shares of our common stock being issued pursuant to the 2019 DRIP Offering. We collectively refer to the DRIP portion of our initial offering and the 2019 DRIP Offering as our DRIP Offerings. See Note 12, Equity — Distribution Reinvestment Plan, for a further discussion. On October 4, 2021, our board authorized the reinstatement of the DRIP. See Note 20, Subsequent Events —Reinstatement of the DRIP, for a further discussion.

~~We conduct~~Until October 1, 2021, we conducted substantially all of our operations through Griffin-American Healthcare REIT IV Holdings, LP, or our operating partnership. ~~We are~~Through September 30, 2021, we were externally advised by Griffin-American Healthcare REIT IV Advisor, LLC, or our advisor, pursuant to an advisory agreement, as amended, or the Advisory Agreement, between us, our operating partnership and our advisor. The Advisory Agreement was effective as of February 16, 2016 and had a one-year initial term, subject to successive one-year renewals upon the mutual consent of the parties. The Advisory Agreement was last renewed pursuant to the mutual consent of the parties on February 11, 2021. On June 23, 2021, in anticipation of the Merger, as defined and ~~expires on February 16, 2022.~~discussed below, we entered into an amendment to the Advisory Agreement, whereby it was agreed that any acquisition fee due to our advisor is to be waived in connection with the REIT Merger, as defined and discussed below. Except as set forth in such amendment to the Advisory Agreement, the terms of the Advisory Agreement continued in full force and effect. Our advisor ~~uses~~used its best efforts, subject to the oversight and review of our board, to, among other things, provide asset management, property management, acquisition, disposition and other advisory services on our behalf consistent with our investment policies and objectives. Our advisor ~~performs~~performed its duties and responsibilities under the Advisory Agreement as our fiduciary. ~~Our~~Prior to the Merger, our advisor iswas 75.0% owned and managed by wholly owned subsidiaries of American Healthcare Investors, LLC, or American Healthcare Investors, and 25.0% owned by a wholly owned subsidiary of Griffin Capital Company, LLC, or Griffin Capital, or collectively, our co-sponsors. American Healthcare Investors iswas 47.1% owned by AHI Group Holdings, LLC, or AHI Group Holdings, 45.1% indirectly owned by Digital Bridge Group, Inc. (NYSE: DBRG) (formerly known as Colony Capital, Inc.), or Digital Bridge, and 7.8% owned by James F. Flaherty III, a former partner of Colony Capital, Inc. We ~~are~~were not affiliated with Griffin Capital, Griffin Capital Securities, LLC, or our dealer manager, Digital Bridge or Mr. Flaherty; however, we ~~are~~were affiliated with our advisor, American Healthcare Investors and AHI Group Holdings. Please see the “Merger with Griffin-American Healthcare REIT III, Inc.” and “AHI Acquisition” sections below for a further discussion of our operations effective October 1, 2021.

We ~~currently~~ operate through 4 reportable business segments: medical office buildings, senior housing, senior housing — RIDEA and skilled nursing facilities. As of ~~June~~September 30, 2021, we owned 87 properties, comprising 92 buildings, or approximately 4,799,000 square feet of gross leasable area, or GLA, for an aggregate contract purchase price of $1,080,381,000. As of ~~June~~September 30, 2021, we also owned a 6.0% interest in a joint venture which ~~owns~~owned a portfolio of integrated senior health campuses and ancillary businesses.

Due to the ongoing coronavirus, or COVID-19, pandemic in the United States and globally, since March 2020, our residents, tenants, operating partners and managers have been materially impacted, and the prolonged economic impact remains

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

uncertain. As the COVID-19 pandemic is still impacting the healthcare system to a degree, it continues to present challenges for us as an owner and operator of healthcare facilities. Since its outset, the impacts of the COVID-19 pandemic have been significant, rapidly and continuously evolving and may continue into the future, especially due to the emergence of the Delta variant which has caused COVID-19 cases and deaths to increase significantly in recent months, making it difficult to ascertain the long-term impact itthe COVID-19 pandemic will have on real estate markets in which we own and/or operate properties and our portfolio of investments. We have evaluated the impacts of the COVID-19 pandemic on our business thus far and incorporated information concerning the impact of COVID-19 into our assessments of liquidity, impairment and collectability from tenants and residents as of ~~June~~September 30, 2021. We will continue to monitor such impacts and will adjust our estimates and assumptions based on the best available information.

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

~~Proposed~~ Merger with Griffin-American Healthcare REIT III, Inc.

In October 2020, our board established a special committee of our board, or our special committee, which consists of all of our independent directors, to investigate and analyze strategic alternatives, including but not limited to, the sale of our assets, a listing of our shares on a national securities exchange, or a merger with another entity, including a merger with another unlisted entity that we expect would enhance our value. On June 23, 2021, we, our operating partnership, our wholly owned subsidiary, Continental Merger Sub, LLC, or merger sub, ~~and~~ Griffin-American Healthcare REIT III, Inc., or GAHR III, and ~~its subsidiary~~American Healthcare REIT Holdings, LP (formerly known as Griffin-American Healthcare REIT III Holdings, ~~LP,~~LP), or ~~GAHR III operating~~the surviving partnership, entered into an Agreement and Plan of Merger, or the Merger Agreement. ~~Subject~~On October 1, 2021, pursuant to ~~the terms and conditions of~~ the Merger Agreement, (i) GAHR III ~~will be~~ merged with and into merger sub, with merger sub being the surviving company, or the REIT Merger, and (ii) our operating partnership ~~will be~~ merged with and into ~~GAHR III operating~~the surviving partnership, with ~~GAHR III operating~~the surviving partnership being the surviving ~~partnership~~entity and being renamed ~~“American~~American Healthcare REIT Holdings, ~~LP”,~~LP, or the Partnership Merger, and, together with the REIT Merger, the Merger.

~~At the effective time~~ As a result of ~~the REIT Merger, each issued~~ and outstanding share of GAHR III’s common stock, $0.01 par value per share, will be converted into the right to receive 0.9266 of a share of our Class I common stock, $0.01 par value per share. Further, at the effective time of the ~~Partnership~~ Merger, ~~(i) each unit~~the separate corporate existence of ~~limited partnership interest in~~ GAHR III operating partnership outstanding as of immediately prior to the effective time of the Partnership Merger will be converted automatically into the right to receive 0.9266 of a Partnership Class I Unit, as defined in the agreement of limited partnership of the surviving partnership and ~~(ii) each unit of limited partnership interest in~~ our operating partnership outstanding as of immediately prior to the effective time of the Partnership Merger will be converted automatically into the right to receive one unit of limited partnership interest of the surviving partnership of like class. ceased.

Following the Merger, ~~we (as~~our company, combined with GAHR III, or the Combined ~~Company) will be named~~Company, was renamed “American Healthcare REIT, Inc.” The REIT Merger is intended to qualify as a “reorganization” under, and within the meaning of, Section 368(a) of the ~~Internal Revenue Code of 1986, as amended.~~Code.

The Merger Agreement may be terminated by either us or GAHR III under certain circumstances, including but not limited to (in each case, with the prior approval of the special committee of the respective board of directors) (i) if the REIT Merger has not been consummated on or before 11:59 p.m. New York time on March 23, 2022; (ii) if the approval of the Merger by our stockholders or the stockholders of GAHR III is not obtained; or (iii) upon a material uncured breach of the respective obligations, covenants or agreements by the other party that would cause the closing conditions in the Merger Agreement not to be satisfied. The consummation of the Merger and the AHI Acquisition (as defined below) is subject to substantial conditions to closing and is not expected to close until the fourth quarter of 2021; therefore, our accompanying condensed consolidated financial statements do not include the Merger or the AHI Acquisition.

If the Merger Agreement is terminated in connection with GAHR III’s acceptance of a Superior Proposal, as defined in the Merger Agreement, or due to GAHR III making a GAHR III Adverse Recommendation Change, as defined in the Merger Agreement, then GAHR III must pay us a termination fee of $50,654,000 and reimburse up to $4,000,000 of documented expenses incurred by us in connection with the Merger. If the Merger Agreement is terminated in connection with our acceptance of a Superior Proposal or due to us making a GAHR IV Adverse Recommendation Change, as defined in the Merger Agreement, then we must pay to GAHR III a termination fee of $23,028,000 and reimburse up to $4,000,000 of documented expenses incurred by GAHR III in connection with the Merger.

The parties to the Merger Agreement have agreed to certain limits on the conduct of their businesses between the signing of the Merger Agreement and the closing of the Merger. Generally, transactions that are not in the ordinary course of business require the consent of the other party.

Also on June 23, 2021, ~~GAHR III, GAHR III operating~~the surviving partnership, our co-sponsors, Platform Healthcare Investor T-II, LLC, Flaherty Trust, Jeffrey T. Hanson, our former Chief Executive Officer and Chairman of the Board of Directors, Danny Prosky, our President and former Chief Operating Officer, and Mathieu B. Streiff, our former Executive Vice President, General Counsel, entered into a contribution and exchange agreement, or the Contribution Agreement, pursuant to which, among other things, ~~GAHR III has~~the surviving partnership agreed to acquire a newly formed entity, or NewCo, which we refer to as the AHI Acquisition, that ~~will own~~owned substantially all of the business and operations of one of our co-sponsors, American Healthcare Investors, as well as all of the equity interests in (i) Griffin-American Healthcare REIT III Advisor, LLC, or GAHR III Advisor, a subsidiary of American Healthcare Investors that ~~serves~~served as the external advisor of GAHR III, and (ii) our ~~advisor, such that GAHR III will become self-managed and (if~~advisor. On October 1, 2021, the ~~Merger does not occur) we will become indirectly managed by GAHR III. The~~ AHI Acquisition ~~is expected to close~~closed immediately prior to the consummation of the Merger. Following the consummation of the Merger, ~~assuming~~the Combined Company has become a self-managed company.

The AHI Acquisition will be treated as a business combination for accounting purposes, with GAHR III as both the legal and accounting acquiror of NewCo. While we are the legal acquiror of GAHR III in the REIT Merger, GAHR III was determined to be the accounting acquiror in the REIT Merger transaction in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 805, Business Combinations, after considering the relative share ownership and the composition of the governing body of the Combined Company. As a result of the completion of the Merger and the AHI Acquisition, ~~is consummated,~~ the ~~Combined Company will be an entirely self-managed company. The Merger is not subject to~~historical information regarding our company’s structure, agreements and financial information presented within this Note 1 and throughout the ~~consummation~~rest of the Notes to Condensed Consolidated Financial Statements has materially changed; however, such information did apply to us as of September 30, 2021. See Note 20, Subsequent Events — Merger with Griffin-American Healthcare REIT III, Inc. and AHI Acquisition, ~~such that~~for a further discussion about the Merger ~~may occur even if~~and the AHI ~~Acquisition does not. The parties to the Contribution Agreement also may elect to proceed with the AHI Acquisition even if the Merger is not consummated.~~

~~Table of Contents~~Acquisition.

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

In addition, on June 23, 2021, in connection with the Merger, we amended the Advisory Agreement with our advisor, such that our advisor agreed to waive any acquisition fee due in connection with the REIT Merger. Except as set forth in such amendment to the Advisory Agreement, the terms of the Advisory Agreement shall continue in full force and effect.

2. Summary of Significant Accounting Policies

The summary of significant accounting policies presented below is designed to assist in understanding our accompanying condensed consolidated financial statements. Such condensed consolidated financial statements and the accompanying notes thereto are the representations of our management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America, or GAAP, in all material respects, and have been consistently applied in preparing our accompanying condensed consolidated financial statements.

Basis of Presentation

Our accompanying condensed consolidated financial statements include our accounts and those of our operating partnership, the wholly owned subsidiaries of our operating partnership and all non-wholly owned subsidiaries in which we have control, as well as any VIEs in which we are the primary beneficiary. The portion of equity in any subsidiary that is not

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

wholly-owned by us is presented in our accompanying condensed consolidated financial statements as noncontrolling interest. We evaluate our ability to control an entity, and whether the entity is a VIE and we are the primary beneficiary, by considering substantive terms of the arrangement and identifying which enterprise has the power to direct the activities of the entity that most significantly impacts the entity’s economic performance.

We operate and intend to continue to operate in an umbrella partnership REIT structure in which our operating partnership, or wholly owned subsidiaries of our operating partnership, will own substantially all of the interests in properties acquired on our behalf. We are the sole general partner of our operating partnership, and as of both ~~June~~September 30, 2021 and December 31, 2020, we owned greater than a 99.99% general partnership interest therein. Our advisor iswas a limited partner, and as of both ~~June~~September 30, 2021 and December 31, 2020, owned less than a 0.01% noncontrolling limited partnership interest in our operating partnership.

Because we are the sole general partner of our operating partnership and have unilateral control over its management and major operating decisions (even if additional limited partners are admitted to our operating partnership), the accounts of our operating partnership are consolidated in our accompanying condensed consolidated financial statements. All intercompany accounts and transactions are eliminated in consolidation.

Interim Unaudited Financial Data

Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the United States Securities and Exchange Commission, or the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to the SEC’s rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments which are, in our view, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim period. Interim results of operations are not necessarily indicative of the results that may be expected for the full year; such full year results may be less favorable.

In preparing our accompanying condensed consolidated financial statements, management has evaluated subsequent events through the financial statement issuance date. We believe that although the disclosures contained herein are adequate to prevent the information presented from being misleading, our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2020 Annual Report on Form 10-K, as filed with the SEC on March 26, 2021.

Use of Estimates

The preparation of our accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the disclosure of contingent assets and liabilities, at the date of our condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include, but are not limited to, the initial and recurring valuation of certain assets acquired and liabilities assumed through property acquisitions, revenues and grant income, allowance for credit losses, impairment of long-lived and intangible assets and contingencies.

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

These estimates are made and evaluated on an on-going basis using information that is currently available as well as various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates, perhaps in material adverse ways, and those estimates could be different under different assumptions or conditions.

Revenue Recognition — Resident Fees and Services Revenue

Disaggregation of Resident Fees and Services Revenue

The following tables disaggregate our resident fees and services revenue by line of business, according to whether such revenue is recognized at a point in time or over time:

Three Months Ended June 30,
2021 2020
Point in Time Over Time Total Point in Time Over Time Total
Senior housing — RIDEA $ 131,000 $ 15,063,000 $ 15,194,000 $ 150,000 $ 16,684,000 $ 16,834,000


	Three Months Ended September 30,
	2021						2020
	Point in Time		Over Time		Total		Point in Time		Over Time		Total
Senior housing — RIDEA	$	150,000	$	14,940,000	$	15,090,000	$	174,000	$	18,774,000	$	18,948,000

Six Months Ended June 30,
2021 2020
Point in Time Over Time Total Point in Time Over Time Total
Senior housing — RIDEA $ 323,000 $ 30,766,000 $ 31,089,000 $ 572,000 $ 32,343,000 $ 32,915,000

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)


	Nine Months Ended September 30,
	2021						2020
	Point in Time		Over Time		Total		Point in Time		Over Time		Total
Senior housing — RIDEA	$	473,000	$	45,706,000	$	46,179,000	$	746,000	$	51,117,000	$	51,863,000

The following tables disaggregate our resident fees and services revenue by payor class:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			2021		2020		2021		2020
Private and other payors	Private and other payors	$	13,611,000	$	15,093,000	$	27,770,000	$	29,466,000	Private and other payors	$	13,556,000	$	17,300,000	$	41,326,000	$	46,766,000
Medicaid	Medicaid	1,583,000		1,741,000		3,319,000		3,449,000		Medicaid	1,534,000		1,648,000		4,853,000		5,097,000
Total resident fees and services	Total resident fees and services	$	15,194,000	$	16,834,000	$	31,089,000	$	32,915,000	Total resident fees and services	$	15,090,000	$	18,948,000	$	46,179,000	$	51,863,000

Accounts Receivable, Net — Resident Fees and Services

The beginning and ending balances of accounts receivable, net — resident fees and services are as follows:

Medicaid Private
and
Other Payors Total
Beginning balance — January 1, 2021
$ 1,123,000 $ 358,000 $ 1,481,000
Ending balance — June 30, 2021
701,000 334,000 1,035,000
Decrease $ (422,000) $ (24,000) $ (446,000)


	Medicaid		Private and Other Payors		Total
Beginning balance — January 1, 2021	$	1,123,000	$	358,000	$	1,481,000
Ending balance — September 30, 2021	257,000		900,000		1,157,000
(Decrease)/increase	$	(866,000)	$	542,000	$	(324,000)

Tenant and Resident Receivables and Allowances

Resident receivables, which are related to resident fees and services, are carried net of an allowance for credit losses. An allowance is maintained for estimated losses resulting from the inability of residents and payors to meet the contractual obligations under their lease or service agreements. Substantially all of such allowances are recorded as direct reductions of resident fees and services revenue as contractual adjustments provided to third-party payors or implicit price concessions in our accompanying condensed consolidated statements of operations. Our determination of the adequacy of these allowances is based primarily upon evaluations of historical loss experience, the residents’ financial condition, security deposits, cash collection patterns by payor and by state, current economic conditions, future expectations in estimating credit losses and other relevant factors. Tenant receivables, which are related to real estate revenue, and unbilled deferred rent receivables are reduced for uncollectible amounts, which are recognized as direct reductions of real estate revenue in our accompanying condensed consolidated statements of operations.

As of ~~June~~September 30, 2021 and December 31, 2020, we had ~~$2,238,000~~$2,219,000 and $2,086,000, respectively, in allowances, which were determined necessary to reduce receivables by our expected future credit losses. For the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, we increased allowances by ~~$563,000~~$839,000 and ~~$541,000,~~$937,000, respectively, and reduced allowances for collections or

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

adjustments by ~~$55,000~~$350,000 and ~~$74,000,~~$126,000, respectively. For the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, $356,000 and ~~$39,000,~~$60,000, respectively, of our receivables were written off against the related allowances.

3. Real Estate Investments, Net

Our real estate investments, net consisted of the following as of ~~June~~September 30, 2021 and December 31, 2020:


		June 30, 2021		December 31, 2020			September 30, 2021		December 31, 2020
Building and improvements	Building and improvements	$	890,610,000	$	884,816,000	Building and improvements	$	892,743,000	$	884,816,000
Land	Land	109,771,000		109,444,000		Land	109,771,000		109,444,000
Furniture, fixtures and equipment	Furniture, fixtures and equipment	9,040,000		8,599,000		Furniture, fixtures and equipment	9,315,000		8,599,000
		1,009,421,000		1,002,859,000			1,011,829,000		1,002,859,000
Less: accumulated depreciation	Less: accumulated depreciation	(96,954,000)		(81,279,000)		Less: accumulated depreciation	(104,726,000)		(81,279,000)
Total	Total	$	912,467,000	$	921,580,000	Total	$	907,103,000	$	921,580,000

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

Depreciation expense for the three months ended ~~June~~September 30, 2021 and 2020 was ~~$7,930,000~~$8,181,000 and ~~$7,893,000,~~$7,966,000, respectively, and for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020 was ~~$15,844,000~~$24,025,000 and ~~$15,732,000,~~$23,698,000, respectively. ~~In addition to the property acquisition transaction discussed below, for~~For the three and ~~six~~nine months ended ~~June~~September 30, 2021, we incurred capital expenditures of ~~$2,140,000~~$1,959,000 and ~~$2,916,000,~~$4,875,000, respectively, for our medical office buildings, $827,000 and ~~$743,000 and $1,058,000,~~$1,885,000, respectively, for our senior housing — RIDEA facilities and $31,000 and $31,000, respectively, for our skilled nursing facilities. We did 0tnot incur any capital expenditures for our ~~skilled nursing and~~ senior housing facilities during the three and ~~six~~nine months ended ~~June~~September 30, 2021.

On February 12, 2021, we acquired a previously unowned unit within one of our buildings at our existing Athens MOB Portfolio, originally purchased in May 2017, for a contract purchase price of $2,950,000. Our advisor was paid, as compensation for services rendered in connection with the investigation, selection and acquisition of such unit, a base acquisition fee of 2.25% of the contract purchase price paid by us, or $66,000. We acquired such unit using cash on hand and borrowed $2,000,000 under the 2018 Credit Facility, as defined in Note 7, Line of Credit and Term Loans, at the time of acquisition.

We accounted for our acquisition completed during the ~~six~~nine months ended ~~June~~September 30, 2021 as an asset acquisition. We incurred and capitalized the base acquisition fee and direct acquisition related expenses of $94,000. The following table summarizes the purchase price of the assets acquired at the time of acquisition based on their relative fair values:


	2021 Acquisition
Building and improvements	$	2,429,000
Land	327,000

In-place lease	288,000



Total assets acquired	$	3,044,000

On April 1, 2021, we disposed of two senior housing facilities located in Fairfield and Sacramento, California for a contract sales price of $6,800,000. Such facilities were part of our existing Northern California Senior Housing Portfolio and were included within our senior housing – RIDEA reporting segment. We recognized a total net loss on such disposition of ~~$199,000.~~$184,000. Our advisor agreed to waive the $136,000 disposition fee and any expense reimbursements for such disposition that may otherwise have been due to our advisor pursuant to the Advisory Agreement. Our advisor did not receive any additional securities, shares of our stock or any other form of consideration or any repayment as a result of the waiver of such disposition fee and expense reimbursements.

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

4. Identified Intangible Assets, Net

Identified intangible assets, net consisted of the following as of ~~June~~September 30, 2021 and December 31, 2020:


		June 30, 2021		December 31, 2020			September 30, 2021		December 31, 2020
Amortized intangible assets:	Amortized intangible assets:					Amortized intangible assets:
In-place leases, net of accumulated amortization of $28,793,000 and $32,134,000 as of June 30, 2021 and December 31, 2020, respectively (with a weighted average remaining life of 8.9 years and 8.8 years as of June 30, 2021 and December 31, 2020, respectively)		$	54,515,000	$	61,166,000
Above-market leases, net of accumulated amortization of $1,156,000 and $1,009,000 as of June 30, 2021 and December 31, 2020, respectively (with a weighted average remaining life of 8.7 years and 9.1 years as of June 30, 2021 and December 31, 2020, respectively)		2,388,000		2,587,000
In-place leases, net of accumulated amortization of $30,663,000 and $32,134,000 as of September 30, 2021 and December 31, 2020, respectively (with a weighted average remaining life of 8.8 years as of both September 30, 2021 and December 31, 2020)						In-place leases, net of accumulated amortization of $30,663,000 and $32,134,000 as of September 30, 2021 and December 31, 2020, respectively (with a weighted average remaining life of 8.8 years as of both September 30, 2021 and December 31, 2020)	$	52,112,000	$	61,166,000
Above-market leases, net of accumulated amortization of $1,252,000 and $1,009,000 as of September 30, 2021 and December 31, 2020, respectively (with a weighted average remaining life of 8.5 years and 9.1 years as of September 30, 2021 and December 31, 2020, respectively)						Above-market leases, net of accumulated amortization of $1,252,000 and $1,009,000 as of September 30, 2021 and December 31, 2020, respectively (with a weighted average remaining life of 8.5 years and 9.1 years as of September 30, 2021 and December 31, 2020, respectively)	2,292,000		2,587,000
Unamortized intangible assets:	Unamortized intangible assets:					Unamortized intangible assets:
Certificates of need	Certificates of need	348,000		348,000		Certificates of need	348,000		348,000
Total	Total	$	57,251,000	$	64,101,000	Total	$	54,752,000	$	64,101,000

Amortization expense on identified intangible assets for the three months ended ~~June~~September 30, 2021 and 2020 was ~~$2,654,000~~$2,358,000 and ~~$4,877,000,~~$4,728,000, respectively, which included ~~$98,000~~$97,000 and ~~$110,000,~~$109,000, respectively, of amortization recorded as a decrease to real estate revenue for above-market leases in our accompanying condensed consolidated statements of operations. Amortization expense on identified intangible assets for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020 was ~~$7,137,000~~$9,495,000 and ~~$9,633,000,~~$14,361,000, respectively, which included ~~$199,000~~$296,000 and ~~$220,000,~~$329,000, respectively, of amortization recorded as a decrease to real estate revenue for above-market leases in our accompanying condensed consolidated statements of operations.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

The aggregate weighted average remaining life of the identified intangible assets was ~~8.9 years and~~ 8.8 years as of ~~June~~both September 30, 2021 and December 31, ~~2020, respectively.~~2020. As of ~~June~~September 30, 2021, estimated amortization expense on the identified intangible assets for the ~~six~~three months ending December 31, 2021 and for each of the next four years ending December 31 and thereafter was as follows:


Year	Year	Amount		Year	Amount
2021	2021	$	4,896,000	2021	$	2,396,000
2022	2022	8,647,000		2022	8,647,000
2023	2023	7,390,000		2023	7,390,000
2024	2024	6,195,000		2024	6,195,000
2025	2025	5,017,000		2025	5,017,000
Thereafter	Thereafter	24,758,000		Thereafter	24,759,000
Total	Total	$	56,903,000	Total	$	54,404,000

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

5. Other Assets, Net

Other assets, net consisted of the following as of ~~June~~September 30, 2021 and December 31, 2020:


		June 30, 2021		December 31, 2020			September 30, 2021		December 31, 2020
Investment in unconsolidated entity	Investment in unconsolidated entity	$	45,556,000	$	46,653,000	Investment in unconsolidated entity	$	45,627,000	$	46,653,000
Deferred rent receivables	Deferred rent receivables	14,499,000		12,395,000		Deferred rent receivables	15,101,000		12,395,000
Prepaid expenses, deposits and other assets	Prepaid expenses, deposits and other assets	3,562,000		9,028,000		Prepaid expenses, deposits and other assets	3,939,000		9,028,000
Lease commissions, net of accumulated amortization of $585,000 and $426,000 as of June 30, 2021 and December 31, 2020, respectively		3,310,000		2,399,000
Deferred financing costs, net of accumulated amortization of $4,338,000 and $3,397,000 as of June 30, 2021 and December 31, 2020, respectively(1)		783,000		1,724,000
Lease commissions, net of accumulated amortization of $687,000 and $426,000 as of September 30, 2021 and December 31, 2020, respectively						Lease commissions, net of accumulated amortization of $687,000 and $426,000 as of September 30, 2021 and December 31, 2020, respectively	3,763,000		2,399,000
Deferred financing costs, net of accumulated amortization of $4,808,000 and $3,397,000 as of September 30, 2021 and December 31, 2020, respectively(1)						Deferred financing costs, net of accumulated amortization of $4,808,000 and $3,397,000 as of September 30, 2021 and December 31, 2020, respectively(1)	313,000		1,724,000
Total	Total	$	67,710,000	$	72,199,000	Total	$	68,743,000	$	72,199,000

___________

(1)Deferred financing costs only include costs related to our line of credit and term loans. Amortization expense on deferred financing costs of our line of credit and term loans for the three months ended ~~June~~September 30, 2021 and 2020 was ~~$471,000~~$470,000 and ~~$470,000,~~$471,000, respectively, and for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020 was ~~$941,000~~$1,411,000 and ~~$939,000,~~$1,410,000, respectively, which is recorded to interest expense in our accompanying condensed consolidated statements of operations. See Note 7, Line of Credit and Term Loans, for a further discussion.

Investment in unconsolidated entity represents our interest in Trilogy REIT Holdings, LLC, or Trilogy, pursuant to an amended joint venture agreement with an indirect, wholly-owned subsidiary of NorthStar Healthcare Income, Inc. and a wholly-owned subsidiary of ~~GAHR III operating~~the surviving partnership. Trilogy owns a portfolio of integrated senior health campuses and ancillary businesses. As of ~~June~~September 30, 2021 and December 31, 2020, we owned a 6.0% interest in such joint venture and the unamortized basis difference of our investment in Trilogy of ~~$16,562,000~~$16,448,000 and $16,791,000, respectively, iswas primarily attributable to the difference between the amount for which we purchased our interest in such joint venture, including transaction costs, and the historical carrying value of the net assets of such joint venture. This difference iswas being amortized over the remaining useful life of the related assets and included in income or loss from unconsolidated entity in our accompanying condensed consolidated statements of operations.

~~The following is summarized financial information of Trilogy:~~

June 30,
2021 December 31,
2020
Balance Sheet Data:
Total assets $ 1,862,179,000 $ 1,882,584,000
Total liabilities $ 1,325,497,000 $ 1,329,832,000

Three Months Ended June 30, Six Months Ended June 30,
2021 2020 2021 2020
Statements of Operations Data:
Revenues $ 255,815,000 $ 232,831,000 $ 489,042,000 $ 500,626,000
Grant income 898,000 29,990,000 9,127,000 29,990,000
Expenses 258,065,000 242,311,000 513,159,000 503,748,000
Net (loss) income $ (1,352,000) $ 20,510,000 $ (14,990,000) $ 26,868,000
Proportional net (loss) income $ (79,000) $ 1,188,000 $ (869,000) $ 1,557,000
Amortization of basis difference (114,000) (114,000) (228,000) (228,000)
(Loss) income from unconsolidated entity $ (193,000) $ 1,074,000 $ (1,097,000) $ 1,329,000

1615

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

6. Mortgage Loans Payable, Net

As of ~~June~~September 30, 2021 and December 31, 2020, mortgage loans payable were ~~$18,474,000~~$18,291,000 ($~~17,572,000,~~17,409,000, net of discount/premium and deferred financing costs) and $18,766,000 ($17,827,000, net of discount/premium and deferred financing costs), respectively. As of ~~June~~September 30, 2021, we had 3 fixed-rate mortgage loans with interest rates ranging from 3.67% to 5.25% per annum, maturity dates ranging from April 1, 2025 to February 1, 2051 and a weighted average effective interest rate of ~~3.92%~~3.91%. As of December 31, 2020, we had 3 fixed-rate mortgage loans with interest rates ranging from 3.67% to 5.25% per annum, maturity dates ranging from April 1, 2025 to February 1, 2051 and a weighted average effective interest rate of 3.93%.

In January 2020, we paid off a mortgage loan payable with a principal balance of $7,738,000, which had an original maturity date of April 1, 2020. We did not incur any prepayment penalties or fees in connection with such payoff. The following table reflects the changes in the carrying amount of mortgage loans payable, net for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020:


		Six Months Ended June 30,					Nine Months Ended September 30,
		2021		2020			2021		2020
Beginning balance	Beginning balance	$	17,827,000	$	26,070,000	Beginning balance	$	17,827,000	$	26,070,000
Additions:	Additions:					Additions:

Amortization of deferred financing costs	Amortization of deferred financing costs	13,000		26,000		Amortization of deferred financing costs	20,000		33,000
Amortization of discount/premium on mortgage loans payable	Amortization of discount/premium on mortgage loans payable	25,000		25,000		Amortization of discount/premium on mortgage loans payable	37,000		37,000
Deductions:	Deductions:					Deductions:
Scheduled principal payments on mortgage loans payable	Scheduled principal payments on mortgage loans payable	(293,000)		(8,017,000)		Scheduled principal payments on mortgage loans payable	(475,000)		(8,166,000)

Ending balance	Ending balance	$	17,572,000	$	18,104,000	Ending balance	$	17,409,000	$	17,974,000

As of ~~June~~September 30, 2021, the principal payments due on our mortgage loans payable for the ~~six~~three months ending December 31, 2021 and for each of the next four years ending December 31 and thereafter were as follows:


Year	Year	Amount		Year	Amount
2021	2021	$	315,000	2021	$	132,000
2022	2022	651,000		2022	651,000
2023	2023	680,000		2023	680,000
2024	2024	711,000		2024	711,000
2025	2025	5,878,000		2025	5,878,000
Thereafter	Thereafter	10,239,000		Thereafter	10,239,000
Total	Total	$	18,474,000	Total	$	18,291,000

7. Line of Credit and Term Loans

We, through our operating partnership, as borrower, entered into a credit agreement, or the 2018 Credit Agreement, as amended, with Bank of America, N.A.;, or Bank of America; KeyBank, National ~~Association;~~Association, or KeyBank; Citizens Bank, National Association; Merrill Lynch, Pierce, Fenner & Smith Incorporated; KeyBanc Capital Markets, Inc., or KeyBanc Capital Markets; and the lenders named therein, to obtain a credit facility with an aggregate maximum principal amount of $530,000,000, or the 2018 Credit Facility. The 2018 Credit Facility consists of a senior unsecured revolving credit facility in the amount of $235,000,000 and senior unsecured term loan facilities in the aggregate amount of $295,000,000. The maximum principal amount of the 2018 Credit Facility may be increased by up to $120,000,000, for a total principal amount of $650,000,000, subject to certain conditions. The 2018 Credit Facility matures on November 19, 2021 and ~~may be extended~~we intend to extend the maturity for 1 12-month period ~~during~~pursuant to the ~~term~~terms of the ~~related credit agreement,~~2018 Credit Agreement, as amended, subject to the satisfaction of certain conditions, including payment of an extension fee.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

At our option, the 2018 Credit Facility bears interest at per annum rates equal to (a)(i) the Eurodollar Rate, as defined in the 2018 Credit Agreement, as amended, plus (ii) a margin ranging from 1.70% to 2.20% based on our Consolidated Leverage Ratio, as defined in the 2018 Credit Agreement, as amended, or (b)(i) the greater of: (1) the prime rate publicly announced by Bank of America ~~N.A.,~~ (2) the Federal Funds Rate, as defined in the 2018 Credit Agreement, as amended, plus 0.50%, (3) the one-month Eurodollar Rate plus 1.00%, and (4) 0.00%, plus (ii) a margin ranging from 0.70% to 1.20% based on our Consolidated Leverage Ratio.

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

As of both ~~June~~September 30, 2021 and December 31, 2020, our aggregate borrowing capacity under the 2018 Credit Facility was $530,000,000. As of ~~June~~September 30, 2021 and December 31, 2020, borrowings outstanding totaled ~~$482,900,000~~$488,900,000 and $476,900,000, respectively, and the weighted average interest rate on such borrowings outstanding was ~~2.25%~~2.05% and 2.12%, respectively, per annum.

On October 1, 2021, we entered into a Second Amendment to the 2018 Credit Agreement, or the Amendment. See Note 20, Subsequent Events — Lines of Credit and Term Loans — Amendment to 2018 Credit Facility, for a further discussion.

8. Derivative Financial Instruments

We use derivative financial instruments to manage interest rate risk associated with our variable-rate term loans and we record such derivative financial instruments in our accompanying condensed consolidated balance sheets as either an asset or a liability measured at fair value. The following table lists the derivative financial instruments held by us as of ~~June~~September 30, 2021 and December 31, 2020, which are included in security deposits, prepaid rent and other liabilities in our accompanying condensed consolidated balance sheets:


							Fair Value										Fair Value
Instrument	Instrument	Notional Amount		Index	Interest Rate	Maturity Date	June 30, 2021		December 31, 2020		Instrument	Notional Amount		Index	Interest Rate	Maturity Date	September 30, 2021		December 31, 2020
Swap	Swap	$	139,500,000	one month LIBOR	2.49%	11/19/21	$	(1,295,000)	$	(2,915,000)	Swap	$	139,500,000	one month LIBOR	2.49%	11/19/21	$	(455,000)	$	(2,915,000)
Swap	Swap	58,800,000		one month LIBOR	2.49%	11/19/21	(546,000)		(1,229,000)		Swap	58,800,000		one month LIBOR	2.49%	11/19/21	(192,000)		(1,229,000)
Swap	Swap	45,000,000		one month LIBOR	0.20%	11/19/21	(16,000)		(27,000)		Swap	45,000,000		one month LIBOR	0.20%	11/19/21	(7,000)		(27,000)
Swap	Swap	36,700,000		one month LIBOR	2.49%	11/19/21	(340,000)		(766,000)		Swap	36,700,000		one month LIBOR	2.49%	11/19/21	(120,000)		(766,000)
Swap	Swap	15,000,000		one month LIBOR	2.53%	11/19/21	(141,000)		(318,000)		Swap	15,000,000		one month LIBOR	2.53%	11/19/21	(50,000)		(318,000)
		$	295,000,000				$	(2,338,000)	$	(5,255,000)		$	295,000,000				$	(824,000)	$	(5,255,000)

As of both ~~June~~September 30, 2021 and December 31, 2020, none of our derivative financial instruments were designated as hedges. For the three months ended ~~June~~September 30, 2021 and 2020, we recorded ~~$1,462,000~~$1,514,000 and ~~$853,000,~~$1,450,000, respectively, and for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, we recorded ~~$2,917,000~~$4,431,000 and ~~$(3,752,000)~~$(2,302,000), respectively, as a decrease (increase) to interest expense in our accompanying condensed consolidated statements of operations related to the change in the fair value of our derivative financial instruments.

See Note 14, Fair Value Measurements, for a further discussion of the fair value of our derivative financial instruments.

9. Identified Intangible Liabilities, Net

As of ~~June~~September 30, 2021 and December 31, 2020, identified intangible liabilities, net consisted of below-market leases of ~~$1,174,000~~$1,115,000 and $1,295,000, respectively, net of accumulated amortization of $730,000 and $608,000, respectively. Amortization expense on below-market leases for the three months ended ~~June~~September 30, 2021 and 2020 was ~~$61,000~~$59,000 and ~~$69,000,~~$78,000, respectively, and for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020 was ~~$122,000~~$181,000 and ~~$161,000,~~$239,000, respectively, which was recorded as an increase to real estate revenue in our accompanying condensed consolidated statements of operations.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

The weighted average remaining life of below-market leases was ~~11.9~~12.0 years and 11.6 years as of ~~June~~September 30, 2021 and December 31, 2020, respectively. As of ~~June~~September 30, 2021, estimated amortization expense on below-market leases for the ~~six~~three months ending December 31, 2021 and for each of the next four years ending December 31 and thereafter was as follows:


Year	Year	Amount		Year	Amount
2021	2021	$	115,000	2021	$	55,000
2022	2022	217,000		2022	217,000
2023	2023	207,000		2023	207,000
2024	2024	161,000		2024	161,000
2025	2025	123,000		2025	123,000
Thereafter	Thereafter	351,000		Thereafter	352,000
Total	Total	$	1,174,000	Total	$	1,115,000

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

10. Commitments and Contingencies

Litigation

We are not presently subject to any material litigation nor, to our knowledge, is any material litigation threatened against us, which if determined unfavorably to us, would have a material adverse effect on our consolidated financial position, results of operations or cash flows.

Environmental Matters

We follow a policy of monitoring our properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at our properties, we are not currently aware of any environmental liability with respect to our properties that would have a material effect on our consolidated financial position, results of operations or cash flows. Further, we are not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability that we believe would require additional disclosure or the recording of a loss contingency.

Other

Our other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business, which include calls/puts to sell/acquire properties. In our view, these matters are not expected to have a material adverse effect on our consolidated financial position, results of operations or cash flows.

11. Redeemable Noncontrolling Interests

As of both ~~June~~September 30, 2021 and December 31, 2020, our advisor owned all of the 208 limited partnership units outstanding in our operating partnership. As of both ~~June~~September 30, 2021 and December 31, 2020, we owned greater than a 99.99% general partnership interest in our operating partnership, and our advisor owned less than a 0.01% limited partnership interest in our operating partnership. Our advisor iswas entitled to special redemption rights of its limited partnership units. The noncontrolling interest of our advisor in our operating partnership, which ~~has~~had redemption features outside of our control, iswas accounted for as a redeemable noncontrolling interest and iswas presented outside of permanent equity in our accompanying condensed consolidated balance ~~sheets.~~sheets as of both September 30, 2021 and December 31, 2020. In connection with the AHI Acquisition, on October 1, 2021, GAHR III redeemed all 208 limited partnership units in our operating partnership owned by our advisor for approximately $2,000.

In connection with our acquisitions of Central Florida Senior Housing Portfolio, Pinnacle Beaumont ALF and Pinnacle Warrenton ALF, we own approximately 98.0% of the joint ventures with an affiliate of Meridian Senior Living, LLC, or Meridian. In connection with our acquisitions of Catalina West Haven ALF and Catalina Madera ALF, we own approximately 90.0% of the joint venture with Avalon Health Care, Inc., or Avalon. The noncontrolling interests held by Meridian and Avalon have redemption features outside of our control and are accounted for as redeemable noncontrolling interests in our accompanying condensed consolidated balance sheets.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

We record the carrying amount of redeemable noncontrolling interests at the greater of: (i) the initial carrying amount, increased or decreased for the noncontrolling interests’ share of net income or loss and distributions; or (ii) the redemption value. The changes in the carrying amount of redeemable noncontrolling interests consisted of the following for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020:


		Six Months Ended June 30,					Nine Months Ended September 30,
		2021		2020			2021		2020
Beginning balance	Beginning balance	$	2,618,000	$	1,462,000	Beginning balance	$	2,618,000	$	1,462,000
Additions	Additions	126,000		1,118,000		Additions	125,000		1,118,000
Distributions	Distributions	(7,000)		(72,000)		Distributions	(8,000)		(81,000)
Adjustment to redemption value	Adjustment to redemption value	75,000		322,000		Adjustment to redemption value	167,000		530,000
Net loss attributable to redeemable noncontrolling interests	Net loss attributable to redeemable noncontrolling interests	(219,000)		(205,000)		Net loss attributable to redeemable noncontrolling interests	(310,000)		(332,000)
Ending balance	Ending balance	$	2,593,000	$	2,625,000	Ending balance	$	2,592,000	$	2,697,000

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

12. Equity

Preferred Stock

~~Pursuant~~As of September 30, 2021, pursuant to our Third Articles of Amendment and Restatement, as supplemented, or our charter, we ~~are~~were authorized to issue 200,000,000 shares of our preferred stock, par value $0.01 per share. As of both ~~June~~September 30, 2021 and December 31, 2020, 0no shares of our preferred stock were issued and outstanding.

Common Stock

~~Our~~As of September 30, 2021, our charter ~~authorizes~~authorized us to issue 1,000,000,000 shares of our common stock, par value $0.01 per share, whereby 900,000,000 shares ~~are~~were classified as Class T common stock and 100,000,000 shares ~~are~~were classified as Class I common stock. See Note 20, Subsequent Events — Amendments to Articles of Incorporation, for a discussion of an amendment to our charter filed on October 1, 2021. Each share of our common stock, regardless of class, will be entitled to one vote per share on matters presented to the common stockholders for approval; provided, however, that stockholders of one share class shall have exclusive voting rights on any amendment to our charter that would alter only the contract rights of that share class, and no stockholders of another share class shall be entitled to vote thereon. As of both ~~June~~September 30, 2021 and December 31, 2020, our advisor owned 20,833 shares of our Class T common stock. In connection with the AHI Acquisition, on October 1, 2021, GAHR III redeemed all 20,833 shares of our Class T common stock owned by our advisor for approximately $192,000.

On February 15, 2019, we terminated our initial offering and we continued to offer shares of our common stock pursuant to the 2019 DRIP Offering. On March 18, 2021, our board authorized the suspension of the DRIP effective with distributions declared for the month of April 2021; however, on October 4, 2021, our board reinstated the DRIP. See the “Distribution Reinvestment Plan” section below for a further discussion.

Through ~~June~~September 30, 2021, we had issued 75,639,681 aggregate shares of our Class T and Class I common stock in connection with the primary portion of our initial offering and 8,177,085 aggregate shares of our Class T and Class I common stock pursuant to our DRIP Offerings. We also granted an aggregate of 105,000 shares of our restricted Class T common stock to our independent directors and repurchased 2,211,338 shares of our common stock under our share repurchase plan through ~~June~~September 30, 2021. As of ~~June~~September 30, 2021 and December 31, 2020, we had 81,731,261 and 81,339,337 aggregate shares of our Class T and Class I common stock, respectively, issued and outstanding.

Distribution Reinvestment Plan

We had registered and reserved $150,000,000 in shares of our common stock for sale pursuant to the DRIP in our initial offering. The DRIP allowed stockholders to purchase additional Class T shares and Class I shares of our common stock through the reinvestment of distributions during our initial offering. Pursuant to the DRIP, distributions with respect to Class T shares were reinvested in Class T shares and distributions with respect to Class I shares were reinvested in Class I shares. On February 15, 2019, we terminated our initial offering and continued to offer up to $100,000,000 in shares of our common stock pursuant to the 2019 DRIP Offering. In connection with our special committee’s strategic alternative review process and in order to facilitate a strategic transaction, on March 18, 2021, our board authorized the suspension of the DRIP, effective as of April 1, ~~2021, unless and until our board reinstates the DRIP.~~2021. As a consequence of the suspension of the DRIP, beginning with the April 2021 distributions, which were paid in May 2021, there were no further issuances of shares pursuant to the DRIP, and stockholders who are participants in the DRIP received or will receive cash distributions instead. On October 4, 2021, our board authorized the reinstatement of the DRIP. See Note 20, Subsequent Events — Reinstatement of the DRIP, for a further discussion.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

Since April 6, 2018, our board has approved and established an estimated per share net asset value, or NAV, on at least an annual basis. Commencing with the distribution payment to stockholders paid in the month following such board approval, shares of our common stock issued pursuant the DRIP were or will be issued at the current estimated per share NAV until such time as our board determines an updated estimated per share NAV.

For the three months ended ~~June~~September 30, 2021, ~~and~~there were no distributions reinvested or shares issued due to the suspension of the DRIP. For the three months ended September 30, 2020, ~~$1,393,000 and $4,997,000, respectively,~~$4,247,000 in distributions were reinvested and ~~151,142 and 523,736~~445,239 shares of our common stock ~~respectively,~~ were issued pursuant to our DRIP Offerings. For the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, $5,499,000 and ~~$11,434,000,~~$15,681,000, respectively, in distributions were reinvested, and 581,491 and ~~1,198,492~~1,643,731 shares of our common stock, respectively, were issued pursuant to our DRIP Offerings. As of ~~June~~September 30, 2021 and December 31, 2020, a total of $77,991,000 and $72,492,000, respectively, in distributions were cumulatively reinvested that resulted in 8,177,085 and 7,595,594 shares of our common stock, respectively, being issued pursuant to our DRIP Offerings.

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

Share Repurchase Plan

Due to the impact the COVID-19 pandemic has had on the United States and globally, and the ongoing uncertainty of the severity and duration of the COVID-19 pandemic and its effects, beginning in March 2020, our board decided to take steps to protect our capital and maximize our liquidity in an effort to strengthen our long-term financial prospects. As a result, on March 31, 2020, our board suspended our share repurchase plan with respect to all repurchase requests other than repurchases resulting from the death or qualifying disability of stockholders, beginning with share repurchase requests submitted for repurchase during the second quarter of 2020. Repurchase requests resulting from the death or qualifying disability of stockholders were not suspended, but remained subject to all terms and conditions of our share repurchase plan, including our board’s discretion to determine whether we have sufficient funds available to repurchase any shares. In connection with our special committee’s strategic alternative review process and in order to facilitate a strategic transaction, on March 18, 2021, our board approved the suspension of our share repurchase plan with respect to all repurchase requests received by us after February 28, 2021, including repurchases resulting from the death or qualifying disability of ~~stockholders, until such time, if any, as~~stockholders. On October 4, 2021, our board ~~determines to reinstate~~authorized the partial reinstatement of our share repurchase plan. See Note 20, Subsequent Events — Amendments to and Partial Reinstatement of Share Repurchase Plan, for a further discussion.

~~Prior to its suspension, our~~Our share repurchase plan ~~allowed~~allows for repurchases of shares of our common stock by us when certain criteria ~~were~~are met. Share repurchases ~~were~~will be made at the sole discretion of our board. Subject to the availability of the funds for share repurchases, we ~~generally limited~~will limit the number of shares of our common stock repurchased during any calendar year to 5.0% of the weighted average number of shares of our common stock outstanding during the prior calendar year; provided, however, that shares subject to a repurchase requested upon the death of a stockholder ~~were~~are not subject to this cap. Funds for the repurchase of shares of our common stock ~~came~~come exclusively from the cumulative proceeds we ~~received~~receive from the sale of shares of our common stock pursuant to our DRIP Offerings.

During our initial offering and with respect to shares repurchased for the quarter ended March 31, 2019, the repurchase amount for shares repurchased under our share repurchase plan was equal to the lesser of (i) the amount per share that a stockholder paid for their shares of our common stock, or (ii) the per share offering price in our initial offering. Commencing with shares repurchased for the quarter ended June 30, 2019, ~~and through the suspension of the share repurchase plan as described above,~~ the repurchase amount for shares repurchased under our share repurchase plan ~~was~~is the lesser of (i) the amount per share the stockholder paid for their shares of our common stock, or (ii) the most recent estimated value of one share of the applicable class of common stock as determined by our board. However, if shares of our common stock were repurchased in connection with a stockholder’s death or qualifying disability, the repurchase price was no less than 100% of the price paid to acquire the shares of our common stock from us. On October 4, 2021, we amended and restated our share repurchase plan to change the repurchase price with respect to repurchases resulting from the death or qualifying disability of stockholders. See Note 20, Subsequent Events — Amendments to and Partial Reinstatement of Share Repurchase Plan, for a further discussion.

For the three months ended ~~June~~September 30, 2021, ~~and 2020,~~ we ~~repurchased 117,228 and 506,560~~did not repurchase any shares of our common stock ~~respectively,~~due to the suspension of our share repurchase plan. For the three months ended September 30, 2020, we repurchased 71,551 shares of our common stock for an aggregate of ~~$1,160,000 and $4,643,000, respectively,~~$706,000 at an average repurchase price of ~~$9.89 and $9.17~~$9.87 per ~~share, respectively.~~share. For the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, we repurchased 189,567 and ~~506,560~~578,111 shares of our common stock, respectively, for an aggregate of $1,874,000 and ~~$4,643,000,~~$5,349,000, respectively, at an average repurchase price of $9.88 and ~~$9.17~~$9.25 per share, respectively. As of ~~June~~September 30, 2021 and December 31, 2020, we cumulatively repurchased 2,211,338 and 2,021,771 shares of our common stock, respectively, for an aggregate of $20,744,000 and $18,870,000, respectively, at an average repurchase price of $9.38 and $9.33 per share, respectively. All shares were repurchased using the cumulative proceeds we received from the sale of shares of our common stock pursuant to our DRIP Offerings.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

Noncontrolling Interest

In connection with our acquisition of Louisiana Senior Housing Portfolio on January 3, 2020, as of both ~~June~~September 30, 2021 and December 31, 2020, we owned an approximate 90.0% interest in our consolidated joint venture that owns such properties. As such, 10.0% of the net earnings of the joint venture were allocated to noncontrolling interests in our accompanying condensed consolidated statements of operations for the three and ~~six~~nine months ended ~~June~~September 30, 2021 and for the period from January 3, 2020 through ~~June~~September 30, 2020, and the carrying amount of such noncontrolling interest is presented in total equity in our accompanying condensed consolidated balance sheets as of ~~June~~September 30, 2021 and December 31, 2020.

13. Related Party Transactions

Fees and Expenses Paid to Affiliates

~~All~~As of September 30, 2021, all of our executive officers and one of our non-independent directors ~~are~~were also executive officers and employees and/or holders of a direct or indirect interest in our advisor, one of our co-sponsors or other affiliated entities. We ~~are~~were affiliated with our advisor, American Healthcare Investors and AHI Group Holdings; however, we ~~are~~were not affiliated with Griffin Capital, our dealer manager, Digital Bridge or Mr. Flaherty. We entered into the Advisory Agreement, as amended, which ~~entitles~~entitled our

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

advisor and its affiliates to specified compensation for certain services, as well as reimbursement of certain expenses. Our board, including a majority of our independent directors, ~~has~~ reviewed the material transactions between our affiliates and us during the ~~six~~nine months ended ~~June~~September 30, 2021. We believe that we have executed all of the transactions set forth below on terms that are fair and reasonable to us and on terms no less favorable to us than those available from unaffiliated third parties.

Fees and expenses to our affiliates incurred for the three and ~~six~~nine months ended ~~June~~September 30, 2021 and 2020 were as follows:


		Three Months Ended June 30,				Six Months Ended June 30,				Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020				2021		2020		2021		2020
Asset management fees(1)	Asset management fees(1)	$	2,451,000	$	2,435,000	$	4,905,000	$	4,846,000		Asset management fees(1)	$	2,454,000	$	2,446,000	$	7,359,000	$	7,292,000
Lease fees(2)		380,000		86,000		421,000		137,000
Property management fees(3)		376,000		375,000		741,000		724,000
Property management fees(2)											Property management fees(2)	383,000		376,000		1,124,000		1,100,000
Lease fees(3)											Lease fees(3)	211,000		117,000		632,000		254,000
Construction management fees(4)	Construction management fees(4)	39,000		41,000		62,000		64,000			Construction management fees(4)	36,000		12,000		98,000		76,000
Operating expenses(5)	Operating expenses(5)	34,000		42,000		79,000		85,000			Operating expenses(5)	24,000		37,000		103,000		122,000
Development fees(6)	Development fees(6)	31,000		2,000		55,000		2,000			Development fees(6)	19,000		22,000		74,000		24,000
Base acquisition fees and reimbursement of acquisition expenses(7)	Base acquisition fees and reimbursement of acquisition expenses(7)	1,000		34,000		182,000		1,441,000			Base acquisition fees and reimbursement of acquisition expenses(7)	2,000		35,000		184,000		1,476,000
Total	Total	$	3,312,000	$	3,015,000	$	6,445,000	$	7,299,000		Total	$	3,129,000	$	3,045,000	$	9,574,000	$	10,344,000

__________

(1)Asset management fees ~~are~~were included in general and administrative in our accompanying condensed consolidated statements of operations.

(2)Property management fees were included in rental expenses or general and administrative expenses in our accompanying condensed consolidated statements of operations, depending on the property type from which the fee was incurred.

(3)Lease fees ~~are~~were capitalized as costs of entering into new leases and included in other assets, net in our accompanying condensed consolidated balance sheets, and amortized over the term of the lease.

~~(3)~~Property management fees are included in rental expenses or general and administrative expenses in our accompanying condensed consolidated statements of operations, depending on the property type from which the fee was incurred.

(4)Construction management fees ~~are~~were capitalized as part of the associated asset and included in real estate investments, net in our accompanying condensed consolidated balance sheets.

(5)We ~~reimburse~~reimbursed our advisor or its affiliates for operating expenses incurred in rendering services to us, subject to certain limitations. For the 12 months ended ~~June~~September 30, 2021 and 2020, our operating expenses did not exceed such

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

limitations. Operating expenses ~~are~~were generally included in general and administrative in our accompanying condensed consolidated statements of operations.

(6)Development fees ~~are~~were expensed as incurred and included in business acquisition expenses in our accompanying condensed consolidated statements of operations.

(7)Such amounts ~~are~~were capitalized as part of the associated asset and included in real estate investments, net in our accompanying condensed consolidated balance sheets or ~~are~~were expensed as incurred and included in business acquisition expenses in our accompanying condensed consolidated statements of operations, as applicable.

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

Accounts Payable Due to Affiliates

The following amounts were outstanding to our affiliates as of ~~June~~September 30, 2021 and December 31, 2020:


Fee	Fee	June 30, 2021		December 31, 2020		Fee	September 30, 2021		December 31, 2020
Asset management fees		$	816,000	$	814,000
Lease commissions						Lease commissions	$	210,000	$	8,000
Operating expenses						Operating expenses	34,000		10,000
Property management fees	Property management fees	123,000		117,000		Property management fees	32,000		117,000
Construction management fees	Construction management fees	58,000		33,000		Construction management fees	31,000		33,000
Lease commissions		13,000		8,000
Development fees	Development fees	11,000		64,000		Development fees	16,000		64,000
Operating expenses		8,000		10,000
Asset management fees						Asset management fees	1,000		814,000
Total	Total	$	1,029,000	$	1,046,000	Total	$	324,000	$	1,046,000

14. Fair Value Measurements

Assets and Liabilities Reported at Fair Value

The table below presents our assets and liabilities measured at fair value on a recurring basis as of ~~June~~September 30, 2021, aggregated by the level in the fair value hierarchy within which those measurements fall:


		Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total			Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Liabilities:	Liabilities:									Liabilities:
Derivative financial instruments	Derivative financial instruments	$	0	$	2,338,000	$	0	$	2,338,000	Derivative financial instruments	$	—	$	824,000	$	—	$	824,000

The table below presents our assets and liabilities measured at fair value on a recurring basis as of December 31, 2020, aggregated by the level in the fair value hierarchy within which those measurements fall:


		Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total			Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Liabilities:	Liabilities:									Liabilities:
Derivative financial instruments	Derivative financial instruments	$	0	$	5,255,000	$	0	$	5,255,000	Derivative financial instruments	$	—	$	5,255,000	$	—	$	5,255,000

There were no transfers into or out of fair value measurement levels during the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020.

We use interest rate swaps to manage interest rate risk associated with variable-rate debt. The valuation of these instruments is determined using widely accepted valuation techniques including a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves, as well as option volatility. The fair values of interest rate swaps are determined by netting the discounted future fixed cash payments and the discounted expected variable

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

cash receipts. The variable cash receipts are based on an expectation of future interest rates derived from observable market interest rate curves.

We incorporate credit valuation adjustments to appropriately reflect both our own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as collateral postings, thresholds, mutual puts and guarantees.

Although we have determined that the majority of the inputs used to value our derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with these instruments utilize Level 3 inputs,

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

such as estimates of current credit spreads, to evaluate the likelihood of default by us and our counterparty. However, as of ~~June~~September 30, 2021, we have assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our derivative positions and have determined that the credit valuation adjustments are not significant to the overall valuation of our derivatives. As a result, we have determined that our derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Financial Instruments Disclosed at Fair Value

Our accompanying condensed consolidated balance sheets include the following financial instruments: cash and cash equivalents, restricted cash, accounts and other receivables, ~~restricted cash,~~ accounts payable and accrued liabilities, accounts payable due to affiliates, mortgage loans payable and borrowings under the 2018 Credit Facility.

We consider the carrying values of cash and cash equivalents, restricted cash, accounts and other receivables ~~restricted cash~~ and accounts payable and accrued liabilities to approximate the fair values for these financial instruments based upon the short period of time between origination of the instruments and their expected realization. The fair value of accounts payable due to affiliates is not determinable due to the related party nature of the accounts payable. These financial assets and liabilities are measured at fair value on a recurring basis based on quoted prices in active markets for identical assets and liabilities, and therefore are classified as Level 1 in the fair value hierarchy.

The fair values of our mortgage loans payable and the 2018 Credit Facility are estimated using discounted cash flow analyses using borrowing rates available to us for debt instruments with similar terms and maturities. We have determined that our mortgage loans payable and the 2018 Credit Facility are classified in Level 2 within the fair value hierarchy as reliance is placed on inputs other than quoted prices that are observable, such as interest rates and yield curves. The carrying amounts and estimated fair values of such financial instruments as of ~~June~~September 30, 2021 and December 31, 2020 were as follows:


		June 30, 2021				December 31, 2020					September 30, 2021				December 31, 2020
		Carrying Amount(1)		Fair Value		Carrying Amount(1)		Fair Value			Carrying Amount(1)		Fair Value		Carrying Amount(1)		Fair Value

Financial Liabilities:	Financial Liabilities:									Financial Liabilities:
Mortgage loans payable	Mortgage loans payable	$	17,572,000	$	20,970,000	$	17,827,000	$	22,052,000	Mortgage loans payable	$	17,409,000	$	20,891,000	$	17,827,000	$	22,052,000
Line of credit and term loans	Line of credit and term loans	$	482,117,000	$	482,931,000	$	475,176,000	$	477,651,000	Line of credit and term loans	$	488,587,000	$	488,995,000	$	475,176,000	$	477,651,000

___________

(1)Carrying amount is net of any discount/premium and deferred financing costs.

15. Income Taxes

As a REIT, we generally will not be subject to federal income tax on taxable income that we distribute to our stockholders. We have elected to treat certain of our consolidated subsidiaries as taxable REIT subsidiaries, or TRS, pursuant to the Code. TRS may participate in services that would otherwise be considered impermissible for REITs and are subject to federal and state income tax at regular corporate tax rates.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

The components of income tax benefit or expense for the three and ~~six~~nine months ended ~~June~~September 30, 2021 and 2020 were as follows:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			2021		2020		2021		2020
Federal deferred	Federal deferred	$	(679,000)	$	(1,000,000)	$	(1,803,000)	$	(1,271,000)	Federal deferred	$	(914,000)	$	(863,000)	$	(2,717,000)	$	(2,134,000)
State deferred	State deferred	(193,000)		(301,000)		(559,000)		(394,000)		State deferred	(232,000)		(327,000)		(791,000)		(721,000)
Federal current	Federal current	0		37,000		0		37,000		Federal current	—		(37,000)		—		—
State current	State current	0		2,000		0		2,000		State current	—		(2,000)		—		—
Valuation allowance	Valuation allowance	872,000		1,301,000		2,362,000		1,665,000		Valuation allowance	1,146,000		1,190,000		3,508,000		2,855,000
Total income tax expense		$	0	$	39,000	$	0	$	39,000
Total income tax benefit										Total income tax benefit	$	—	$	(39,000)	$	—	$	—

Current Income Tax

Federal and state income taxes are generally a function of the level of income recognized by our TRS.

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

Deferred Taxes

Deferred income tax is generally a function of the period’s temporary differences (primarily basis differences between tax and financial reporting for real estate assets and equity investments) and generation of tax net operating losses that may be realized in future periods depending on sufficient taxable income.

We recognize the financial statement effects of an uncertain tax position when it is more likely than not, based on the technical merits of the tax position, that such a position will be sustained upon examination by the relevant tax authorities. If the tax benefit meets the “more likely than not” threshold, the measurement of the tax benefit will be based on our estimate of the ultimate tax benefit to be sustained if audited by the taxing authority. As of both ~~June~~September 30, 2021 and December 31, 2020, we did not have any tax benefits or liabilities for uncertain tax positions that we believe should be recognized in our accompanying condensed consolidated financial statements.

We assess the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A valuation allowance is established if we believe it is more likely than not that all or a portion of the deferred tax assets are not realizable. As of both ~~June~~September 30, 2021 and December 31, 2020, our valuation allowance fully reserves the net deferred tax asset due to inherent uncertainty of future income. We will continue to monitor industry and economic conditions, and our ability to generate taxable income based on our business plan and available tax planning strategies, which would allow us to utilize the tax benefits of the net deferred tax assets and thereby allow us to reverse all, or a portion of, our valuation allowance in the future.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

16. Leases

Lessor

We have operating leases with tenants that expire at various dates through 2040. For the three months ended ~~June~~September 30, 2021 and 2020, we recognized ~~$21,988,000~~$22,120,000 and ~~$21,842,000~~$21,519,000 of real estate revenue, respectively, related to operating lease payments, of which ~~$4,860,000~~$5,013,000 and ~~$4,814,000,~~$4,592,000, respectively, was for variable lease payments. For the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, we recognized ~~$43,934,000~~$66,054,000 and ~~$43,305,000~~$64,824,000 of real estate revenue, respectively, related to operating lease payments, of which ~~$9,804,000~~$14,817,000 and ~~$9,269,000,~~$13,861,000, respectively, was for variable lease payments. As of ~~June~~September 30, 2021, the following table sets forth the undiscounted cash flows for future minimum base rents due under operating leases for the ~~six~~three months ending December 31, 2021 and for each of the next four years ending December 31 and thereafter for the properties that we wholly own:


Year	Year	Amount		Year	Amount
2021	2021	$	32,752,000	2021	$	16,361,000
2022	2022	62,663,000		2022	64,121,000
2023	2023	58,696,000		2023	60,213,000
2024	2024	53,151,000		2024	54,662,000
2025	2025	47,761,000		2025	49,138,000
Thereafter	Thereafter	278,887,000		Thereafter	283,142,000
Total	Total	$	533,910,000	Total	$	527,637,000

Lessee

We have ground lease obligations that generally require fixed annual rental payments and may also include escalation clauses and renewal options. These leases expire at various dates through 2107, excluding extension options. Certain of our lease agreements include rental payments that are adjusted periodically based on the United States Bureau of Labor Statistics’ Consumer Price Index, and may include other variable lease costs (i.e., common area maintenance, property taxes and insurance). Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

~~Table of Contents~~

~~GRIFFIN-AMERICAN HEALTHCARE REIT IV, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)~~

For the three months ended ~~June~~September 30, 2021 and 2020, operating lease costs were ~~$210,000~~$226,000 and ~~$228,000,~~$206,000, respectively, and for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, operating lease costs were ~~$418,000~~$644,000 and ~~$437,000,~~$643,000, respectively, which are included in rental expenses in our accompanying condensed consolidated statements of operations. Such costs also include variable lease costs, which are immaterial. Additional information related to our operating leases for the periods presented below was as follows:


		June 30, 2021		December 31, 2020			September 30, 2021		December 31, 2020
Weighted average remaining lease term (in years)	Weighted average remaining lease term (in years)	79.0		79.5		Weighted average remaining lease term (in years)	78.7		79.5
Weighted average discount rate	Weighted average discount rate	5.74	%	5.74	%	Weighted average discount rate	5.74	%	5.74	%

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

As of ~~June~~September 30, 2021, the following table sets forth the undiscounted cash flows of our scheduled obligations for future minimum payments for the ~~six~~three months ending December 31, 2021 and for each of the next four years ending December 31 and thereafter, as well as the reconciliation of those cash flows to operating lease liabilities on our accompanying condensed consolidated balance sheet:


Year	Year	Amount		Year	Amount
2021	2021	$	306,000	2021	$	213,000
2022	2022	526,000		2022	526,000
2023	2023	530,000		2023	530,000
2024	2024	534,000		2024	534,000
2025	2025	538,000		2025	538,000
Thereafter	Thereafter	46,565,000		Thereafter	46,565,000
Total undiscounted operating lease payments	Total undiscounted operating lease payments	48,999,000		Total undiscounted operating lease payments	48,906,000
Less: interest	Less: interest	39,028,000		Less: interest	38,885,000
Present value of operating lease liabilities	Present value of operating lease liabilities	$	9,971,000	Present value of operating lease liabilities	$	10,021,000

17. Segment Reporting

As of ~~June~~September 30, 2021, we evaluated our business and made resource allocations based on 4 reportable business segments — medical office buildings, senior housing, senior housing — RIDEA and skilled nursing facilities. Our medical office buildings are typically leased to multiple tenants under separate leases, thus requiring active management and responsibility for many of the associated operating expenses (much of which are, or can effectively be, passed through to the tenants). Our senior housing and skilled nursing facilities are primarily single-tenant properties for which we lease the facilities to unaffiliated tenants under triple-net and generally master leases that transfer the obligation for all facility operating costs (including maintenance, repairs, taxes, insurance and capital expenditures) to the tenant. Our senior housing — RIDEA properties include senior housing facilities that are owned and operated utilizing a RIDEA structure.

While we believe that net income (loss), as defined by GAAP, is the most appropriate earnings measurement, we evaluate our segments’ performance based upon segment net operating income, or NOI. We define segment NOI as total revenues and grant income, less rental expenses and property operating expenses, which excludes depreciation and amortization, general and administrative expenses, business acquisition expenses, interest expense, gain or loss on disposition of real estate investments, income or loss from unconsolidated entity, other income and income tax expense for each segment. We believe that segment NOI serves as an appropriate supplemental performance measure to net income (loss) because it allows investors and our management to measure unlevered property-level operating results and to compare our operating results to the operating results of other real estate companies and between periods on a consistent basis.

Interest expense, depreciation and amortization and other expenses not attributable to individual properties are not allocated to individual segments for purposes of assessing segment performance. Non-segment assets primarily consist of corporate assets including our joint venture investment in an unconsolidated entity, cash and cash equivalents, other receivables and other assets not attributable to individual properties.

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

Summary information for the reportable segments during the three and ~~six~~nine months ended ~~June~~September 30, 2021 and 2020 was as follows:


		Medical Office Buildings		Senior Housing — RIDEA		Skilled Nursing Facilities		Senior Housing		Three Months Ended June 30, 2021			Medical Office Buildings		Senior Housing — RIDEA		Skilled Nursing Facilities		Senior Housing		Three Months Ended September 30, 2021
Revenues:	Revenues:											Revenues:
Real estate revenue	Real estate revenue	$	16,805,000	$	—	$	2,991,000	$	2,192,000	$	21,988,000	Real estate revenue	$	16,921,000	$	—	$	2,996,000	$	2,203,000	$	22,120,000
Resident fees and services	Resident fees and services	—		15,194,000		—		—		15,194,000		Resident fees and services	—		15,090,000		—		—		15,090,000
Total revenues	Total revenues	16,805,000		15,194,000		2,991,000		2,192,000		37,182,000		Total revenues	16,921,000		15,090,000		2,996,000		2,203,000		37,210,000
Expenses:	Expenses:											Expenses:
Rental expenses	Rental expenses	5,726,000		—		180,000		223,000		6,129,000		Rental expenses	6,072,000		—		145,000		172,000		6,389,000
Property operating expenses	Property operating expenses	—		14,445,000		—		—		14,445,000		Property operating expenses	—		14,540,000		—		—		14,540,000
Segment net operating income	Segment net operating income	$	11,079,000	$	749,000	$	2,811,000	$	1,969,000	$	16,608,000	Segment net operating income	$	10,849,000	$	550,000	$	2,851,000	$	2,031,000	$	16,281,000
Expenses:	Expenses:											Expenses:
General and administrative	General and administrative									$	3,659,000	General and administrative									$	4,304,000
Business acquisition expenses	Business acquisition expenses									2,438,000		Business acquisition expenses									3,800,000
Depreciation and amortization	Depreciation and amortization									10,597,000		Depreciation and amortization									10,746,000
Other income (expense):	Other income (expense):											Other income (expense):
Interest expense:	Interest expense:											Interest expense:
Interest expense (including amortization of deferred financing costs and debt discount/premium)	Interest expense (including amortization of deferred financing costs and debt discount/premium)									(4,869,000)		Interest expense (including amortization of deferred financing costs and debt discount/premium)									(4,961,000)
Gain in fair value of derivative financial instruments	Gain in fair value of derivative financial instruments									1,462,000		Gain in fair value of derivative financial instruments									1,514,000
Loss on disposition of real estate investments										(199,000)
Loss from unconsolidated entity										(193,000)
Gain on disposition of real estate investments												Gain on disposition of real estate investments									15,000
Income from unconsolidated entity												Income from unconsolidated entity									70,000
Other income	Other income									9,000		Other income									33,000
Total net other expense	Total net other expense									(3,790,000)		Total net other expense									(3,329,000)
Net loss	Net loss									$	(3,876,000)	Net loss									$	(5,898,000)

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)


		Medical Office Buildings		Senior Housing — RIDEA		Skilled Nursing Facilities		Senior Housing		Three Months Ended June 30, 2020			Medical Office Buildings		Senior Housing — RIDEA		Skilled Nursing Facilities		Senior Housing		Three Months Ended September 30, 2020
Revenues:
Revenues and grant income:												Revenues and grant income:
Real estate revenue	Real estate revenue	$	16,575,000	$	—	$	2,993,000	$	2,274,000	$	21,842,000	Real estate revenue	$	16,338,000	$	—	$	2,979,000	$	2,202,000	$	21,519,000
Resident fees and services	Resident fees and services	—		16,834,000		—		—		16,834,000		Resident fees and services	—		18,948,000		—		—		18,948,000
Total revenues		16,575,000		16,834,000		2,993,000		2,274,000		38,676,000
Grant income												Grant income	—		864,000		—		—		864,000
Total revenues and grant income												Total revenues and grant income	16,338,000		19,812,000		2,979,000		2,202,000		41,331,000
Expenses:	Expenses:											Expenses:
Rental expenses	Rental expenses	5,619,000		—		182,000		195,000		5,996,000		Rental expenses	5,607,000		—		125,000		173,000		5,905,000
Property operating expenses	Property operating expenses	—		14,442,000		—		—		14,442,000		Property operating expenses	—		17,397,000		—		—		17,397,000
Segment net operating income	Segment net operating income	$	10,956,000	$	2,392,000	$	2,811,000	$	2,079,000	$	18,238,000	Segment net operating income	$	10,731,000	$	2,415,000	$	2,854,000	$	2,029,000	$	18,029,000
Expenses:	Expenses:											Expenses:
General and administrative	General and administrative									$	3,840,000	General and administrative									$	3,672,000
Business acquisition expenses	Business acquisition expenses									8,000		Business acquisition expenses									57,000
Depreciation and amortization	Depreciation and amortization									12,720,000		Depreciation and amortization									12,669,000
Other income (expense):	Other income (expense):											Other income (expense):
Interest expense:	Interest expense:											Interest expense:
Interest expense (including amortization of deferred financing costs and debt discount/premium)	Interest expense (including amortization of deferred financing costs and debt discount/premium)									(4,974,000)		Interest expense (including amortization of deferred financing costs and debt discount/premium)									(4,839,000)
Gain in fair value of derivative financial instruments	Gain in fair value of derivative financial instruments									853,000		Gain in fair value of derivative financial instruments									1,450,000
Income from unconsolidated entity										1,074,000
Impairment of real estate investments												Impairment of real estate investments									(3,064,000)
Loss from unconsolidated entity												Loss from unconsolidated entity									(377,000)
Other income	Other income									261,000		Other income									8,000
Total net other expense	Total net other expense									(2,786,000)		Total net other expense									(6,822,000)
Loss before income taxes	Loss before income taxes									(1,116,000)		Loss before income taxes									(5,191,000)
Income tax expense										(39,000)
Income tax benefit												Income tax benefit									39,000
Net loss	Net loss									$	(1,155,000)	Net loss									$	(5,152,000)

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)


		Medical Office Buildings		Senior Housing — RIDEA		Skilled Nursing Facilities		Senior Housing		Six Months Ended June 30, 2021			Medical Office Buildings		Senior Housing — RIDEA		Skilled Nursing Facilities		Senior Housing		Nine Months Ended September 30, 2021
Revenues:	Revenues:											Revenues:
Real estate revenue	Real estate revenue	$	33,557,000	$	—	$	5,991,000	$	4,386,000	$	43,934,000	Real estate revenue	$	50,478,000	$	—	$	8,987,000	$	6,589,000	$	66,054,000
Resident fees and services	Resident fees and services	—		31,089,000		—		—		31,089,000		Resident fees and services	—		46,179,000		—		—		46,179,000
Total revenues	Total revenues	33,557,000		31,089,000		5,991,000		4,386,000		75,023,000		Total revenues	50,478,000		46,179,000		8,987,000		6,589,000		112,233,000
Expenses:	Expenses:											Expenses:
Rental expenses	Rental expenses	11,431,000		—		325,000		397,000		12,153,000		Rental expenses	17,503,000		—		470,000		569,000		18,542,000
Property operating expenses	Property operating expenses	—		29,639,000		—		—		29,639,000		Property operating expenses	—		44,179,000		—		—		44,179,000
Segment net operating income	Segment net operating income	$	22,126,000	$	1,450,000	$	5,666,000	$	3,989,000	$	33,231,000	Segment net operating income	$	32,975,000	$	2,000,000	$	8,517,000	$	6,020,000	$	49,512,000
Expenses:	Expenses:											Expenses:
General and administrative	General and administrative									$	7,406,000	General and administrative									$	11,710,000
Business acquisition expenses	Business acquisition expenses									2,752,000		Business acquisition expenses									6,552,000
Depreciation and amortization	Depreciation and amortization									22,999,000		Depreciation and amortization									33,745,000
Other income (expense):	Other income (expense):											Other income (expense):
Interest expense:	Interest expense:											Interest expense:
Interest expense (including amortization of deferred financing costs and debt discount/premium)	Interest expense (including amortization of deferred financing costs and debt discount/premium)									(9,595,000)		Interest expense (including amortization of deferred financing costs and debt discount/premium)									(14,556,000)
Gain in fair value of derivative financial instruments	Gain in fair value of derivative financial instruments									2,917,000		Gain in fair value of derivative financial instruments									4,431,000
Loss on disposition of real estate investments	Loss on disposition of real estate investments									(199,000)		Loss on disposition of real estate investments									(184,000)
Loss from unconsolidated entity	Loss from unconsolidated entity									(1,097,000)		Loss from unconsolidated entity									(1,027,000)
Other income	Other income									16,000		Other income									49,000
Total net other expense	Total net other expense									(7,958,000)		Total net other expense									(11,287,000)
Net loss	Net loss									$	(7,884,000)	Net loss									$	(13,782,000)

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)


		Medical Office Buildings		Senior Housing — RIDEA		Skilled Nursing Facilities		Senior Housing		Six Months Ended June 30, 2020			Medical Office Buildings		Senior Housing — RIDEA		Skilled Nursing Facilities		Senior Housing		Nine Months Ended September 30, 2020
Revenues:
Revenues and grant income:												Revenues and grant income:
Real estate revenue	Real estate revenue	$	32,846,000	$	—	$	6,005,000	$	4,454,000	$	43,305,000	Real estate revenue	$	49,184,000	$	—	$	8,984,000	$	6,656,000	$	64,824,000
Resident fees and services	Resident fees and services	—		32,915,000		—		—		32,915,000		Resident fees and services	—		51,863,000		—		—		51,863,000
Total revenues		32,846,000		32,915,000		6,005,000		4,454,000		76,220,000
Grant income												Grant income	—		864,000		—		—		864,000
Total revenues and grant income												Total revenues and grant income	49,184,000		52,727,000		8,984,000		6,656,000		117,551,000
Expenses:	Expenses:											Expenses:
Rental expenses	Rental expenses	11,009,000		—		334,000		475,000		11,818,000		Rental expenses	16,616,000		—		459,000		648,000		17,723,000
Property operating expenses	Property operating expenses	—		27,459,000		—		—		27,459,000		Property operating expenses	—		44,856,000		—		—		44,856,000
Segment net operating income	Segment net operating income	$	21,837,000	$	5,456,000	$	5,671,000	$	3,979,000	$	36,943,000	Segment net operating income	$	32,568,000	$	7,871,000	$	8,525,000	$	6,008,000	$	54,972,000
Expenses:	Expenses:											Expenses:
General and administrative	General and administrative									$	8,288,000	General and administrative									$	11,960,000
Business acquisition expenses	Business acquisition expenses									17,000		Business acquisition expenses									74,000
Depreciation and amortization	Depreciation and amortization									25,250,000		Depreciation and amortization									37,919,000
Other income (expense):	Other income (expense):											Other income (expense):
Interest expense:	Interest expense:											Interest expense:
Interest expense (including amortization of deferred financing costs and debt discount/premium)	Interest expense (including amortization of deferred financing costs and debt discount/premium)									(10,284,000)		Interest expense (including amortization of deferred financing costs and debt discount/premium)									(15,123,000)
Loss in fair value of derivative financial instruments	Loss in fair value of derivative financial instruments									(3,752,000)		Loss in fair value of derivative financial instruments									(2,302,000)
Impairment of real estate investments												Impairment of real estate investments									(3,064,000)
Income from unconsolidated entity	Income from unconsolidated entity									1,329,000		Income from unconsolidated entity									952,000
Other income	Other income									270,000		Other income									278,000
Total net other expense	Total net other expense									(12,437,000)		Total net other expense									(19,259,000)
Loss before income taxes										(9,049,000)
Income tax expense										(39,000)
Net loss	Net loss									$	(9,088,000)	Net loss									$	(14,240,000)

Assets by reportable segment as of ~~June~~September 30, 2021 and December 31, 2020 were as follows:


		June 30, 2021		December 31, 2020			September 30, 2021		December 31, 2020
Medical office buildings	Medical office buildings	$	577,845,000	$	583,131,000	Medical office buildings	$	570,415,000	$	583,131,000
Senior housing — RIDEA	Senior housing — RIDEA	232,223,000		238,910,000		Senior housing — RIDEA	227,978,000		238,910,000
Skilled nursing facilities	Skilled nursing facilities	117,801,000		119,247,000		Skilled nursing facilities	115,565,000		119,247,000
Senior housing	Senior housing	98,505,000		100,370,000		Senior housing	97,243,000		100,370,000
Other	Other	49,407,000		51,115,000		Other	52,695,000		51,115,000
Total assets	Total assets	$	1,075,781,000	$	1,092,773,000	Total assets	$	1,063,896,000	$	1,092,773,000

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

18. Concentration of Credit Risk

Financial instruments that potentially subject us to a concentration of credit risk are primarily cash and cash equivalents, restricted cash and accounts and other ~~receivables and restricted cash.~~receivables. Cash and cash equivalents are generally invested in investment-grade, short-term instruments with a maturity of three months or less when purchased. We have cash and cash equivalents in financial institutions that are insured by the Federal Deposit Insurance Corporation, or FDIC. As of ~~June~~September 30, 2021 and December 31, 2020, we had cash and cash equivalents in excess of FDIC insured limits. We believe this risk is not significant. Concentration of credit risk with respect to accounts receivable from tenants is limited. In general, we perform credit evaluations of prospective tenants and security deposits are obtained at the time of property acquisition and upon lease execution.

Based on leases in effect as of ~~June~~September 30, 2021, 2 states in the United States accounted for 10.0% or more of our total property portfolio’s annualized base rent or annualized NOI. Our properties located in Missouri and Michigan accounted for approximately ~~12.2%~~12.4% and ~~10.4%~~10.6%, respectively, of our total property portfolio’s annualized base rent or annualized NOI. Accordingly, there is a geographic concentration of risk subject to fluctuations in each state’s economy.

Based on leases in effect as of ~~June~~September 30, 2021, our 4 reportable business segments, medical office buildings, skilled nursing facilities, senior housing and senior housing — RIDEA, accounted for ~~67.2%~~68.9%, ~~14.6%~~14.9%, ~~10.4%~~10.7% and ~~7.8%~~5.5%, respectively, of our total property portfolio’s annualized base rent or annualized NOI.

As of ~~June~~September 30, 2021, we had 1 tenant that accounted for 10.0% or more of our total property portfolio’s annualized base rent or annualized NOI, as follows:

Tenant

Annualized
Base Rent/
NOI(1)

Percentage of
Annualized
Base Rent/NOI

Real Estate Investment

Reportable
Segment

GLA
(Sq Ft)

Lease Expiration
Date

Tenant

Annualized
Base Rent/
NOI(1)

Percentage of
Annualized
Base Rent/NOI

Real Estate Investment

Reportable
Segment

GLA
(Sq Ft)

Lease Expiration
Date

RC Tier Properties, LLC

7,937,000

11.1%

Missouri SNF Portfolio

Skilled Nursing

385,000

09/30/33

RC Tier Properties, LLC

7,937,000

11.3%

Missouri SNF Portfolio

Skilled Nursing

385,000

09/30/33

___________

(1)Amount is based on contractual base rent from leases in effect as of ~~June~~September 30, 2021 for our non–RIDEA properties and annualized NOI for our senior housing — RIDEA facilities. The loss of this tenant or its inability to pay rent could have a material adverse effect on our business and results of operations.

19. Per Share Data

Basic earnings (loss) per share for all periods presented are computed by dividing net income (loss) applicable to common stock by the weighted average number of shares of our common stock outstanding during the period. Net income (loss) applicable to common stock is calculated as net income (loss) attributable to controlling interest less distributions allocated to participating securities of ~~$5,000~~$3,000 and $4,000, respectively, for the three months ended ~~June~~September 30, 2021 and 2020 and ~~$9,000~~$12,000 and ~~$11,000,~~$15,000, respectively, for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020. Diluted earnings (loss) per share are computed based on the weighted average number of shares of our common stock and all potentially dilutive securities, if any. Nonvested shares of our restricted common stock and redeemable limited partnership units of our operating partnership are participating securities and give rise to potentially dilutive shares of our common stock. As of ~~June~~September 30, 2021 and 2020, there were ~~39,000~~27,000 and ~~42,000~~45,000 nonvested shares, respectively, of our restricted common stock outstanding, but such shares were excluded from the computation of diluted earnings per share because such shares were anti-dilutive during these periods. As of both ~~June~~September 30, 2021 and 2020, there were 208 redeemable limited partnership units of our operating partnership outstanding, but such units were excluded from the computation of diluted earnings per share because such units were anti-dilutive during these periods.

~~20. Subsequent Events~~

~~Registration Statement on Form S-4~~

In connection with the Merger, on July 16, 2021, we filed with the SEC a registration statement on Form S-4 (File No. 333-257974), or the Form S-4, that contains a joint proxy statement/prospectus for purposes of the Securities Act of 1933, as amended, with respect to the approval of the Merger and other ancillary agreements in connection therewith by our stockholders and the GAHR III stockholders, as well as the issuance of up to 179,658,356 shares of our Class I common stock to GAHR III stockholders in exchange for shares of GAHR III common stock pursuant to the Merger Agreement. The Form S-4 was declared effective by the SEC on July 30, 2021.

Table of Contents

~~GRIFFIN-AMERICAN~~AMERICAN HEALTHCARE REIT, ~~IV,~~ INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

20. Subsequent Events

Merger with Griffin-American Healthcare REIT III, Inc. and AHI Acquisition

As discussed in Note 1, Organization and Description of Business, on October 1, 2021, we completed the REIT Merger pursuant to the Merger Agreement with GAHR III. At the effective time of the REIT Merger, each issued and outstanding share of GAHR III’s common stock, $0.01 par value per share, converted into the right to receive 0.9266 shares of our Class I common stock, $0.01 par value per share. Further, at the effective time of the Partnership Merger, (i) each unit of limited partnership interest in the surviving partnership outstanding as of immediately prior to the effective time of the Partnership Merger was converted automatically into the right to receive 0.9266 of a Partnership Class I Unit, as defined in the agreement of limited partnership, as amended, of the surviving partnership and (ii) each unit of limited partnership interest in our operating partnership outstanding as of immediately prior to the effective time of the Partnership Merger was converted automatically into the right to receive one unit of limited partnership interest of the surviving partnership of like class.

Also on October 1, 2021, the AHI Acquisition closed immediately prior to the consummation of the Merger and pursuant to the Contribution Agreement, American Healthcare Investors contributed substantially all of its business and operations to the surviving partnership, including its interest in GAHR III Advisor and our advisor, and Griffin Capital contributed its current ownership interest in GAHR III Advisor and our advisor to the surviving partnership. In exchange for these contributions, the surviving partnership issued limited partnership units, or Surviving Partnership OP Units. Subject to working capital and other customary adjustments, the total approximate value of these Surviving Partnership OP Units at the time of consummation of the transactions contemplated by the Contribution Agreement was approximately $131,674,000, with a reference value for purposes thereof of $8.71 per unit, such that the surviving partnership issued 15,117,529 Surviving Partnership OP Units as consideration, or the Closing Date Consideration. The Combined Company following the Merger has become self-managed and was named “American Healthcare REIT, Inc.”

In addition to the Closing Date Consideration, we may in the future pay cash “earnout” consideration to American Healthcare Investors based on the fees that we may earn from our potential sponsorship of, and investment advisory services rendered to, American Healthcare RE Fund, L.P., a healthcare-related, real-estate-focused, private investment fund currently under consideration by American Healthcare Investors, or the Earnout Consideration. The Earnout Consideration is uncapped in amount and, if ever payable by us to American Healthcare Investors, will be due on the seventh anniversary of the closing of the AHI Acquisition (subject to acceleration in certain events, including if we achieve certain fee-generation milestones from our sponsorship of the private investment fund). American Healthcare Investors’ ability to receive the Earnout Consideration is also subject to vesting conditions relating to the private investment fund’s deployed equity capital and the continuous employment of at least two of its principals throughout the vesting period.

Amendments to Articles of Incorporation

On October 1, 2021, we filed the Fourth Articles of Amendment and Restatement to our charter, or the Charter Amendment, with the State Department of Assessments and Taxation of Maryland, and the Charter Amendment became effective upon filing. The changes to the Charter Amendment include, among other things, the following: (i) the removal of certain limitations relating to (a) suitability of stockholders and (b) collection of an internalization fee; (ii) the removal or revision of certain limitations required by the North American Securities Administrators Association and making other conforming and ministerial changes; (iii) revisions in order to bring our charter more in line with those of publicly-listed companies; and (iv) the change in common stock we are authorized to issue from 900,000,000 shares classified as Class T common stock and 100,000,000 shares classified as Class I common stock to 200,000,000 shares classified as Class T common stock and 800,000,000 shares classified as Class I common stock.

Second Amended and Restated Agreement of Limited Partnership

On October 1, 2021, in connection with the Partnership Merger, merger sub entered into the Second Amended and Restated Agreement of Limited Partnership of American Healthcare REIT, Inc., which amends and supersedes the Amended and Restated Agreement of Limited Partnership of the surviving partnership, or the Operating Partnership Agreement. The Operating Partnership Agreement reflects, among other things, the following: (i) the change of the surviving partnership’s name to “American Healthcare REIT Holdings, LP,” (ii) the change of the general partner of the surviving partnership to merger sub, (iii) the conversion of units of partnership interest in the surviving partnership outstanding as of immediately prior to the effective time of the Partnership Merger into “Partnership Class I Units” pursuant to the Partnership Merger, (iv) the conversion of units of partnership interest in our operating partnership outstanding as of immediately prior to the effective time of the Partnership Merger into units of limited partnership interest of the surviving partnership of like class, and (v) to make other updates to reflect the effects of the mergers consummated pursuant to the Merger Agreement.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

Lines of Credit and Term Loans

Amendment to 2018 Credit Facility

On October 1, 2021, we entered into the Amendment, which provide for, among other things, the following: (i) revisions to financial covenant calculations to exclude the assets, liabilities and operating performance of Trilogy or any subsidiary thereof; (ii) our operating partnership to pledge the equity interests in each direct and indirect subsidiary that owns an unencumbered asset; (iii) updates regarding restrictions and limitations on certain investments during the remainder of the term of the 2018 Credit Facility; and (iv) updates to the certain financial covenants to reflect the Combined Company subsequent to the Merger.

Assumption of Obligations Under GAHR III 2019 Corporate Line of Credit

On October 1, 2021, upon consummation of the Merger, we assumed GAHR III’s obligations, through the surviving partnership, under the credit agreement, as amended, or the 2019 Corporate Credit Agreement, with Bank of America, KeyBank, Citizens Bank, and a syndicate of other banks, as lenders, with respect to a credit facility with a maximum principal amount of $480,000,000, or the 2019 Corporate Line of Credit. The 2019 Corporate Line of Credit consists of a senior unsecured term loan facility in an amount of $480,000,000. The maximum principal amount of term loans under the 2019 Corporate Line of Credit may be increased by up to $370,000,000, for a total principal amount of $850,000,000, subject to certain conditions. The 2019 Corporate Line of Credit matures on January 25, 2022 and may be extended for 1 12-month period during the term of the 2019 Corporate Credit Agreement, subject to satisfaction of certain conditions, including payment of an extension fee. Upon consummation of the Merger, a previously available $150,000,000 senior unsecured revolving credit facility was cancelled, and a ratable amendment to certain financial covenants to account for the Combined Company was made.

At our option, the 2019 Corporate Line of Credit bears interest at per annum rates equal to (a) (i) the Eurodollar Rate, as defined in the 2019 Corporate Credit Agreement, plus (ii) a margin ranging from 1.85% to 2.80% based on the Consolidated Leverage Ratio, as defined in the 2019 Corporate Credit Agreement, or (b) (i) the greater of: (1) the prime rate publicly announced by Bank of America, (2) the Federal Funds Rate, as defined in the 2019 Corporate Credit Agreement, plus 0.50%, (3) the one-month Eurodollar Rate plus 1.00%, and (4) 0.00%, plus (ii) a margin ranging from 0.85% to 1.80% based on the Consolidated Leverage Ratio. Accrued interest on the 2019 Corporate Line of Credit is payable monthly. The loans may be repaid in whole or in part without prepayment premium or penalty, subject to certain conditions.

Assumption of GAHR III Obligations Under 2019 Trilogy Credit Facility

On October 1, 2021, upon consummation of the Merger, we assumed GAHR III’s obligations under the amended and restated loan agreement, or the 2019 Trilogy Credit Agreement, with KeyBank; CIT Bank, N.A.; Regions Bank; KeyBanc Capital Markets; Regions Capital Markets; Bank of America; The Huntington National Bank; and a syndicate of other banks, as lenders named therein, regarding a senior secured revolving credit facility with an aggregate maximum principal amount of $360,000,000, consisting of: (i) a $325,000,000 secured revolver supported by real estate assets and ancillary business cash flow and (ii) a $35,000,000 accounts receivable revolving credit facility supported by eligible accounts receivable, or the 2019 Trilogy Credit Facility. We may obtain up to $35,000,000 in the form of swing line loans and up to $15,000,000 in the form of standby letters of credit under the 2019 Trilogy Credit Facility. The proceeds of the 2019 Trilogy Credit Facility may be used for acquisitions, debt repayment and general corporate purposes. The maximum principal amount of the 2019 Trilogy Credit Facility may be increased by up to $140,000,000, for a total principal amount of $500,000,000, subject to certain conditions. The 2019 Trilogy Credit Facility matures on September 5, 2023 and may be extended for 1 12-month period during the term of the 2019 Trilogy Credit Agreement, subject to the satisfaction of certain conditions, including payment of an extension fee.

At our option, the 2019 Trilogy Credit Facility bears interest at per annum rates equal to (a) the London Inter-Bank Offer Rate, or LIBOR, plus 2.75% for LIBOR Rate Loans, as defined in the 2019 Trilogy Credit Agreement, and (b) for Base Rate Loans, as defined in the 2019 Trilogy Credit Agreement, 1.75% plus the greater of: (i) the fluctuating annual rate of interest announced from time to time by KeyBank as its prime rate, (ii) 0.50% above the Federal Funds Effective Rate, as defined in the 2019 Trilogy Credit Agreement, and (iii) 1.00% above the one-month LIBOR. Accrued interest on the 2019 Trilogy Credit Facility is payable monthly. The 2019 Trilogy Credit Facility may be repaid in whole or in part without prepayment fees or penalty, subject to certain conditions. We are required to pay fees on the unused portion of the lenders’ commitments under the 2019 Trilogy Credit Facility, with respect to any day during a calendar quarter, at a per annum rate equal to (a) 0.15% if the sum of the Aggregate Real Estate Revolving Credit Obligations, as defined in the 2019 Trilogy Credit Agreement, outstanding on such day is greater than 50.00% of the commitments or 0.20% if the sum of the Aggregate Real Estate Revolving Credit Obligations on such day is less than or equal to 50.00% of the commitments, and (b) 0.15% if the sum of the Aggregate A/R Revolving Credit Obligations, as defined in the 2019 Trilogy Credit Agreement, outstanding on such day is greater than 50.00% of the commitments or 0.20% if the sum of the Aggregate A/R Revolving Credit Obligations on such day is less than or equal to 50.00% of the commitments, which fees shall be measured and payable on a quarterly basis.

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

Reinstatement of the DRIP

On October 4, 2021, our board reinstated the DRIP and as a result, beginning with the October 2021 distribution, which was paid in November 2021, stockholders who previously enrolled as participants in the DRIP (including former GAHR III stockholders who participated in the GAHR III distribution reinvestment plan) received or will receive distributions in shares of our common stock pursuant to the terms of the DRIP, instead of cash distributions.

Amendments to and Partial Reinstatement of Share Repurchase Plan

On October 4, 2021, our board authorized our amended and restated share repurchase plan that included the change in the repurchase price with respect to repurchases resulting from the death or qualifying disability (as such term is defined in the share repurchase plan) of stockholders from 100% of the price paid by the stockholder to acquire shares of our Class T common stock or Class I common stock, as applicable, to the most recently published estimated NAV per share. In addition, on October 4, 2021, our board authorized the partial reinstatement of our share repurchase plan with respect to requests to repurchase shares resulting from the death or qualifying disability of stockholders, effective with respect to qualifying repurchases for the fiscal quarter ending December 31, 2021, which will be paid on or about January 1, 2022. All share repurchase requests other than those requests resulting from the death or qualifying disability of stockholders, shall be rejected.

Distributions Declared

Our board authorized a daily distribution to our Class T and Class I stockholders of record as of the close of business on ~~each day~~October 27, 2021. This distribution for the month of ~~the period commencing on July 1,~~October 2021 ~~and ending~~ ~~on August 31, 2021. The daily distributions will be calculated based on 365 days in the calendar year and will be~~was equal to ~~$0.001095890~~$0.033333333 per share of our common stock, which is equal to an annualized distribution rate of $0.40 per share. The ~~distributions will be aggregated and~~distribution was paid in cash ~~on a monthly basis,~~or shares of our common stock pursuant to the DRIP. The distribution was paid in ~~August~~ ~~and September 2021,~~November 2021, only from legally available funds.

Director Appointments and Resignation

On October 1, 2021, immediately following the effective time of the REIT Merger, our board was increased from 5 members to 9 members. Our board appointed Harold H. Greene, J. Grayson Sanders and Gerald W. Robinson to our board as independent directors. Messrs. Greene, Sanders and Robinson were independent directors on GAHR III’s board of directors immediately prior to the effective time of the REIT Merger. Our board also appointed Mr. Prosky and Mr. Streiff as directors. On October 1, 2021, Richard S. Welch resigned from our board and no longer serves as our director.

Messrs. Greene, Sanders and Robinson satisfy the independent director standards applicable to us and, as independent directors, are entitled to receive the same compensation and reimbursement of expenses that we pay to each of our independent directors; Messrs. Prosky and Streiff also serve as our executive officers and therefore will not receive compensation for services rendered as directors. We also issued 5,000 shares of restricted Class T common stock to each of Messrs. Greene, Sanders and Robinson in connection with their appointment to our board.

Officer Transitions and Appointments

Effective October 1, 2021, Jeffrey T. Hanson was appointed as our Executive Chairman of the Board of Directors and thereby no longer serves as our Chief Executive Officer. In addition, effective October 1, 2021, Danny Prosky was appointed Chief Executive Officer and thereby no longer serves as our Chief Operating Officer but continues in the role of President, and Mathieu B. Streiff was appointed as our Chief Operating Officer and thereby no longer serves as our Executive Vice President, General Counsel. Also effective October 1, 2021, Gabriel M. Willhite was appointed as our Executive Vice President, General Counsel, filling the vacancy created by Mr. Streiff’s resignation from such position.

Employment Agreements

On October 1, 2021, immediately prior to the closing of the AHI Acquisition, GAHR III (through a wholly owned subsidiary) entered into offer letters with each of Mr. Hanson, Mr. Prosky, Mr. Streiff and Brian S. Peay, GAHR III’s chief financial officer, relating to their employment with GAHR III following the closing of the AHI Acquisition and relating to their employment with us following the consummation of the REIT Merger. Upon the closing of the REIT Merger, we indirectly assumed (by virtue of the REIT Merger and our acquisition of GAHR III’s wholly owned subsidiary that is party to the offer letters) GAHR III’s obligations under these offer letters.

Issuance of Restricted Stock Awards to Key Executives and Employees

As a result of the REIT Merger, under our incentive plan, as amended, or our 2015 Incentive Plan, certain of our key executives received initial grants of 477,901 time-based restricted stock and 159,301 performance-based restricted units representing the right to receive shares of our Class T common stock upon vesting. The time-based restricted stock vest in three equal annual installments on October 1, 2022, October 1, 2023 and October 1, 2024 (subject to continuous employment through

3234

Table of Contents

AMERICAN HEALTHCARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) — (Continued)

each vesting date). The performance-based restricted stock will cliff vest in the first quarter of 2025 (subject to continuous employment through that vesting date) with the amount vesting depending on meeting certain key performance criteria as further described in the 2015 Incentive Plan.

Also in connection with the Merger, on October 4, 2021, certain of our key employees were granted 319,149 of restricted Class T common stock under our 2015 Incentive Plan, which will cliff vest on October 4, 2024 (subject to continuous employment through that vesting date).

Registration Rights Agreement

On October 1, 2021, at the consummation of the AHI Acquisition, GAHR III and the surviving partnership entered into a registration rights agreement, or the Registration Rights Agreement, with Griffin-American Strategic Holdings, LLC, or HoldCo, pursuant to which, subject to certain limitations therein, as promptly as practicable following the later of the expiration of (i) the period commencing on the closing of the AHI Acquisition and ending upon the earliest to occur of (a) the second anniversary date of the issuance of the Surviving Partnership OP Units issued in connection with the AHI Acquisition, (b) a change of control of Merger Sub, and (c) the listing of shares of our common stock on a national securities exchange, or the Lock-Up Period; and (ii) the date on which we are eligible to file a registration statement (but in any event no later than 180 days after such date), we, as the indirect parent company of the surviving partnership, are required to file a shelf registration statement with the SEC under the Securities Act of 1933, as amended, covering the resale of the shares of our Class I common stock issued or issuable in redemption of the Surviving Partnership OP Units that the surviving partnership issued as consideration in the AHI Acquisition. The Registration Rights Agreement also grants HoldCo (or any successor holder of such shares) demand rights to request additional registration statement filings as well as “piggyback” registration rights, in each case on or after the expiration of the Lock-Up Period. In connection with the Merger, we assumed from GAHR III the Registration Rights Agreement and GAHR III’s obligations thereunder in their entirety.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The use of the words “we,” “us” or “our” refers to American Healthcare REIT, Inc. (formerly known as Griffin-American Healthcare REIT IV, Inc.) and its subsidiaries, including Griffin-American Healthcare REIT IV Holdings, LP, except where otherwise noted. Capitalized terms related to ~~a proposed~~the merger with Griffin-American Healthcare REIT III, Inc., or GAHR III, are defined and further discussed below in the ~~“Factors Which May Influence Results of Operations — Proposed Merger with GAHR III”~~“Overview and Background” section.

The following discussion should be read in conjunction with our accompanying condensed consolidated financial statements and notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q and in our 2020 Annual Report on Form 10-K, as filed with the United States Securities and Exchange Commission, or the SEC, on March 26, 2021. Such condensed consolidated financial statements and information have been prepared to reflect our financial position as of ~~June~~September 30, 2021 and December 31, 2020, together with our results of operations for the three and ~~six~~nine months ended ~~June~~September 30, 2021 and 2020 and cash flows for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020.

Forward-Looking Statements

Historical results and trends should not be taken as indicative of future operations. Our statements contained in this report that are not historical facts are forward-looking. Actual results may differ materially from those included in the forward-looking statements. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies and expectations, are generally identifiable by use of the words “expect,” “project,” “may,” “will,” “should,” “could,” ~~��would,~~“would,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “opinion,” “predict,” “potential,” “seek” and any other comparable and derivative terms or the negatives thereof. Our ability to predict results or the actual effect of future plans and strategies is inherently uncertain. Factors which could have a material adverse effect on our operations on a consolidated basis include, but are not limited to: changes in economic conditions generally and the real estate market specifically; the effects of the coronavirus, or COVID-19, pandemic, including its effects on the healthcare industry, senior housing and skilled nursing facilities and the economy in general; legislative and regulatory changes, including changes to laws governing the taxation of real estate investment trusts, or REITs; the availability of capital; changes in interest rates; the risk that the Merger will not be consummated within the expected time period or at all; the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; the inability of GAHR III or us to obtain the approval of the Merger from its or our stockholders or the failure to satisfy the other conditions to completion of the Merger; GAHR III’s inability to consummate the AHI Acquisition, as defined in the “Factors Which May Influence Results of Operations — ~~Proposed Merger with GAHR III” section below;~~ risks related to disruption of management’s attention from the ongoing business operations due to the Merger; uncertainty from the expected discontinuance of the London Inter-bank Offered Rate, or LIBOR, and the transition to any other interest rate benchmark; competition in the real estate industry; changes in accounting principles generally accepted in the United States of America, or GAAP, policies and guidelines applicable to REITs; the success of our investment strategy; and the availability of financing; and our ongoing relationship with American Healthcare Investors, LLC, or American Healthcare Investors, and Griffin Capital Company, LLC, or Griffin Capital, or collectively, our co-sponsors, and their affiliates.financing. These risks and uncertainties should be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. Forward-looking statements in this Quarterly Report on Form 10-Q speak only as of the date on which such statements are made, and undue reliance should not be placed on such statements. We undertake no obligation to update any such statements that may become untrue because of subsequent events. Additional information concerning us and our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Overview and Background

We raised $754,118,000 through a best efforts initial public offering, or our initial offering, that commenced on February 16, 2016, and issued 75,639,681 aggregate shares of our Class T and Class I common stock. In addition, during our initial offering, we issued 3,253,535 aggregate shares of our Class T and Class I common stock pursuant to our distribution reinvestment plan, as amended, or the DRIP, for a total of $31,021,000 in distributions reinvested. Following the termination of our initial offering on February 15, 2019, we continued issuing shares of our common stock pursuant to the DRIP through a subsequent offering, or the 2019 DRIP Offering, which commenced on March 1, 2019. On March 18, 2021, ~~in connection with our special committee’s strategic alternative review process,~~ our board of directors, or our board, authorized the suspension of the DRIP, effective as of April 1, 2021. As of ~~June~~September 30, 2021, a total of $46,970,000 in distributions were reinvested that resulted in 4,923,550 shares of our common stock being issued pursuant to the 2019 DRIP Offering. We collectively refer to the

~~Table of Contents~~

DRIP portion of our initial offering and the 2019 DRIP Offering as our DRIP Offerings. See Note 20, Subsequent Events — Reinstatement of the DRIP, to our accompanying condensed consolidated financial statements.

~~We conduct~~

Table of Contents

Until October 2021, we conducted substantially all of our operations through Griffin-American Healthcare REIT IV Holdings, LP, or our operating partnership. ~~We are~~Through September 30, 2021, we were externally advised by Griffin-American Healthcare REIT IV Advisor, LLC, or our advisor, pursuant to an advisory agreement, as amended, or the Advisory Agreement, between us, our operating partnership and our advisor. The Advisory Agreement was effective as of February 16, 2016 and had a one-year initial term, subject to successive one-year renewals upon the mutual consent of the parties. The Advisory Agreement was last renewed pursuant to the mutual consent of the parties on February 11, 2021. On June 23, 2021, in anticipation of the Merger, as defined and ~~expires on February 16, 2022.~~discussed below, we entered into an amendment to the Advisory Agreement, whereby it was agreed that any acquisition fee due to our advisor is to be waived in connection with the REIT Merger, as defined and discussed below. Except as set forth in such amendment to the Advisory Agreement, the terms of the Advisory Agreement continued in full force and effect. Our advisor ~~uses~~used its best efforts, subject to the oversight and review of our board, to, among other things, provide asset management, property management, acquisition, disposition and other advisory services on our behalf consistent with our investment policies and objectives. Our advisor ~~performs~~performed its duties and responsibilities under the Advisory Agreement as our fiduciary. ~~Our~~Prior to the Merger, our advisor iswas 75.0% owned and managed by wholly owned subsidiaries of American Healthcare Investors, LLC, or American Healthcare Investors, and 25.0% owned by a wholly owned subsidiary of Griffin ~~Capital.~~Capital Company, LLC, or Griffin Capital, or collectively, our co-sponsors. American Healthcare Investors iswas 47.1% owned by AHI Group Holdings, LLC, or AHI Group Holdings, 45.1% indirectly owned by Digital Bridge Group, Inc. (NYSE: DBRG) (formerly known as Colony Capital, Inc.), or Digital Bridge, and 7.8% owned by James F. Flaherty III, a former partner of Colony Capital, Inc. We ~~are~~were not affiliated with Griffin Capital, Griffin Capital Securities, LLC, or our dealer manager, Digital Bridge or Mr. Flaherty; however, we ~~are~~were affiliated with our advisor, American Healthcare Investors and AHI Group Holdings. Please see the “Merger with Griffin-American Healthcare REIT III, Inc.” and “AHI Acquisition” sections below for a further discussion of our operations effective October 1, 2021.

We ~~currently~~ operate through four reportable business segments: medical office buildings, senior housing, senior housing — RIDEA and skilled nursing facilities. As of ~~June~~September 30, 2021, we owned 87 properties, comprising 92 buildings, or approximately 4,799,000 square feet of gross leasable area, or GLA, for an aggregate contract purchase price of $1,080,381,000. As of ~~June~~September 30, 2021, we also owned a 6.0% interest in a joint venture which ~~owns~~owned a portfolio of integrated senior health campuses and ancillary businesses.

On March 18, 2021, our board, at the recommendation of the audit committee of our board, comprised solely of independent directors, unanimously approved and established an updated estimated per share net asset value, or NAV, of our common stock of $9.22 calculated as of September 30, 2020. We provide this updated estimated per share NAV to assist broker-dealers in connection with their obligations under Financial Industry Regulatory Authority, or FINRA, Rule 2231 with respect to customer account statements. The updated estimated per share NAV is based on the estimated value of our assets less the estimated value of our liabilities, divided by the number of shares of Class T and Class I common stock outstanding on a fully diluted basis. The valuation was performed in accordance with the methodology provided in Practice Guideline 2013-01, Valuations of Publicly Registered Non-Listed REITs, or the Practice Guideline, issued by the Institute for Portfolio Alternatives, or the IPA, in April 2013, in addition to guidance from the SEC. On April 2, 2020, the board previously determined an estimated per share NAV of our common stock of $9.54 calculated as of December 31, 2019. See our Current Report on Form 8-K filed with the SEC on March 19, 2021 for more information on the methodologies and assumptions used to determine, and the limitations and risks of, our updated estimated per share NAV.

Merger with Griffin-American Healthcare REIT III, Inc.

On June 23, 2021, we, our operating partnership, our wholly owned subsidiary, Continental Merger Sub, LLC, or merger sub, Griffin-American Healthcare REIT III, Inc., or GAHR III, and American Healthcare REIT Holdings, LP (formerly known as Griffin-American Healthcare REIT III Holdings, LP), or the surviving partnership, entered into an Agreement and Plan of Merger, or the Merger Agreement. On October 1, 2021, pursuant to the Merger Agreement, (i) GAHR III merged with and into merger sub, with merger sub being the surviving company, or the REIT Merger, and (ii) our operating partnership merged with and into the surviving partnership, with the surviving partnership being the surviving entity and being renamed American Healthcare REIT Holdings, LP, or the Partnership Merger, and, together with the REIT Merger, the Merger. As a result of and at the effective time of the Merger, the separate corporate existence of GAHR III and our operating partnership ceased.

At the effective time of the REIT Merger, each issued and outstanding share of GAHR III’s common stock, $0.01 par value per share, converted into the right to receive 0.9266 shares of our Class I common stock, $0.01 par value per share. Further, at the effective time of the Partnership Merger, (i) each unit of limited partnership interest in the surviving partnership outstanding as of immediately prior to the effective time of the Partnership Merger was converted automatically into the right to receive 0.9266 of a Partnership Class I Unit, as defined in the agreement of limited partnership, as amended, of the surviving partnership and (ii) each unit of limited partnership interest in our operating partnership outstanding as of immediately prior to the effective time of the Partnership Merger was converted automatically into the right to receive one unit of limited partnership interest of the surviving partnership of like class.

Table of Contents

Following the Merger, our company, combined with GAHR III, or the Combined Company, was renamed “American Healthcare REIT, Inc.” The REIT Merger is intended to qualify as a “reorganization” under, and within the meaning of, Section 368(a) of the Code. Based on data as of September 30, 2021, the Combined Company has a healthcare real estate portfolio consisting of 311 buildings and campuses in 36 states (as well as the United Kingdom & Isle of Man). On a pro forma basis, the Combined Company portfolio would have a leased percentage rate as of September 30, 2021 of approximately 94.1% for its leased, non-RIDEA assets, 78.1% for its senior housing-RIDEA assets and 77.8% for its integrated senior health campuses.

AHI Acquisition

Also on June 23, 2021, the surviving partnership, our co-sponsors, Platform Healthcare Investor T-II, LLC, Flaherty Trust, Jeffrey T. Hanson, our former Chief Executive Officer and Chairman of the Board of Directors, Danny Prosky, our President and former Chief Operating Officer, and Mathieu B. Streiff, our former Executive Vice President, General Counsel, entered into a contribution and exchange agreement, or the Contribution Agreement, pursuant to which, among other things, the surviving partnership agreed to acquire a newly formed entity, or NewCo, which we refer to as the AHI Acquisition, that owned substantially all of the business and operations of one of our co-sponsors, American Healthcare Investors, as well as all of the equity interests in (i) Griffin-American Healthcare REIT III Advisor, LLC, or GAHR III Advisor, a subsidiary of American Healthcare Investors that served as the external advisor of GAHR III, and (ii) our advisor. On October 1, 2021, the AHI Acquisition closed immediately prior to the consummation of the Merger. Following the consummation of the Merger, the Combined Company has become a self-managed company.

The AHI Acquisition will be treated as a business combination for accounting purposes, with GAHR III as both the legal and accounting acquiror of NewCo. While we are the legal acquiror of GAHR III in the REIT Merger, GAHR III was determined to be the accounting acquiror in the REIT Merger transaction in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 805, Business Combinations, after considering the relative share ownership and the composition of the governing body of the Combined Company. As a result of the completion of the Merger and the AHI Acquisition, the historical information regarding our company’s structure, agreements and financial information presented within this Item 2 has materially changed; however, such information did apply to us as of September 30, 2021. See Note 20, Subsequent Events — Merger with Griffin-American Healthcare REIT III, Inc. and AHI Acquisition, to our accompanying condensed consolidated financial statements and our Current Report on Form 8-K filed with the SEC on October 1, 2021, for additional information regarding the Merger and the AHI Acquisition.

Critical Accounting Policies

The complete listing of our Critical Accounting Policies was previously disclosed in our 2020 Annual Report on Form 10-K, as filed with the SEC on March 26, 2021, and there have been no material changes to our Critical Accounting Policies as disclosed therein, except as included within Note 2, Summary of Significant Accounting Policies, to our accompanying condensed consolidated financial statements.

Interim Unaudited Financial Data

For a discussion of interim unaudited financial data, see Note 2, Summary of Significant Accounting Policies — Interim Unaudited Financial Data, to our accompanying condensed consolidated financial statements. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2020 Annual Report on Form 10-K, as filed with the SEC on March 26, 2021.

Acquisition and Disposition in 2021

For a discussion of our acquisition and disposition in 2021, See Note 3, Real Estate Investments, Net, to our accompanying condensed consolidated financial statements.

~~Table of Contents~~

Factors Which May Influence Results of Operations

Other than ~~a proposed merger with GAHR III and~~ the effects of the COVID-19 pandemic discussed below, as well as other national economic conditions affecting real estate generally, we are not aware of any material trends or uncertainties that may reasonably be expected to have a material impact, favorable or unfavorable, on revenues or income from the acquisition, disposition, management and operation of our properties. In addition, see Part II, Item 1A, Risk Factors, of this Quarterly Report on Form 10-Q and those Risk Factors previously disclosed in our 2020 Annual Report on Form 10-K, as filed with the SEC on March 26, 2021.

~~Proposed Merger with GAHR III~~

In October 2020, our board established a special committee of our board, or our special committee, which consists of all of our independent directors, to investigate and analyze strategic alternatives, including but not limited to, the sale of our assets, a listing of our shares on a national securities exchange, or a merger with another entity, including a merger with another unlisted entity that we expect would enhance our value. On June 23, 2021, we, our operating partnership, our wholly owned subsidiary, Continental Merger Sub, LLC, or merger sub, and GAHR III, and its subsidiary Griffin-American Healthcare REIT III Holdings, LP, or GAHR III operating partnership, entered into an Agreement and Plan of Merger, or the Merger Agreement. Subject to the terms and conditions of the Merger Agreement, (i) GAHR III will be merged with and into merger sub, with merger sub being the surviving company, or the REIT Merger, and (ii) our operating partnership will be merged with and into GAHR III operating partnership, with GAHR III operating partnership being the surviving partnership and being renamed “American Healthcare REIT Holdings, LP”, or the Partnership Merger, and, together with the REIT Merger, the Merger.

At the effective time of the REIT Merger, each issued and outstanding share of GAHR III’s common stock, $0.01 par value per share, will be converted into the right to receive 0.9266 of a share of our Class I common stock, $0.01 par value per share. Further, at the effective time of the Partnership Merger, (i) each unit of limited partnership interest in GAHR III operating partnership outstanding as of immediately prior to the effective time of the Partnership Merger will be converted automatically into the right to receive 0.9266 of a Partnership Class I Unit, as defined in the agreement of limited partnership of the surviving partnership and (ii) each unit of limited partnership interest in our operating partnership outstanding as of immediately prior to the effective time of the Partnership Merger will be converted automatically into the right to receive one unit of limited partnership interest of the surviving partnership of like class.

Following the Merger, we (as combined with GAHR III, or the Combined Company) will be named “American Healthcare REIT, Inc.” The REIT Merger is intended to qualify as a “reorganization” under, and within the meaning of, Section 368(a) of the Internal Revenue Code of 1986, as amended, or the Code. Based on data as of June 30, 2021, the Combined Company after the completion of the Merger would have a healthcare real estate portfolio consisting of 312 buildings and campuses in 36 states (as well as the United Kingdom & Isle of Man). On a pro forma basis, the Combined Company portfolio would have a leased percentage rate as of June 30, 2021 of approximately 93.7% for its leased, non-RIDEA assets, 72.8% for its senior housing-RIDEA assets and 76.0% for its integrated senior health campuses.

The Merger Agreement may be terminated by either us or GAHR III under certain circumstances, including but not limited to (in each case, with the prior approval of the special committee of the respective board of directors) (i) if the REIT Merger has not been consummated on or before 11:59 p.m. New York time on March 23, 2022; (ii) if the approval of the Merger by our stockholders or the stockholders of GAHR III is not obtained; or (iii) upon a material uncured breach of the respective obligations, covenants or agreements by the other party that would cause the closing conditions in the Merger Agreement not to be satisfied. The consummation of the Merger and the AHI Acquisition is subject to substantial conditions to closing and is not expected to close until the fourth quarter of 2021; therefore, our accompanying condensed consolidated financial statements do not include the Merger or the AHI Acquisition.

Also on June 23, 2021, GAHR III, GAHR III operating partnership, our co-sponsors, Platform Healthcare Investor T-II, LLC, Flaherty Trust, Jeffrey T. Hanson, our Chief Executive Officer and Chairman of the Board of Directors, Danny Prosky, our President and Chief Operating Officer, and Mathieu B. Streiff, our Executive Vice President, General Counsel, entered into a contribution and exchange agreement, or the Contribution Agreement, pursuant to which, among other things, GAHR III has

~~Table of Contents~~

agreed to acquire a newly formed entity, or the AHI Acquisition, that will own substantially all of the business and operations of one of our co-sponsors, American Healthcare Investors, as well as all of the equity interests in (i) Griffin-American Healthcare REIT III Advisor, LLC, a subsidiary of American Healthcare Investors that serves as the external advisor of GAHR III, and (ii) our advisor, such that GAHR III will become self-managed and (if the Merger does not occur) we will become indirectly managed by GAHR III. The AHI Acquisition is expected to close immediately prior to the consummation of the Merger. Following the consummation of the Merger, assuming the AHI Acquisition is consummated, the Combined Company will be an entirely self-managed company. The Merger is not subject to the consummation of the AHI Acquisition, such that the Merger may occur even if the AHI Acquisition does not. The parties to the Contribution Agreement also may elect to proceed with the AHI Acquisition even if the Merger is not consummated.

~~See our Current Report on Form 8-K filed with the SEC on June 24, 2021, for additional information regarding the Merger.~~

Ongoing Impact of the COVID-19 Pandemic

Due to the ongoing COVID-19 pandemic in the United States and globally, since March 2020, our residents, tenants, operating partners and managers have been materially impacted, and the prolonged economic impact remains uncertain. As the COVID-19 pandemic is still impacting the healthcare system to a degree, it continues to present challenges for us as an owner and operator of healthcare facilities. Since its outset, the impacts of the COVID-19 pandemic have been significant, rapidly and continuously evolving and may continue into the future, especially due to the emergence of the Delta variant which has caused

Table of Contents

COVID-19 cases and deaths to increase significantly in the third quarter of 2021, making it difficult to ascertain the long-term impact itthe COVID-19 pandemic will have on real estate markets in which we own and/or operate properties and our portfolio of investments. COVID-19 is particularly dangerous among the senior population and results in heightened risk to our senior housing and skilled nursing facilities, and we continue to work diligently to implement and maintain aggressive protocols at such facilities as well as actively collaborate with our tenants, operating partners and managers to respond and take action to mitigate the impact of the COVID-19 pandemic. We have evaluated the impacts of the COVID-19 pandemic on our business thus far and incorporated information concerning the impact of COVID-19 into our assessments of liquidity, impairment and collectability from tenants and residents as of ~~June~~September 30, 2021. We will continue to monitor such impacts and will adjust our estimates and assumptions based on the best available information.

Since March 2020, we have taken actions to strengthen our balance sheet and preserve liquidity in response to the COVID-19 pandemic, including reducing the stockholder distribution rate and temporarily suspending our share repurchase plan. We believe that the long-term stability of our portfolio of investments will return once the virus has been controlled. Each type of real estate asset we own has been impacted by the COVID-19 pandemic to varying degrees. ~~In states where lockdown orders have been lifted or modified, the downward trends in our portfolio appear to have somewhat moderated, but we have not yet witnessed a significant rebound.~~

In the early months of the pandemic, the businesses of our medical office tenants were negatively impacted when many of the states had implemented “stay at home” orders, thereby creating unprecedented revenue pressure on such tenants and their ability to pay rent on a timely basis. Substantially all of our physician practices and other medical service providers of non-essential and elective services in our medical office buildings are now ~~open. However, there remains~~open and as a ~~risk~~result, our medical office building segment rebounded quickly from the initial shock of ~~reclosures in states where infection rates rise, or where a resurgence~~the pandemic and has demonstrated remarkable resilience. This trend has continued despite the emergence of ~~COVID-19 emerges, which may put additional pressure on our operations.~~the Delta variant.

The COVID-19 pandemic has resulted in a significant decline in the resident occupancies of our senior housing and skilled nursing facilities and an increase in COVID-19 related operating ~~expenses; therefore,~~expenses, especially in our skilled nursing segment where personal protective equipment, or PPE, costs and the shortage of healthcare personnel resulting in more costly short-term hires, present ongoing challenges. Therefore, our immediate focus at such properties continues to be on resident occupancy recovery and operating expense management. While we experienced steady recovery in early 2021, the emergence of the Delta variant has slowed the recovery in our senior housing and skilled nursing segments as we are seeing case counts reach levels not seen since January 2021. In addition, since the fourth quarter of 2020, COVID-19 vaccines have become available to certain parts of the population, which we believe will be important to a rebound in our resident occupancy levels over time. As of ~~August~~November 1, 2021, based on information provided by our operators, the majority of our residents have been fully vaccinated.

The information in this Quarterly Report on Form 10-Q is based on data currently available to us and will likely change as the COVID-19 pandemic progresses. Despite improving macroeconomic conditions and the emergence of vaccines, surges in COVID-19 cases, including variants of the strain, such as those ~~recently~~ experienced in Europe and the U.S., ~~may cause people to self-quarantine or governments to shut~~could slow down ~~nonessential businesses again.~~the recovery of the U.S. and the global economy. We continue to closely monitor COVID-19 developments and are continuously assessing the implications to our business, residents, tenants, operating partners, managers and our portfolio of investments. We believe that the government-imposed or self-imposed lockdowns and restrictions have created pent-up demand for doctors’ visits and move-ins into senior housing facilities; however, we cannot predict with reasonable certainty when such demand will return to pre-COVID-19 pandemic levels. The medical community understands

~~Table of Contents~~

COVID-19 far better today than it did at the onset of the pandemic, and we are now equipped with greater therapeutics and other treatments to mitigate its impact. Likewise, we are optimistic about the favorable reports regarding the efficacy of vaccines. The COVID-19 pandemic has had, and may continue to have, an adverse effect on the operations of our business, and therefore, we are unable to predict the full extent or nature of the future impact to our financial condition and results of operations at this time. We expect the trends discussed above with respect to the impact of the COVID-19 pandemic to continue. Thus, the lasting impact of the COVID-19 pandemic over the next 12 months could be significant and will largely depend on future developments, including the duration of the crisis and the success of efforts to contain or treat COVID-19 and its variants, such as the ~~widespread availability and~~ use of effective vaccines and availability of vaccine boosters, which cannot be predicted with confidence at this time. See the “Results of Operations” and “Liquidity and Capital Resources” sections below for a further discussion.

Scheduled Lease Expirations

Excluding our senior housing — RIDEA facilities, as of ~~June~~September 30, 2021, our properties were 95.7% leased and during the remainder of 2021, ~~2.0%~~1.5% of the leased GLA is scheduled to expire. Our leasing strategy focuses on negotiating renewals for leases scheduled to expire during the next 12 months. In the future, if we are unable to negotiate renewals, we will try to identify new tenants or collaborate with existing tenants who are seeking additional space to occupy. As of ~~June~~September 30, 2021, our remaining weighted average lease term was ~~8.0~~7.8 years, excluding our senior housing — RIDEA facilities.

For the three and ~~six~~nine months ended ~~June~~September 30, 2021, our senior housing — RIDEA facilities were ~~70.3%~~71.1% and ~~69.0%~~69.7% leased, respectively. Substantially all of our leases with residents at such properties are for a term of one year or less.

Table of Contents

Results of Operations

Comparison of the Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2021 and 2020

Our operating results are primarily comprised of income derived from our portfolio of properties and expenses in connection with the acquisition and operation of such properties. In general, and under a normal operating environment without the disruption of the COVID-19 pandemic, we expect amounts related to our portfolio of operating properties to increase in the future due to fixed annual rent escalations on our portfolio of ~~properties and based on a full year of operations for recently acquired~~ properties.

We segregate our operations into reporting segments in order to assess the performance of our business in the same way that management reviews our performance and makes operating decisions. As of ~~June~~September 30, 2021, we operated through four reportable business segments, with activities related to investing in medical office buildings, senior housing, senior housing — RIDEA and skilled nursing facilities.

The COVID-19 pandemic has had a significant adverse impact on the operations of our real estate portfolio. Although we have experienced some delays in receiving rent payments from our tenants, as of ~~June~~September 30, 2021, we have collected 100% of contractual rent from our leased, non-RIDEA senior housing and skilled nursing facility tenants. Most of our skilled nursing facilities provide behavioral health services with resident occupancies that are less impacted by either the COVID-19 pandemic or restrictions on elective surgeries than traditional skilled nursing facilities. In addition, substantially all of the contractual rent through ~~June~~September 2021 from our medical office building tenants has been received. However, given the significant ongoing uncertainty of the impact of the COVID-19 pandemic over the next 12 months, we are unable to predict the impact it will have on such tenants’ continued ability to pay rent.

~~Table of Contents~~

Except where otherwise noted, the changes in our condensed consolidated results of operations for 2021 as compared to 2020 are primarily due to the disruption to our normal operations as a result of the COVID-19 pandemic, grant income received and costs incurred related to ~~facilitate a strategic transaction. In addition, there are changes in our operating results by reporting segment due to transitioning~~ the ~~operations of the five senior housing facilities within Northern California Senior Housing Portfolio to a RIDEA structure in March 2020.~~Merger. As of ~~June~~September 30, 2021 and 2020, we owned the following types of properties:


		June 30,											September 30,
		2021					2020						2021					2020
		Number of Buildings	Aggregate Contract Purchase Price		Leased %		Number of Buildings	Aggregate Contract Purchase Price		Leased %			Number of Buildings	Aggregate Contract Purchase Price		Leased %		Number of Buildings	Aggregate Contract Purchase Price		Leased %
Medical office buildings	Medical office buildings	43	$	608,072,000	93.2	%	43	$	605,122,000	92.5	%	Medical office buildings	43	$	608,072,000	93.2	%	43	$	605,122,000	93.0	%
Senior housing — RIDEA	Senior housing — RIDEA	24	252,709,000		(1)		26	264,349,000		(1)		Senior housing — RIDEA	24	252,709,000		(1)		26	264,349,000		(1)
Senior housing	Senior housing	14	101,800,000		100	%	14	101,800,000		100	%	Senior housing	14	101,800,000		100	%	14	101,800,000		100	%
Skilled nursing facilities	Skilled nursing facilities	11	117,800,000		100	%	11	117,800,000		100	%	Skilled nursing facilities	11	117,800,000		100	%	11	117,800,000		100	%
Total/weighted average(2)	Total/weighted average(2)	92	$	1,080,381,000	95.7	%	94	$	1,089,071,000	95.5	%	Total/weighted average(2)	92	$	1,080,381,000	95.7	%	94	$	1,089,071,000	95.4	%

___________

(1)For the three months ended ~~June~~September 30, 2021 and 2020, the leased percentage for the resident units of our senior housing — RIDEA facilities was ~~70.3%~~71.1% and ~~77.4%~~71.6%, respectively, and for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, the leased percentage for the resident units of our senior housing — RIDEA facilities was ~~69.0%~~69.7% and ~~79.8%~~77.2%, respectively, based on daily average occupancy of licensed beds or units.

(2)Leased percentage excludes our senior housing — RIDEA facilities.

Table of Contents

Revenues and Grant Income

Our primary sources of revenue include rent generated by our leased, non – RIDEA properties, and resident fees and services revenue from our RIDEA properties. The amount of revenue generated by our properties depends principally on our ability to maintain the occupancy rates of currently leased space and to lease available space at market rates. Revenues and grant income by reportable segment consisted of the following for the periods presented:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			2021		2020		2021		2020
Real Estate Revenue	Real Estate Revenue									Real Estate Revenue
Medical office buildings	Medical office buildings	$	16,805,000	$	16,575,000	$	33,557,000	$	32,846,000	Medical office buildings	$	16,921,000	$	16,338,000	$	50,478,000	$	49,184,000
Skilled nursing facilities	Skilled nursing facilities	2,991,000		2,993,000		5,991,000		6,005,000		Skilled nursing facilities	2,996,000		2,979,000		8,987,000		8,984,000
Senior housing	Senior housing	2,192,000		2,274,000		4,386,000		4,454,000		Senior housing	2,203,000		2,202,000		6,589,000		6,656,000
Total real estate revenue	Total real estate revenue	21,988,000		21,842,000		43,934,000		43,305,000		Total real estate revenue	22,120,000		21,519,000		66,054,000		64,824,000
Resident Fees and Services Revenue	Resident Fees and Services Revenue									Resident Fees and Services Revenue
Senior housing — RIDEA	Senior housing — RIDEA	15,194,000		16,834,000		31,089,000		32,915,000		Senior housing — RIDEA	15,090,000		18,948,000		46,179,000		51,863,000
Total resident fees and services	Total resident fees and services	15,194,000		16,834,000		31,089,000		32,915,000		Total resident fees and services	15,090,000		18,948,000		46,179,000		51,863,000
Total revenues		$	37,182,000	$	38,676,000	$	75,023,000	$	76,220,000
Grant Income										Grant Income
Senior housing — RIDEA										Senior housing — RIDEA	—		864,000		—		864,000
Total grant income										Total grant income	—		864,000		—		864,000
Total revenues and grant income										Total revenues and grant income	$	37,210,000	$	41,331,000	$	112,233,000	$	117,551,000

For the three months ended ~~June~~September 30, 2021 and 2020, real estate revenue was primarily comprised of base rent of ~~$15,980,000~~$16,520,000 and ~~$15,837,000,~~$15,847,000, respectively, and expense recoveries of ~~$4,826,000~~$4,963,000 and ~~$4,700,000,~~$4,575,000, respectively. For the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, real estate revenue was primarily comprised of base rent of ~~$32,061,000~~$48,581,000 and ~~$31,697,000,~~$47,544,000, respectively, and expense recoveries of ~~$9,603,000~~$14,566,000 and ~~$9,122,000,~~$13,697,000, respectively. For the three and ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, resident fees and services revenue consisted of rental fees related to resident leases and extended health care fees.

The decrease in resident fees and services for both the three and nine months ended September 30, 2021, compared to the three and nine months ended September 30, 2020, is primarily related to lower occupancy rates in our facilities due to the prolonged operational disruption as a result of the COVID-19 pandemic. The decrease in resident fees and services for the nine months ended September 30, 2021, compared to the nine months ended September 30, 2020 was partially offset by the impact of the transition of five senior housing facilities within Northern California Senior Housing Portfolio to a RIDEA structure in March 2020 resulting in higher resident fees and services in the comparable period.

For both the three and nine months ended September 30, 2021, we did not recognize any government grants. For both the three and nine months ended September 30, 2020, we recognized $864,000 of grant income at our senior housing — RIDEA facilities related to government grants through the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, economic stimulus programs.

Table of Contents

Rental Expenses and Property Operating Expenses

Rental expenses and rental expenses as a percentage of real estate revenue, as well as property operating expenses and property operating expenses as a percentage of resident fees and services revenue and grant income, by reportable segment consisted of the following for the periods presented:


		Three Months Ended June 30,								Six Months Ended June 30,									Three Months Ended September 30,								Nine Months Ended September 30,
		2021				2020				2021				2020					2021				2020				2021				2020
Rental Expenses	Rental Expenses																	Rental Expenses
Medical office buildings	Medical office buildings	$	5,726,000	34.1	%	$	5,619,000	33.9	%	$	11,431,000	34.1	%	$	11,009,000	33.5	%	Medical office buildings	$	6,072,000	35.9	%	$	5,607,000	34.3	%	$	17,503,000	34.7	%	$	16,616,000	33.8	%
Senior housing	Senior housing	223,000		10.2	%	195,000		8.6	%	397,000		9.1	%	475,000		10.7	%	Senior housing	172,000		7.8	%	173,000		7.9	%	569,000		8.6	%	648,000		9.7	%
Skilled nursing facilities	Skilled nursing facilities	180,000		6.0	%	182,000		6.1	%	325,000		5.4	%	334,000		5.6	%	Skilled nursing facilities	145,000		4.8	%	125,000		4.2	%	470,000		5.2	%	459,000		5.1	%
Total rental expenses	Total rental expenses	$	6,129,000	27.9	%	$	5,996,000	27.5	%	$	12,153,000	27.7	%	$	11,818,000	27.3	%	Total rental expenses	$	6,389,000	28.9	%	$	5,905,000	27.4	%	$	18,542,000	28.1	%	$	17,723,000	27.3	%
Property Operating Expenses	Property Operating Expenses																	Property Operating Expenses
Senior housing — RIDEA	Senior housing — RIDEA	$	14,445,000	95.1	%	$	14,442,000	85.8	%	$	29,639,000	95.3	%	$	27,459,000	83.4	%	Senior housing — RIDEA	$	14,540,000	96.4	%	$	17,397,000	87.8	%	$	44,179,000	95.7	%	$	44,856,000	85.1	%
Total property operating expenses	Total property operating expenses	$	14,445,000	95.1	%	$	14,442,000	85.8	%	$	29,639,000	95.3	%	$	27,459,000	83.4	%	Total property operating expenses	$	14,540,000	96.4	%	$	17,397,000	87.8	%	$	44,179,000	95.7	%	$	44,856,000	85.1	%

For the three months ended ~~June~~September 30, 2021 and 2020, property operating expenses primarily consisted of administration and benefits expense of ~~$10,951,000~~$10,921,000 and ~~$7,897,000,~~$8,634,000, respectively, and for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, property operating expenses primarily consisted of administration and benefits expense of ~~$22,399,000~~$33,320,000 and ~~$15,049,000,~~$23,683,000, respectively. The ~~increase~~decrease in property operating expenses for the three ~~and six~~ months ended ~~June~~September 30, 2021, compared to the three ~~and six~~ months ended ~~June~~September 30, 2020, is primarily ~~due to the transition of five senior housing facilities within Northern California Senior Housing Portfolio to~~because we experienced a ~~RIDEA structure~~significant increase in ~~March 2020. Overall, property operating expenses have also significantly increased in the three and six months ended 2021, compared to the three and six months ended June 30, 2020, due to~~ labor costs, ~~the single largest expense line item for senior housing — RIDEA facilities,~~ as well as the costs of COVID-19 testing of employees and residents in ~~these~~our facilities and the costs of ~~personal protective equipment, or~~ PPE and other supplies required as a result of the COVID-19 ~~pandemic.~~pandemic in the prior year, which decreased in the current year in line with the normalization of such costs and with the decline in COVID-19 case counts and increase in vaccination rates. Senior housing — RIDEA facilities typically have a higher percentage of direct operating expenses to revenue than medical office buildings, skilled nursing facilities and leased, ~~non – RIDEA~~non-RIDEA senior housing facilities due to the nature of RIDEA facilities where we conduct day-to-day operations.

General and Administrative

General and administrative expenses consisted of the following for the periods presented:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			2021		2020		2021		2020
Asset management and property management oversight fees — affiliates	Asset management and property management oversight fees — affiliates	$	2,536,000	$	2,599,000	$	5,076,000	$	5,010,000	Asset management and property management oversight fees — affiliates	$	2,540,000	$	2,529,000	$	7,616,000	$	7,539,000
Professional and legal fees	Professional and legal fees	555,000		570,000		1,155,000		2,098,000		Professional and legal fees	1,278,000		566,000		2,433,000		2,664,000
Bank charges	Bank charges	179,000		189,000		359,000		318,000		Bank charges	175,000		183,000		534,000		501,000
Transfer agent services	Transfer agent services	120,000		115,000		244,000		249,000		Transfer agent services	118,000		119,000		362,000		368,000
Directors’ and officers’ liability insurance	Directors’ and officers’ liability insurance	89,000		64,000		165,000		129,000		Directors’ and officers’ liability insurance	89,000		65,000		254,000		194,000
Board of directors fees	Board of directors fees	61,000		74,000		130,000		142,000		Board of directors fees	64,000		64,000		194,000		206,000
Restricted stock compensation	Restricted stock compensation	41,000		55,000		84,000		98,000		Restricted stock compensation	21,000		73,000		105,000		171,000
Franchise taxes	Franchise taxes	38,000		76,000		110,000		116,000		Franchise taxes	15,000		54,000		125,000		170,000
Other	Other	40,000		98,000		83,000		128,000		Other	4,000		19,000		87,000		147,000
Total	Total	$	3,659,000	$	3,840,000	$	7,406,000	$	8,288,000	Total	$	4,304,000	$	3,672,000	$	11,710,000	$	11,960,000

The ~~decrease~~increase in general and administrative expenses for the three ~~and six~~ months ended ~~June~~September 30, 2021, compared to the three ~~and six~~ months ended ~~June~~September 30, 2020, is primarily due to ~~a decrease~~an increase in professional and legal fees from transitioning the ~~operations of the five senior housing facilities within Northern California~~operator at Central Florida Senior Housing Portfolio ~~to a RIDEA structure~~ in ~~March 2020.~~

~~Table of Contents~~

September 2021.

Business Acquisition Expenses

For the three months ended ~~June~~September 30, 2021 and 2020, business acquisition expenses were ~~$2,438,000~~$3,800,000 and ~~$8,000,~~$57,000, respectively, and for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, business acquisition expenses were ~~$2,752,000~~$6,552,000 and ~~$17,000,~~$74,000, respectively. The increase in such expenses for the ~~three and six~~nine months ended ~~June~~September 30, 2021, compared to the ~~three and six~~ nine

Table of Contents

months ended ~~June~~September 30, 2020, was primarily due to ~~$2,975,000~~$6,753,000 in third-party ~~advisory~~legal costs and professional services fees ~~to our special committee~~incurred related to the Merger. Such increase was partially offset by the recovery of costs of $400,000 during the ~~six~~nine months ended ~~June~~September 30, 2021 that were incurred in prior periods in the pursuit of a portfolio of properties that did not result in an acquisition.

Depreciation and Amortization

For the three months ended ~~June~~September 30, 2021 and 2020, depreciation and amortization was ~~$10,597,000~~$10,746,000 and ~~$12,720,000,~~$12,669,000, respectively, and consisted primarily of depreciation on our operating properties of ~~$7,930,000~~$8,181,000 and ~~$7,893,000,~~$7,966,000, respectively, and amortization on our identified intangible assets of ~~$2,556,000~~$2,261,000 and ~~$4,767,000,~~$4,619,000, respectively. For the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, depreciation and amortization was ~~$22,999,000~~$33,745,000 and ~~$25,250,000,~~$37,919,000, respectively, and consisted primarily of depreciation on our operating properties of ~~$15,844,000~~$24,025,000 and ~~$15,732,000,~~$23,698,000, respectively, and amortization on our identified intangible assets of ~~$6,938,000~~$9,199,000 and ~~$9,413,000,~~$14,032,000, respectively. Approximately ~~$1,531,000~~$3,333,000 of the decrease in amortization expense on our identified intangible assets for the ~~six~~nine months ended ~~June~~September 30, 2021 as compared to the ~~six~~nine months ended ~~June~~September 30, 2020 is related to in-place leases recognized in January 2020 and totaling $8,974,000 that were fully amortized during the ~~six~~nine months ended ~~June~~September 30, 2021.

Interest Expense

Interest expense, including gain or loss in fair value of derivative financial instruments, consisted of the following for the periods presented:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			2021		2020		2021		2020
Interest expense:	Interest expense:									Interest expense:
Line of credit and term loans and derivative financial instruments	Line of credit and term loans and derivative financial instruments	$	4,181,000	$	4,290,000	$	8,218,000	$	8,908,000	Line of credit and term loans and derivative financial instruments	$	4,274,000	$	4,145,000	$	12,492,000	$	13,053,000
Mortgage loans payable	Mortgage loans payable	198,000		195,000		398,000		386,000		Mortgage loans payable	198,000		204,000		596,000		590,000
Amortization of deferred financing costs:	Amortization of deferred financing costs:									Amortization of deferred financing costs:
Line of credit and term loans	Line of credit and term loans	471,000		470,000		941,000		939,000		Line of credit and term loans	470,000		471,000		1,411,000		1,410,000
Mortgage loans payable	Mortgage loans payable	6,000		6,000		13,000		26,000		Mortgage loans payable	7,000		7,000		20,000		33,000
(Gain) loss in fair value of derivative financial instruments	(Gain) loss in fair value of derivative financial instruments	(1,462,000)		(853,000)		(2,917,000)		3,752,000		(Gain) loss in fair value of derivative financial instruments	(1,514,000)		(1,450,000)		(4,431,000)		2,302,000
Amortization of debt discount/premium	Amortization of debt discount/premium	13,000		13,000		25,000		25,000		Amortization of debt discount/premium	12,000		12,000		37,000		37,000
Total	Total	$	3,407,000	$	4,121,000	$	6,678,000	$	14,036,000	Total	$	3,447,000	$	3,389,000	$	10,125,000	$	17,425,000

The decrease in interest expense for the ~~three~~nine months ended ~~June~~September 30, 2021, compared to the ~~three~~nine months ended June 30, 2020, is primarily related to the increase of the gain in fair value recognized on our derivative financial instruments that we entered into in February 2019. The decrease in interest expense for the six months ended June 30, 2021, compared to the six months ended JuneSeptember 30, 2020, is primarily related to a change to a gain in fair value recognized on our derivative financial instruments from a loss in fair value recognized on our derivative financial instruments, respectively, as such instruments approach maturity in November 2021, ~~and~~as well as a decline in interest rates on our line of credit and term loans. See Note 6, Mortgage Loans Payable, Net, Note 7, Line of Credit and Term Loans and Note 8, Derivative Financial Instruments, to our accompanying condensed consolidated financial statements, for a further discussion.

~~Table of Contents~~

Liquidity and Capital Resources

Our sources of funds primarily consist of operating cash flows and borrowings. In the normal course of business, our principal demands for funds are for payment of operating expenses, capital improvement expenditures, interest on our indebtedness, distributions to our stockholders and repurchases of our common stock. Upon consummation of the Merger, on October 1, 2021, we assumed GAHR III's obligations, through the surviving partnership, with respect to a credit facility with a maximum principal amount of $480,000,000, or the 2019 Corporate Line of Credit. In addition, on October 1, 2021, upon consummation of the Merger, we assumed GAHR III's obligations under an amended and restated loan agreement regarding a senior secured revolving credit facility with an aggregate maximum principal amount of $360,000,000, or the 2019 Trilogy Credit Facility. We ~~estimate that we will require approximately $4,978,000~~also entered into an amendment to ~~pay interest on~~ our ~~outstanding indebtedness~~credit agreement for the remainder of 2021, based on interest rates in effect as of June 30, 2021, and that we will require $483,215,000 to pay principal on our outstanding indebtedness for the remainder of 2021. Such principal on our outstanding indebtedness includes $482,900,000 of outstanding principal as of June 30, 2021 on our line of credit and term loans, ~~that are scheduled to mature on November 19, 2021; however, we have~~as amended, or the ~~ability and intend to pursue a new credit facility or alternatively satisfy certain conditions pursuant~~2018 Credit Facility. We refer to the ~~related credit agreement~~2019 Corporate Line of Credit, 2019 Trilogy Credit Facility and ~~pay~~ the ~~required fee in order to exercise our option to extend~~2018 Credit Facility as the ~~maturity date for one year. We also require resources to make certain payments to our advisor and its affiliates.~~Credit Facilities. See Note ~~13, Related Party Transactions,~~20, Subsequent Events — Lines of Credit and Term Loans, to our accompanying condensed consolidated financial statements, for a further discussion, and ~~Note 13, Related Party Transactions of~~ our ~~2020 Annual~~Current Report on Form ~~10-K, as~~8-K filed with the SEC on ~~March 26,~~October 5, 2021 for ~~a summary~~more information on the amendments to or assumption of ~~our payments to our advisor and its affiliates. Generally, cash needs for such items will be met primarily from operations or borrowings, as needed.~~the Credit Facilities. Our total capacity to pay operating expenses, capital improvement expenditures, interest, distributions and repurchases is a function of our current cash position, our borrowing capacity on our ~~line of credit,~~Credit Facilities, as well as any future indebtedness that we may incur. ~~In connection with~~

Table of Contents

As of October 31, 2021, the ~~Merger, we are subject~~Combined Company’s aggregate borrowing capacity under the Credit Facilities was $1,370,000,000. As of October 31, 2021, the Combined Company’s aggregate borrowings outstanding under the Credit Facilities was $1,205,634,000. The 2018 Credit Facility is scheduled to ~~certain limitations~~mature on ~~borrowing between~~November 19, 2021. We intend to extend the ~~signing~~maturity date of the ~~Merger~~2018 Credit Facility for an additional 12 months pursuant to the terms of the 2018 Credit Agreement, as amended, and expect to pay an extension fee of approximately $795,000. The 2019 Corporate Line of Credit is scheduled to mature on January 25, 2022; however, we intend to combine our 2019 Corporate Line of Credit and the ~~closing~~2018 Credit Facility into one joint credit facility and pay any related fees. As of October 31, 2021, we had an aggregate of $164,366,000 available on the Merger. Generally, borrowing transactions require consent of the other party, unless such borrowing made by us (i) is in connection with existing debt facilities; (ii) in the aggregate does not exceed $500,000; (iii) is completedCredit Facilities. We believe that these resources will be sufficient to satisfy our cash requirements for the ~~purpose of refinancing existing indebtedness; or (iv) was previously disclosed upon execution of the Merger Agreement.~~foreseeable future.

Due to the impact the COVID-19 pandemic has had on the United States and globally, and the uncertainty of the severity and duration of the COVID-19 pandemic and its effects, beginning in March 2020, our board decided to take steps to protect our capital and maximize our liquidity in an effort to strengthen our long-term financial prospects by decreasing our distributions to stockholders and ~~partially~~temporarily suspending our share repurchase plan. Consequently, our board approved a reduced ~~daily~~ distribution rate for April 2020 through ~~August~~October 2021 ~~equal to $0.001095890 per share of~~for our Class T and Class I common stock, which is equal to an annualized distribution rate of $0.40 per share, a decrease from the annualized rate of $0.60 per share previously paid by us. See the “Distributions” section below for a further discussion. In addition, on March 31, 2020, our board suspended our share repurchase plan with respect to all repurchase requests other than repurchases resulting from the death or qualifying disability of stockholders, beginning with share repurchase requests submitted for repurchase during the second quarter of 2020. Furthermore, in connection with our special committee’s strategic alternative review process and in order to facilitate a strategic transaction, on March 18, 2021, our board authorized the suspension of the DRIP, effective as of April 1, 2021, and also approved the suspension of our share repurchase plan with respect to all repurchase requests received by us after February 28, 2021, including repurchases resulting from the death or qualifying disability of stockholders. ~~Our board shall determine if and when it is in the best interest of our company and stockholders to reinstate our DRIP or share repurchase plan.~~ For a further discussion, see our Current Report on Form 8-K filed with the SEC on March 19, 2021. ~~As of June 30,~~On October 4, 2021, our ~~cash~~board authorized the reinstatement of the DRIP and a partial reinstatement of our share repurchase plan with respect to repurchase requests resulting from the death or qualifying disability of stockholders. See Note 20, Subsequent Events — Reinstatement of the DRIP and — Amendments to and Partial Reinstatement of Share Repurchase Plan, to our accompanying condensed consolidated financial statements for a further discussion, and our Current Report on ~~hand was $21,336,000~~Form 8-K filed with the SEC on October 5, 2021 for more information on the reinstatement of the DRIP and ~~we had $47,100,000 available on~~partial reinstatement of our ~~line of credit. We believe that these resources will be sufficient to satisfy our cash requirements for the foreseeable future.~~share repurchase plan.

A capital plan for each investment is established upon acquisition that contemplates the estimated capital needs of that investment, including costs of refurbishment, tenant improvements or other major capital expenditures. The capital plan also sets forth the anticipated sources of the necessary capital, which may include operating cash generated by the investment, capital reserves, a line of credit or other loan established with respect to the investment, other borrowings or additional equity investments from us or joint venture partners. The capital plan for each investment is adjusted through ongoing, regular reviews of our portfolio or as necessary to respond to unanticipated additional capital needs. Based on the budget for the properties ~~we own as~~ of ~~June 30, 2021,~~the Combined Company, we estimate that our discretionary expenditures for capital and tenant improvements could require up to ~~$5,411,000~~$33,809,000 for the remaining ~~six~~three months of 2021. ~~As of June 30, 2021, we had $532,000 of restricted cash in loan impounds and reserve accounts to fund a portion of such capital expenditures.~~

Other Liquidity Needs

In the event that there is a shortfall in net cash available due to various factors, including, without limitation, the timing of distributions or the collection of receivables, we may seek to obtain capital to pay distributions by means of secured or unsecured debt financing through one or more third parties, or our advisor or its affiliates. There are currently no limits or restrictions on the use of proceeds from our advisor or its affiliates which would prohibit us from making the proceeds available for distribution. We may also pay distributions from cash from capital transactions, including, without limitation, the sale of one or more of our properties.

~~Table of Contents~~

Cash Flows

The following table sets forth changes in cash flows:


		Six Months Ended June 30,					Nine Months Ended September 30,
		2021		2020			2021		2020
Cash, cash equivalents and restricted cash — beginning of period	Cash, cash equivalents and restricted cash — beginning of period	$	18,125,000	$	15,846,000	Cash, cash equivalents and restricted cash — beginning of period	$	18,125,000	$	15,846,000
Net cash provided by operating activities	Net cash provided by operating activities	13,886,000		19,047,000		Net cash provided by operating activities	16,556,000		29,943,000
Net cash provided by (used in) investing activities		475,000		(72,548,000)
Net cash used in investing activities						Net cash used in investing activities	(1,573,000)		(74,761,000)
Net cash (used in) provided by financing activities	Net cash (used in) provided by financing activities	(9,974,000)		58,947,000		Net cash (used in) provided by financing activities	(15,939,000)		52,368,000
Cash, cash equivalents and restricted cash — end of period	Cash, cash equivalents and restricted cash — end of period	$	22,512,000	$	21,292,000	Cash, cash equivalents and restricted cash — end of period	$	17,169,000	$	23,396,000

Table of Contents

The following summary discussion of our changes in our cash flows is based on our accompanying condensed consolidated statements of cash flows and is not meant to be an all-inclusive discussion of the changes in our cash flows for the periods presented below.

Operating Activities

For the ~~six~~nine months ended ~~June~~September 30, 2021, ~~and 2020,~~ cash flows provided by operating activities ~~primarily related~~was $16,556,000, compared to ~~the~~ cash flows provided by ~~our property operations, offset~~operating activities of $29,943,000 for the nine months ended September 30, 2020. The decrease in cash provided by operating activities of $13,387,000 was primarily due to payments of general and administrative expenses, interest payments on our outstanding indebtedness and ~~business acquisition expenses. See~~payment of costs related to the ~~“Results~~Merger of ~~Operations” section above for a further discussion. In general, cash flows provided by operating activities will be affected by~~$6,753,000 during the ~~timing~~nine months ended September 30, 2021, as well as grant income of ~~cash receipts and payments.~~$864,000 recognized during the nine months ended September 30, 2020.

Investing Activities

For the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, cash flows used in investing activities related to our property acquisitions in the amount of ~~$3,375,000~~$3,385,000 and ~~$67,932,000,~~$68,032,000, respectively, and the payment of ~~$2,334,000~~$4,384,000 and ~~$4,616,000,~~$6,729,000, respectively, for capital expenditures. For the ~~six~~nine months ended ~~June~~September 30, 2021, cash flows used in investing activities were offset by ~~$6,184,000~~$6,196,000 in net proceeds from the sale of two senior housing facilities, which were part of the Northern California Senior Housing Portfolio. We anticipate that cash flows used in investing activities will primarily be affected by the timing of capital expenditures, and generally will decrease as compared to prior years as we have substantially completed the acquisition phase of our real estate investment strategy.

Financing Activities

For the ~~six~~nine months ended ~~June~~September 30, 2021, cash flows used in financing activities ~~related primarily~~was $15,939,000, compared to $10,772,000 in distributions to our common stockholders, the payment of offering costs of $2,705,000 primarily in connection with our initial offering and share repurchases of $1,874,000, partially offset by net borrowings on our line of credit of $6,000,000. For the six months ended June 30, 2020, cash flows provided by financing activities ~~related~~of $52,368,000 for the nine months ended September 30, 2020. The $68,307,000 change from cash provided by financing activities to cash used in financing activities was primarily due to the decrease in net ~~borrowings~~borrowing proceeds on our ~~line~~2018 Credit Facility of ~~credit~~$70,700,000 and an increase of ~~$82,700,000, partially offset by $10,042,000~~$7,768,000 in distributions paid to our common stockholders, partially offset by the January 2020 payoff of one mortgage loan payable with a principal balance of $7,738,000 and a decrease in share repurchases of ~~$4,643,000.~~$3,475,000. The increase in distributions paid in cash for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020 was primarily due to the suspension of the DRIP by our board on March 18, 2021, resulting in no further issuances of shares pursuant to the DRIP, and stockholders who were participants in the DRIP received cash distributions instead beginning with the May 2021 payment date. The decrease in share repurchases paid ~~for~~in the ~~six~~nine months ended ~~June~~September 30, 2021 compared to the ~~six~~nine months ended ~~June~~September 30, 2020 was primarily related to the partial suspension of our share repurchase plan in March 2020 by our board to protect our capital and maximize our liquidity in response to the impact of the COVID-19 pandemic. See Note 12, Equity, and Note 20, Subsequent Events — Reinstatement of the DRIP and — Amendments to and Partial Reinstatement of Share Repurchase Plan, to our accompanying condensed consolidated financial statements, for a further discussion regarding our share repurchase ~~plan.~~plan and DRIP distributions. Overall, we anticipate cash flows from financing activities to decrease in the future.

~~Table of Contents~~

Distributions

Prior to March 31, 2020, our board authorized a daily distribution to our stockholders of record as of the close of business on each day of the period commencing on May 1, 2016 and ending on March 31, 2020. The daily distributions were calculated based on 365 days in the calendar year and were equal to $0.001643836 per share of our Class T and Class I common stock, which was equal to an annualized distribution rate of $0.60 per share. These distributions were aggregated and paid monthly in arrears in cash or shares of our common stock pursuant to our DRIP Offerings, only from legally available funds.

In response to the COVID-19 pandemic and its effects to our business and operations, at the end of the first quarter of 2020, our board decided to take steps to protect our capital and maximize our liquidity in an effort to strengthen our long-term financial prospects by reducing our distribution payments to stockholders. Consequently, our board authorized a daily distribution to our stockholders of record as of the close of business on each day of the period commencing on April 1, 2020 and ending on August 31, 2021, which was ~~or will be~~ calculated based on 365 days in the calendar year and iswas equal to $0.001095890 per share of our Class T and Class I common stock. Such daily distribution iswas equal to an annualized distribution rate of $0.40 per share. The distributions were ~~or will be~~ aggregated and paid in cash or shares of our common stock pursuant to the DRIP on a monthly basis, in arrears, only from legally available funds.

Our board of directors also authorized distributions to our Class T and Class I stockholders of record as of the close of business on September 17, 2021 and October 27, 2021. The distributions were equal to $0.0328767 and $0.033333333 per share of our common stock for the months of September 2021 and October 2021, respectively, which was equal to an annualized distribution of $0.40 per share. The distributions were paid in cash in September 2021 and November 2021, respectively, only from legally available funds.

Table of Contents

As discussed above, in connection with our special committee’s strategic alternative review process, on March 18, 2021, our board authorized the suspension of the DRIP, effective as of April 1, ~~2021, until such time, if any, as our board determines to reinstate the DRIP.~~2021. As a result, beginning with the April 2021 distributions, which were paid in May 2021, there were no further issuances of shares pursuant to the DRIP, and stockholders who are participants in the DRIP received or will receive cash distributions instead. As also discussed above, on October 4, 2021, our board authorized the reinstatement of the DRIP and as a result, beginning with the October 2021 distribution, which were paid in November 2021, stockholders who previously enrolled as participants in the DRIP (including former GAHR III stockholders who participated in the GAHR III distribution reinvestment plan) received distributions in shares of our common stock pursuant to the terms of the DRIP, instead of cash distributions. See Note 20, Subsequent Events — Reinstatement of the DRIP, to our accompanying condensed consolidated financial statements, for a further discussion, and our Current Report on Form 8-K filed with the SEC on October 5, 2021 for more information on the reinstatement of the DRIP and the declaration of October 2021 distribution.

The amount of distributions paid to our stockholders is determined by our board and is dependent on a number of factors, including funds available for payment of distributions, our financial condition, capital expenditure requirements and annual distribution requirements needed to maintain our qualification as a REIT under the Code. We have not established any limit on the amount of borrowings that may be used to fund distributions, except that, in accordance with our organizational documents and Maryland law, we may not make distributions that would: (i) cause us to be unable to pay our debts as they become due in the usual course of business; or (ii) cause our total assets to be less than the sum of our total liabilities plus senior liquidation preferences.

The distributions paid for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, along with the amount of distributions reinvested pursuant to our DRIP Offerings and the sources of distributions as compared to cash flows from operations were as follows:


		Six Months Ended June 30,									Nine Months Ended September 30,
		2021				2020					2021				2020
Distributions paid in cash	Distributions paid in cash	$	10,772,000			$	10,042,000			Distributions paid in cash	$	21,700,000			$	13,932,000
Distributions reinvested	Distributions reinvested	5,499,000				11,434,000				Distributions reinvested	5,499,000				15,681,000
		$	16,271,000			$	21,476,000				$	27,199,000			$	29,613,000
Sources of distributions:	Sources of distributions:									Sources of distributions:
Cash flows from operations	Cash flows from operations	$	13,886,000	85.3	%	$	19,047,000	88.7	%	Cash flows from operations	$	16,556,000	60.9	%	$	29,613,000	100	%
Proceeds from borrowings	Proceeds from borrowings	2,385,000		14.7		2,429,000		11.3		Proceeds from borrowings	10,643,000		39.1		—		—
		$	16,271,000	100	%	$	21,476,000	100	%		$	27,199,000	100	%	$	29,613,000	100	%

As of ~~June~~September 30, 2021, any distributions of amounts in excess of our current and accumulated earnings and profits have resulted in a return of capital to our stockholders, and all or any portion of a distribution to our stockholders may have been paid from net offering proceeds and borrowings. The payment of distributions from our net offering proceeds and borrowings have reduced the amount of capital we ultimately invested in assets and negatively impacted the amount of income available for future distributions.

~~Table of Contents~~

The distributions paid for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, along with the amount of distributions reinvested pursuant to our DRIP Offerings and the sources of our distributions as compared to funds from operations attributable to controlling interest, or FFO, were as follows:


		Six Months Ended June 30,									Nine Months Ended September 30,
		2021				2020					2021				2020
Distributions paid in cash	Distributions paid in cash	$	10,772,000			$	10,042,000			Distributions paid in cash	$	21,700,000			$	13,932,000
Distributions reinvested	Distributions reinvested	5,499,000				11,434,000				Distributions reinvested	5,499,000				15,681,000
		$	16,271,000			$	21,476,000				$	27,199,000			$	29,613,000
Sources of distributions:	Sources of distributions:									Sources of distributions:
FFO attributable to controlling interest	FFO attributable to controlling interest	$	16,271,000	100	%	$	17,819,000	83.0	%	FFO attributable to controlling interest	$	23,126,000	85.0	%	$	29,361,000	99.1	%

Proceeds from borrowings	Proceeds from borrowings	—		—		3,657,000		17.0		Proceeds from borrowings	4,073,000		15.0		252,000		0.9
		$	16,271,000	100	%	$	21,476,000	100	%		$	27,199,000	100	%	$	29,613,000	100	%

Table of Contents

The payment of distributions from sources other than FFO may reduce the amount of proceeds available for investment and operations or cause us to incur additional interest expense as a result of borrowed funds. For a further discussion of FFO, a non-GAAP financial measure, including a reconciliation of our GAAP net income (loss) to FFO, see the “Funds from Operations and Modified Funds from Operations” section below.

Financing

We anticipate that our overall leverage will not exceed 50.0% of the combined market value of all of our properties, including the properties acquired as part of the Merger, and other real estate-related investments, as determined at the end of each calendar year. For these purposes, the fair market value of each asset will be equal to the purchase price paid for the asset or, if the asset was appraised subsequent to the date of purchase, then the fair market value will be equal to the value reported in the most recent independent appraisal of the asset. Our policies do not limit the amount we may borrow with respect to any individual investment. As of ~~June~~September 30, 2021, our aggregate borrowings were ~~40.0%~~40.5% of the combined market value of all of our real estate investments.

Under our charter, we have a limitation on borrowing that precludes us from borrowing in excess of 300% of our net assets without the approval of a majority of our independent directors. Net assets for purposes of this calculation are defined to be our total assets (other than intangibles), valued at cost prior to deducting depreciation, amortization, bad debt and other non-cash reserves, less total liabilities. Generally, the preceding calculation is expected to approximate 75.0% of the aggregate cost of our real estate and real estate-related investments before depreciation, amortization, bad debt and other similar non-cash reserves. In addition, we may incur mortgage debt and pledge some or all of our real properties as security for that debt to obtain funds to acquire additional real estate or for working capital. Furthermore, we may borrow if we ~~otherwise~~otherwise deem it necessary or ~~advisable~~advisable to ensure that we maintain our qualification as a REIT for federal income tax purposes. As of ~~August 13, 2021 and June~~September 30, 2021, our leverage did not exceed 300% of the value of our net assets.

Mortgage Loans Payable, Net

For a discussion of our mortgage loans payable, net, see Note 6, Mortgage Loans Payable, Net, to our accompanying condensed consolidated financial statements.

~~Line~~Lines of Credit and Term Loans

For a discussion of our line of credit and term loans, see Note 7, Line of Credit and Term Loans and Note 20, Subsequent Events — Lines of Credit and Term Loans, to our accompanying condensed consolidated financial statements.

REIT Requirements

In order to maintain our qualification as a REIT for federal income tax purposes, we are required to distribute to our stockholders a minimum of 90.0% of our annual taxable income, excluding net capital gains. Existing Internal Revenue Service, or IRS, guidance includes a safe harbor pursuant to which publicly offered REITs can satisfy the distribution requirement by distributing a combination of cash and stock to stockholders. In general, to qualify under the safe harbor, each stockholder must elect to receive either cash or stock, and the aggregate cash component of the distribution to stockholders must represent at least 20.0% of the total distribution. In the event that there is a shortfall in net cash available due to factors including, without limitation, the timing of such distributions or the timing of the collection of receivables, we may seek to obtain capital to pay distributions by means of secured and unsecured debt financing through one or more unaffiliated third parties. We may also pay distributions from cash from capital transactions including, without limitation, the sale of one or more of our properties.

~~Table of Contents~~

Commitments and Contingencies

For a discussion of our commitments and contingencies, see Note 10, Commitments and Contingencies, to our accompanying condensed consolidated financial statements.

Debt Service Requirements

A significant liquidity need is the payment of principal and interest on our outstanding indebtedness. As of ~~June~~September 30, 2021, we had ~~$18,474,000~~$18,291,000 ($~~17,572,000,~~17,409,000, net of discount/premium and deferred financing costs) of fixed-rate mortgage loans payable outstanding secured by our properties. As of ~~June~~September 30, 2021, we had ~~$482,900,000~~$488,900,000 outstanding and ~~$47,100,000~~$41,100,000 remained available under ~~our line of credit.~~the 2018 Credit Facility. See Note 6, Mortgage Loans Payable, Net, and Note 7, Line of Credit and Term Loans, to our accompanying condensed consolidated financial statements.

We are required by the terms of certain loan documents to meet certain reporting requirements and covenants, such as leverage ratios, net worth ratios, debt service coverage ratios and fixed charge coverage ratios. As of ~~June~~September 30, 2021, we

Table of Contents

were in compliance with all such covenants and requirements on our Combined Company mortgage loans payable and ~~our line of credit and term loans.~~the Credit Facilities. As of ~~June~~September 30, 2021, the weighted average effective interest rate on our outstanding debt, factoring in our fixed-rate interest rate swaps, was ~~3.53%~~3.32% per annum.

Contractual Obligations

The following table provides information with respect to: (i) the maturity and scheduled principal repayment of our secured mortgage loans payable and ~~our line of credit and term loans;~~the 2018 Credit Facility; (ii) interest payments on our mortgage loans payable and ~~our line of credit and term loans;~~the 2018 Credit Facility; and (iii) ground lease obligations as of ~~June~~September 30, 2021:


		Payments Due by Period											Payments Due by Period
		2021		2022-2023		2024-2025		Thereafter		Total			2021		2022-2023		2024-2025		Thereafter		Total
Principal payments — fixed-rate debt	Principal payments — fixed-rate debt	$	315,000	$	1,331,000	$	6,589,000	$	10,239,000	$	18,474,000	Principal payments — fixed-rate debt	$	132,000	$	1,331,000	$	6,589,000	$	10,239,000	$	18,291,000
Interest payments — fixed-rate debt	Interest payments — fixed-rate debt	361,000		1,370,000		1,113,000		4,970,000		7,814,000		Interest payments — fixed-rate debt	179,000		1,370,000		1,113,000		4,970,000		7,632,000
Principal payments — variable-rate debt	Principal payments — variable-rate debt	482,900,000		—		—		—		482,900,000		Principal payments — variable-rate debt	488,900,000		—		—		—		488,900,000
Interest payments — variable-rate debt (based on rates in effect as of June 30, 2021)		4,617,000		—		—		—		4,617,000
Interest payments — variable-rate debt (based on rates in effect as of September 30, 2021)												Interest payments — variable-rate debt (based on rates in effect as of September 30, 2021)	1,691,000		—		—		—		1,691,000
Ground lease obligations	Ground lease obligations	306,000		1,056,000		1,072,000		46,565,000		48,999,000		Ground lease obligations	213,000		1,056,000		1,072,000		46,565,000		48,906,000
Total	Total	$	488,499,000	$	3,757,000	$	8,774,000	$	61,774,000	$	562,804,000	Total	$	491,115,000	$	3,757,000	$	8,774,000	$	61,774,000	$	565,420,000

Off-Balance Sheet Arrangements

As of ~~June~~September 30, 2021, we had no off-balance sheet transactions, nor do we currently have any such arrangements or obligations.

Inflation

During the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, inflation has not significantly affected our operations because of the moderate inflation rate; however, we expect to be exposed to inflation risk as income from future long-term tenant leases will be the primary source of our cash flows from operations. There are provisions in the majority of our tenant leases that will protect us from the impact of inflation. These provisions include negotiated rental increases, reimbursement billings for operating expense pass-through charges and real estate tax and insurance reimbursements. However, due to the long-term nature of the anticipated leases, among other factors, the leases may not re-set frequently enough to cover inflation.

Related Party Transactions

For a summary of related party transactions, see Note 13, Related Party Transactions, to our accompanying condensed consolidated financial statements and Note 13, Related Party Transactions of our 2020 Annual Report on Form 10-K, as filed with the SEC on March 26, 2021.

~~Table of Contents~~

Funds from Operations and Modified Funds from Operations

Due to certain unique operating characteristics of real estate companies, the National Association of Real Estate Investment Trusts, or NAREIT, an industry trade group, has promulgated a measure known as funds from operations, a non-GAAP measure, which we believe to be an appropriate supplemental performance measure to reflect the operating performance of a REIT. The use of funds from operations is recommended by the REIT industry as a supplemental performance measure, and our management uses FFO to evaluate our performance over time. FFO is not equivalent to our net income (loss) as determined under GAAP.

We define FFO, a non-GAAP measure, consistent with the standards established by the White Paper on funds from operations approved by the Board of Governors of NAREIT, or the White Paper. The White Paper defines funds from operations as net income (loss) computed in accordance with GAAP, excluding gains or losses from sales of certain real estate assets and impairment writedowns of certain real estate assets and investments, plus depreciation and amortization related to real estate, and after adjustments for unconsolidated partnerships and joint ventures. While impairment charges are excluded from the calculation of FFO as described above, investors are cautioned that impairments are based on estimated future undiscounted cash flows. Adjustments for unconsolidated partnerships and joint ventures are calculated to reflect funds from operations. Our FFO calculation complies with NAREIT’s policy described above.

Historical accounting for real estate involves the use of GAAP. Any other method of accounting for real estate such as the fair value method cannot be construed to be any more accurate or relevant than the comparable methodologies of real estate

Table of Contents

valuation found in GAAP. Nevertheless, we believe that the use of FFO, which excludes the impact of real estate-related depreciation and amortization and impairments, provides a further understanding of our performance to investors and to our management, and when compared year over year, reflects the impact on our operations from trends in occupancy rates, rental rates, operating costs, general and administrative expenses and interest costs, which may not be immediately apparent from net income (loss).

However, FFO and modified funds from operations attributable to controlling interest, or MFFO, as described below, should not be construed to be more relevant or accurate than the current GAAP methodology in calculating net income (loss) or in its applicability in evaluating our operating performance. The method utilized to evaluate the value and performance of real estate under GAAP should be construed as a more relevant measure of operational performance and considered more prominently than the non-GAAP FFO and MFFO measures and the adjustments to GAAP in calculating FFO and MFFO.

The IPA, an industry trade group, has standardized a measure known as modified funds from operations, which the IPA has recommended as a supplemental performance measure for publicly registered, non-listed REITs and which we believe to be another appropriate supplemental performance measure to reflect the operating performance of a publicly registered, non-listed REIT having the characteristics described above. MFFO is not equivalent to our net income (loss) as determined under GAAP, and MFFO may not be a useful measure of the impact of long-term operating performance on value if we do not continue to operate with a limited life and targeted exit strategy, as currently intended. We believe that, because MFFO excludes expensed acquisition fees and expenses that affect our operations only in periods in which properties are acquired and that we consider more reflective of investing activities, as well as other non-operating items included in FFO, MFFO can provide, on a going forward basis, an indication of the sustainability (that is, the capacity to continue to be maintained) of our operating performance after the period in which we are acquiring our properties and once our portfolio is in place. By providing MFFO, we believe we are presenting useful information that assists investors and analysts to better assess the sustainability of our operating performance after our initial offering stage has been completed and our properties have been acquired. We also believe that MFFO is a recognized measure of sustainable operating performance by the publicly registered, non-listed REIT industry. Further, we believe MFFO is useful in comparing the sustainability of our operating performance after our initial offering stage and acquisitions are completed with the sustainability of the operating performance of other real estate companies that are not as involved in acquisition activities. Investors are cautioned that MFFO should only be used to assess the sustainability of our operating performance after our initial offering stage has been completed and properties have been acquired, as it excludes expensed acquisition fees and expenses that have a negative effect on our operating performance during the periods in which properties are acquired.

~~Table of Contents~~

We define MFFO, a non-GAAP measure, consistent with the Practice Guideline issued by the IPA. The Practice Guideline defines modified funds from operations as funds from operations further adjusted for the following items included in the determination of GAAP net income (loss): expensed acquisition fees and costs; amounts relating to deferred rent and amortization of above- and below-market leases and liabilities (which are adjusted in order to reflect such payments from a GAAP accrual basis to closer to an expected to be received cash basis of disclosing the rent and lease payments); accretion of discounts and amortization of premiums on debt investments; mark-to-market adjustments included in net income (loss); gains or losses included in net income (loss) from the extinguishment or sale of debt, hedges, foreign exchange, derivatives or securities holdings where trading of such holdings is not a fundamental attribute of the business plan; unrealized gains or losses resulting from consolidation from, or deconsolidation to, equity accounting; and after adjustments for consolidated and unconsolidated partnerships and joint ventures, with such adjustments calculated to reflect modified funds from operations on the same basis. Our MFFO calculation complies with the IPA’s Practice Guideline described above.

Our management uses MFFO and the adjustments used to calculate it in order to evaluate our performance against other publicly registered, non-listed REITs which intend to have limited lives with short and defined acquisition periods and targeted exit strategies shortly thereafter. As noted above, MFFO may not be a useful measure of the impact of long-term operating performance if we do not continue to operate in this manner. We believe that our use of MFFO and the adjustments used to calculate it allow us to present our performance in a manner that reflects certain characteristics that are unique to publicly registered, non-listed REITs, such as their limited life, limited and defined acquisition period and targeted exit strategy, and hence, that the use of such measures may be useful to investors.

Presentation of this information is intended to provide useful information to investors as they compare the operating performance of different REITs, although it should be noted that not all REITs calculate funds from operations and modified funds from operations the same way, so comparisons with other REITs may not be meaningful. Furthermore, FFO and MFFO are not necessarily indicative of cash flow available to fund cash needs and should not be considered as an alternative to net income (loss) as an indication of our performance, as an alternative to cash flows from operations, which is an indication of our liquidity, or indicative of funds available to fund our cash needs including our ability to make distributions to our stockholders. FFO and MFFO should be reviewed in conjunction with other measurements as an indication of our performance. MFFO may be useful in assisting management and investors in assessing the sustainability of operating performance in future operating

Table of Contents

periods, and in particular, after the offering and acquisition stages are complete. FFO and MFFO are not useful measures in evaluating net asset value because impairments are taken into account in determining net asset value but not in determining FFO and MFFO.

Neither the SEC, NAREIT nor any other regulatory body has passed judgment on the acceptability of the adjustments that we use to calculate FFO or MFFO. In the future, the SEC, NAREIT or another regulatory body may decide to standardize the allowable adjustments across the publicly registered, non-listed REIT industry and we would have to adjust our calculation and characterization of FFO or MFFO.

For both the three and ~~six~~nine months ended ~~June~~September 30, ~~2021,~~2020, we recognized government grants through economic stimulus programs of the ~~Coronavirus Aid, Relief, and Economic Security~~CARES Act as grant income or ~~the CARES Act,~~ within income or loss from an unconsolidated entity. Such amounts were established for eligible healthcare providers to preserve liquidity in response to the COVID-19 pandemic. The government grants helped mitigate some of the negative impact that the COVID-19 pandemic had on our financial condition and results of operations. Without such relief funds, the COVID-19 pandemic impact would have had a material adverse impact to our FFO and MFFO. For the three months ended ~~June~~September 30, 2021 and 2020, FFO would have been approximately ~~$7,856,000~~$5,809,000 and ~~$10,485,000,~~$10,662,000, respectively, ~~excluding government grants recognized by our unconsolidated entity. For~~and for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, FFO would have been approximately ~~$16,713,000~~$22,522,000 and ~~$15,901,000,~~$26,563,000, respectively, excluding government grants ~~recognized by our unconsolidated entity.~~recognized. For the three months ended ~~June~~September 30, 2021 and 2020, MFFO would have been approximately ~~$7,807,000~~$7,659,000 and ~~$8,687,000,~~$8,200,000, respectively, ~~excluding government grants recognized by our unconsolidated entity. For~~and for the ~~six~~nine months ended ~~June~~September 30, 2021 and 2020, MFFO would have been approximately ~~$14,872,000~~$22,531,000 and ~~$17,828,000,~~$26,028,000, respectively, excluding government grants ~~recognized by our unconsolidated entity.~~

recognized.

4750

Table of Contents

The following is a reconciliation of net income or loss, which is the most directly comparable GAAP financial measure, to FFO and MFFO for the periods presented below:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			2021		2020		2021		2020
Net loss	Net loss	$	(3,876,000)	$	(1,155,000)	$	(7,884,000)	$	(9,088,000)	Net loss	$	(5,898,000)	$	(5,152,000)	$	(13,782,000)	$	(14,240,000)
Add:	Add:									Add:
Depreciation and amortization related to real estate — consolidated properties	Depreciation and amortization related to real estate — consolidated properties	10,597,000		12,720,000		22,999,000		25,250,000		Depreciation and amortization related to real estate — consolidated properties	10,746,000		12,669,000		33,745,000		37,919,000
Depreciation and amortization related to real estate — unconsolidated entity	Depreciation and amortization related to real estate — unconsolidated entity	967,000		878,000		1,912,000		1,760,000		Depreciation and amortization related to real estate — unconsolidated entity	977,000		880,000		2,889,000		2,640,000
Loss on disposition of real estate investments — unconsolidated entity		3,000		—		3,000		—
Loss on disposition of real estate investments		199,000		—		199,000		—
Impairment of real estate investments — consolidated properties										Impairment of real estate investments — consolidated properties	—		3,064,000		—		3,064,000
(Gain) loss on disposition of real estate investments — consolidated properties										(Gain) loss on disposition of real estate investments — consolidated properties	(15,000)		—		184,000		—
Impairments and gain or loss on disposition of real estate investments, net — unconsolidated entity										Impairments and gain or loss on disposition of real estate investments, net — unconsolidated entity	4,000		99,000		7,000		99,000
Net loss attributable to noncontrolling interests	Net loss attributable to noncontrolling interests	104,000		209,000		368,000		376,000		Net loss attributable to noncontrolling interests	121,000		232,000		489,000		608,000
Less:	Less:									Less:
Depreciation, amortization and loss on disposition — noncontrolling interests	Depreciation, amortization and loss on disposition — noncontrolling interests	(85,000)		(249,000)		(334,000)		(479,000)		Depreciation, amortization and loss on disposition — noncontrolling interests	(72,000)		(250,000)		(406,000)		(729,000)
FFO attributable to controlling interest	FFO attributable to controlling interest	$	7,909,000	$	12,403,000	$	17,263,000	$	17,819,000	FFO attributable to controlling interest	$	5,863,000	$	11,542,000	$	23,126,000	$	29,361,000

Business acquisition expenses(1)	Business acquisition expenses(1)	$	2,438,000	$	8,000	$	2,752,000	$	17,000	Business acquisition expenses(1)	$	3,800,000	$	57,000	$	6,552,000	$	74,000
Amortization of above- and below-market leases(2)	Amortization of above- and below-market leases(2)	37,000		41,000		77,000		59,000		Amortization of above- and below-market leases(2)	38,000		31,000		115,000		90,000

Change in deferred rent(3)	Change in deferred rent(3)	(1,104,000)		(1,149,000)		(1,977,000)		(2,223,000)		Change in deferred rent(3)	(523,000)		(1,009,000)		(2,500,000)		(3,232,000)
(Gain) loss in fair value of derivative financial instruments(4)	(Gain) loss in fair value of derivative financial instruments(4)	(1,462,000)		(853,000)		(2,917,000)		3,752,000		(Gain) loss in fair value of derivative financial instruments(4)	(1,514,000)		(1,450,000)		(4,431,000)		2,302,000
Adjustments for unconsolidated entity(5)	Adjustments for unconsolidated entity(5)	42,000		155,000		224,000		328,000		Adjustments for unconsolidated entity(5)	49,000		(91,000)		273,000		237,000
Adjustments for noncontrolling interests(5)	Adjustments for noncontrolling interests(5)	—		—		—		(6,000)		Adjustments for noncontrolling interests(5)	—		—		—		(6,000)
MFFO attributable to controlling interest	MFFO attributable to controlling interest	$	7,860,000	$	10,605,000	$	15,422,000	$	19,746,000	MFFO attributable to controlling interest	$	7,713,000	$	9,080,000	$	23,135,000	$	28,826,000
Weighted average Class T and Class I common shares outstanding — basic and diluted	Weighted average Class T and Class I common shares outstanding — basic and diluted	81,687,564		80,402,887		81,599,875		80,352,269		Weighted average Class T and Class I common shares outstanding — basic and diluted	81,704,261		80,788,359		81,635,053		80,498,693
Net loss per Class T and Class I common share — basic and diluted	Net loss per Class T and Class I common share — basic and diluted	$	(0.05)	$	(0.01)	$	(0.10)	$	(0.11)	Net loss per Class T and Class I common share — basic and diluted	$	(0.07)	$	(0.06)	$	(0.17)	$	(0.18)
FFO attributable to controlling interest per Class T and Class I common share — basic and diluted	FFO attributable to controlling interest per Class T and Class I common share — basic and diluted	$	0.10	$	0.15	$	0.21	$	0.22	FFO attributable to controlling interest per Class T and Class I common share — basic and diluted	$	0.07	$	0.14	$	0.28	$	0.36
MFFO attributable to controlling interest per Class T and Class I common share — basic and diluted	MFFO attributable to controlling interest per Class T and Class I common share — basic and diluted	$	0.10	$	0.13	$	0.19	$	0.25	MFFO attributable to controlling interest per Class T and Class I common share — basic and diluted	$	0.09	$	0.11	$	0.28	$	0.36

___________

(1)In evaluating investments in real estate, we differentiate the costs to acquire the investment from the operations derived from the investment. Such information would be comparable only for publicly registered, non-listed REITs that have completed their acquisition activity and have other similar operating characteristics. By excluding business acquisition expenses that have been deducted as expenses in the determination of GAAP net income or loss, we believe MFFO provides useful supplemental information that is comparable for each type of real estate investment and is consistent with management’s analysis of the investing and operating performance of our properties. Business acquisition expenses include payments to our advisor or its affiliates and third parties.

(2)Under GAAP, above- and below-market leases are assumed to diminish predictably in value over time and amortized, similar to depreciation and amortization of other real estate-related assets that are excluded from FFO. However, because real estate values and market lease rates historically rise or fall with market conditions, including inflation, interest rates, the business cycle, unemployment and consumer spending, we believe that by excluding charges relating to the amortization of above- and below-market leases, MFFO may provide useful supplemental information on the performance of the real estate.

(3)Under GAAP, as a lessor, rental revenue is recognized on a straight-line basis over the terms of the related lease (including rent holidays). As a lessee, we record amortization of right-of-use assets and accretion of lease liabilities for

Table of Contents

our operating leases. This may result in income or expense recognition that is significantly different than the underlying contract terms. By adjusting for such amounts, MFFO may provide useful supplemental information on the realized

~~Table of Contents~~

economic impact of lease terms, providing insight on the expected contractual cash flows of such lease terms, and aligns results with management’s analysis of operating performance.

(4)Under GAAP, we are required to include changes in fair value of our derivative financial instruments in the determination of net income or loss. We believe that adjusting for the change in fair value of our derivative financial instruments to arrive at MFFO is appropriate because such adjustments may not be reflective of on-going operations and reflect unrealized impacts on value based only on then current market conditions, although they may be based upon general market conditions. The need to reflect the change in fair value of our derivative financial instruments is a continuous process and is analyzed on a quarterly basis in accordance with GAAP.

(5)Includes all adjustments to eliminate the unconsolidated entity’s share or noncontrolling interests’ share, as applicable, of the adjustments described in notes (1) – (4) above to convert our FFO to MFFO.

Net Operating Income

NOI is a non-GAAP financial measure that is defined as net income (loss), computed in accordance with GAAP, generated from properties before general and administrative expenses, business acquisition expenses, depreciation and amortization, interest expense, loss on disposition of real estate investments, income or loss from unconsolidated entity, other income and income tax expense. NOI is not equivalent to our net income (loss) as determined under GAAP and may not be a useful measure in measuring operational income or cash flows. Furthermore, NOI should not be considered as an alternative to net income (loss) as an indication of our performance, as an alternative to cash flows from operations, as an indication of our liquidity, or indicative of cash flow available to fund our cash needs including our ability to make distributions to our stockholders. NOI should not be construed to be more relevant or accurate than the current GAAP methodology in calculating net income (loss) or in its applicability in evaluating our operating performance. Investors are also cautioned that NOI should only be used to assess our operational performance in periods in which we have not incurred or accrued any business acquisition expenses.

We believe that NOI is an appropriate supplemental performance measure to reflect the performance of our operating assets because NOI excludes certain items that are not associated with the operations of the properties. We believe that NOI is a widely accepted measure of comparative operating performance in the real estate community. However, our use of the term NOI may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount.

For both the three and nine months ended September 30, 2021, we did not recognize any government grants. For both the three and nine months ended September 30, 2020, we recognized government grants through economic stimulus programs of the CARES Act as grant income. The government grants helped mitigate some of the negative impact that the COVID-19 pandemic had on our financial condition. Without such relief proceeds, the negative impact of the COVID-19 pandemic would have had a material adverse impact to our NOI. For the three and nine months ended September 30, 2020, NOI would have been approximately $17,165,000 and $54,108,000, respectively, excluding government grants recognized.

To facilitate understanding of this financial measure, the following is a reconciliation of net income or loss, which is the most directly comparable GAAP financial measure, to NOI for the periods presented below:


		Three Months Ended June 30,				Six Months Ended June 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			2021		2020		2021		2020
Net loss	Net loss	$	(3,876,000)	$	(1,155,000)	$	(7,884,000)	$	(9,088,000)	Net loss	$	(5,898,000)	$	(5,152,000)	$	(13,782,000)	$	(14,240,000)
General and administrative	General and administrative	3,659,000		3,840,000		7,406,000		8,288,000		General and administrative	4,304,000		3,672,000		11,710,000		11,960,000
Business acquisition expenses	Business acquisition expenses	2,438,000		8,000		2,752,000		17,000		Business acquisition expenses	3,800,000		57,000		6,552,000		74,000
Depreciation and amortization	Depreciation and amortization	10,597,000		12,720,000		22,999,000		25,250,000		Depreciation and amortization	10,746,000		12,669,000		33,745,000		37,919,000
Interest expense	Interest expense	3,407,000		4,121,000		6,678,000		14,036,000		Interest expense	3,447,000		3,389,000		10,125,000		17,425,000
Loss on disposition of real estate investments		199,000		—		199,000		—
Loss (income) from unconsolidated entity		193,000		(1,074,000)		1,097,000		(1,329,000)
Impairment of real estate investments										Impairment of real estate investments	—		3,064,000		—		3,064,000
(Gain) loss on disposition of real estate investments										(Gain) loss on disposition of real estate investments	(15,000)		—		184,000		—
(Income) loss from unconsolidated entity										(Income) loss from unconsolidated entity	(70,000)		377,000		1,027,000		(952,000)
Other income	Other income	(9,000)		(261,000)		(16,000)		(270,000)		Other income	(33,000)		(8,000)		(49,000)		(278,000)
Income tax expense		—		39,000		—		39,000
Income tax benefit										Income tax benefit	—		(39,000)		—		—
Net operating income	Net operating income	$	16,608,000	$	18,238,000	$	33,231,000	$	36,943,000	Net operating income	$	16,281,000	$	18,029,000	$	49,512,000	$	54,972,000

Table of Contents

Subsequent Events

For a discussion of subsequent events, see Note 20, Subsequent Events, to our accompanying condensed consolidated financial statements.

~~Table of Contents~~

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Market risk includes risks that arise from changes in interest rates, commodity prices, equity prices and other market changes that affect market sensitive instruments. In pursuing our business plan, we expect that the primary market risk to which we will be exposed is interest rate risk. There were no material changes in our market risk exposures, or in the methods we use to manage market risk, from those that were provided for in our 2020 Annual Report on Form 10-K, as filed with the SEC on March 26, 2021.

Interest Rate Risk

We are exposed to the effects of interest rate changes primarily as a result of long-term debt used to acquire properties and other permitted investments. Our interest rate risk is monitored using a variety of techniques. Our interest rate risk management objectives are to limit the impact of interest rate changes on earnings, prepayment penalties and cash flows and to lower overall borrowing costs while taking into account variable interest rate risk. To achieve our objectives, we may borrow at fixed or variable rates.

We have entered into, and may continue to enter into, derivative financial instruments such as interest rate swaps in order to mitigate our interest rate risk on a related financial instrument. We do not apply hedge accounting treatment to these derivatives; therefore, changes in the fair value of interest rate derivative financial instruments are recorded as a component of interest expense in gain or loss in fair value of derivative financial instruments in our accompanying condensed consolidated statements of operations. As of ~~June~~September 30, 2021, our interest rate swap liabilities are recorded in our accompanying condensed consolidated balance sheets at their aggregate fair value of ~~$2,338,000.~~$824,000. We will not enter into derivatives or interest rate transactions for speculative purposes.

In July 2017, the Financial Conduct Authority, or FCA, that regulates LIBOR announced its intention to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee, which identified the Secured Overnight Financing Rate, or SOFR, as its preferred alternative to United States dollar LIBOR in derivatives and other financial contracts. In March 2021, the FCA confirmed its intention to cease publishing one-week and two-month LIBOR after December 31, 2021 and all remaining LIBOR after June 30, 2023. At this time, it is not known whether or when SOFR or other alternative reference rates will attain market traction as replacements for LIBOR.

WeAs of September 30, 2021, we have variable rate debt outstanding under our credit facilities and derivative financial instruments maturing on November 19, 2021 that are indexed to LIBOR. We intend to extend the maturity date of such variable rate credit facilities for an additional 12 months pursuant to the terms of the 2018 Credit Agreement, as amended. As such, we are monitoring and evaluating the related risks of the discontinuation of LIBOR, which include possible changes to the interest on loans or amounts received and paid on derivative ~~instruments.~~instruments we may enter into in the future. These risks arise in connection with transitioning contracts to a new alternative rate, including any resulting value transfer that may occur. The value of loans or derivative instruments tied to LIBOR could also be impacted if LIBOR is discontinued. For some instruments, the method of transitioning to an alternative rate may be challenging, as they may require negotiation with the respective counterparty. If a contract is not transitioned to an alternative rate and LIBOR is discontinued, the impact on our contracts is likely to vary. If LIBOR is discontinued, interest rates on our current or future indebtedness may be adversely affected. Currently we cannot estimate the overall impact of the phase-out of LIBOR on our current debt agreements, although it is possible that an alternative variable rate could raise our borrowing costs. It is not possible to predict whether LIBOR will continue to be viewed as an acceptable market “benchmark” prior to June 30, 2023, and it is possible that LIBOR will become unavailable prior to that point. This could result, for example, if a sufficient number of banks decline to make submissions to the LIBOR administrator. In that case, the risks associated with the transition to an alternative reference rate will be accelerated and magnified.

5053

Table of Contents

As of ~~June~~September 30, 2021, the table below presents the principal amounts and weighted average interest rates by year of expected maturity to evaluate the expected cash flows and sensitivity to interest rate changes.


		Expected Maturity Date																								Expected Maturity Date
		2021			2022			2023			2024			2025			Thereafter			Total			Fair Value			2021			2022			2023			2024			2025			Thereafter			Total			Fair Value

Fixed-rate debt — principal payments	Fixed-rate debt — principal payments	$	315,000		$	651,000		$	680,000		$	711,000		$	5,878,000		$	10,239,000		$	18,474,000		$	20,970,000	Fixed-rate debt — principal payments	$	132,000		$	651,000		$	680,000		$	711,000		$	5,878,000		$	10,239,000		$	18,291,000		$	20,891,000
Weighted average interest rate on maturing fixed-rate debt	Weighted average interest rate on maturing fixed-rate debt	4.48		%	4.49		%	4.49		%	4.50		%	3.85		%	3.83		%	3.92		%	—		Weighted average interest rate on maturing fixed-rate debt	4.36		%	4.49		%	4.49		%	4.50		%	3.85		%	3.83		%	3.92		%	—
Variable-rate debt — principal payments	Variable-rate debt — principal payments	$	482,900,000		$	—		$	—		$	—		$	—		$	—		$	482,900,000		$	482,931,000	Variable-rate debt — principal payments	$	488,900,000		$	—		$	—		$	—		$	—		$	—		$	488,900,000		$	488,995,000
Weighted average interest rate on maturing variable-rate debt (based on rates in effect as of June 30, 2021)		2.25		%	—		%	—		%	—		%	—		%	—		%	2.25		%	—
Weighted average interest rate on maturing variable-rate debt (based on rates in effect as of September 30, 2021)																									Weighted average interest rate on maturing variable-rate debt (based on rates in effect as of September 30, 2021)	2.05		%	—		%	—		%	—		%	—		%	—		%	2.05		%	—

Mortgage Loans Payable, Net and Line of Credit and Term Loans

Mortgage loans payable was ~~$18,474,000~~$18,291,000 ($~~17,572,000,~~17,409,000, net of discount/premium and deferred financing costs) as of ~~June~~September 30, 2021. As of ~~June~~September 30, 2021, we had three fixed-rate mortgage loans payable with interest rates ranging from 3.67% to 5.25% per annum. In addition, as of ~~June~~September 30, 2021, we had ~~$482,900,000~~$488,900,000 outstanding under our line of credit and term loans at a weighted average interest rate of ~~2.25%~~2.05% per annum.

As of ~~June~~September 30, 2021, the weighted average effective interest rate on our outstanding debt, factoring in our fixed-rate interest rate swaps, was ~~3.53%~~3.32% per annum. An increase in the variable interest rate on our variable-rate line of credit and term loans constitutes a market risk. As of ~~June~~September 30, 2021, a 0.50% increase in the market rates of interest would have increased our overall annualized interest expense on our variable-rate line of credit and term loans by ~~$953,000,~~$983,000, or ~~5.53%~~5.63% of total annualized interest expense on our mortgage loans payable and our line of credit and term loans. See Note 6, Mortgage Loans Payable, Net, and Note 7, Line of Credit and Term Loans, to our accompanying condensed consolidated financial statements, for a further discussion.

Other Market Risk

In addition to changes in interest rates, the value of our investments is subject to fluctuations based on changes in local and regional economic conditions and changes in the creditworthiness of tenants, which may affect our ability to refinance our debt if necessary.

Item 4. Controls and Procedures.

(a) Evaluation of disclosure controls and procedures. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the rules and forms, and that such information is accumulated and communicated to us, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and we necessarily were required to apply our judgment in evaluating whether the benefits of the controls and procedures that we adopt outweigh their costs.

As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, an evaluation as of ~~June~~September 30, 2021 was conducted under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures, as of ~~June~~September 30, 2021, were effective at the reasonable assurance level.

(b) Changes in internal control over financial reporting. There were no changes in internal control over financial reporting that occurred during the fiscal quarter ended ~~June~~September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

5154

Table of Contents

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

For a discussion of our legal proceedings, see Note 10, Commitments and Contingencies — Litigation, to our accompanying condensed consolidated financial statements.

Item 1A. Risk Factors.

The use of the words “we,” “us” or “our” refers to ~~Griffin-American~~American Healthcare REIT, ~~IV,~~ Inc. and its subsidiaries, including Griffin-American Healthcare REIT IV Holdings, LP, except where otherwise noted.

There were no material changes from the risk factors previously disclosed in our 2020 Annual Report on Form 10-K, as filed with the SEC on March 26, 2021, except as noted below.

Risks Related to ~~Investments~~Our Business

The COVID-19 pandemic has adversely impacted, and will likely continue to adversely impact, our business and financial results, and the ultimate impact will depend on future developments, which are highly uncertain and cannot be predicted, including the scope and duration of the pandemic and actions taken by governmental authorities in ~~Real Estate~~response to the pandemic.

AIn December 2019, COVID-19 was identified in Wuhan, China. This virus continues to spread globally including in the United States. As a result of the COVID-19 pandemic and related shelter-in-place, business re-opening and quarantine restrictions, our property values, NOI and revenues may decline, and our tenants, operating partners and managers have been, and may continue to be, limited in their ability to generate income, service patients and residents and/or properly manage our properties. In addition, based on preliminary information available to management as of October 29, 2021, we have experienced an approximate 14.9% and 4.5% decline in resident occupancies since February 2020, as well as a significant increase in costs to care for residents, at our senior housing — RIDEA facilities and our integrated senior health campuses, respectively. Our leased, non-RIDEA senior housing and skilled nursing facility tenants have also experienced, and may continue to experience, similar pressures related to occupancy declines and expense increases, which may impact their ability to pay rent and have an adverse effect on our operations. However, through October 2021, substantially all rents have been collected from such leased, non-RIDEA senior housing and skilled nursing facility tenants. Given the significant uncertainty of the impact of the COVID-19 pandemic, we are unable to predict the impact it will have on such tenants’ continued ability to pay rent. Therefore, information provided regarding prior rent collections should not serve as an indication of expected future rent collections. As such, our immediate focus continues to be on resident occupancy recovery and operating expense management.

The emergence of the Delta variant and other new variants may put additional pressure on our operations. Additionally, the public perception of a risk of a pandemic or media coverage of the COVID-19 pandemic and related deaths or confirmed cases, or public perception of health risks linked to perceived regional healthcare safety in our senior housing or SNFs, particularly if focused on regions in which our properties are located, may adversely affect our business operations by reducing occupancy demand at our facilities. We have also held discussions with our tenants, operating partners and managers and they have expressed that the ultimate impact of the COVID-19 pandemic on their business operations is uncertain.

Although vaccines for COVID-19 that have been approved for use are generally effective, vaccine boosters may be necessary and there can be no assurance that efforts to vaccinate the public will be successful in ending the pandemic or that vaccines will be effective against variants such as the Delta variant. The rapid development and fluidity of this situation continues to preclude any prediction as to the ultimate adverse impact of the COVID-19 pandemic on economic and market conditions, and, as a result, present material uncertainty and risk with respect to us and the performance of our investments. The full extent of the impact and effects of the COVID-19 pandemic will depend on future developments, including, among other factors, the success of efforts to contain or treat COVID-19 and its variants, the use and distribution of effective vaccines and availability of such vaccines and vaccine boosters, potential resurgences of COVID-19, along with the related travel advisories, quarantines and business restrictions, the recovery time of the disrupted supply chains and industries, the impact of the labor market interruptions, the impact of government interventions, and the performance or valuation outlook for healthcare REIT markets and certain property types. The COVID-19 pandemic and the current financial, economic and capital markets environment, and future developments in these and other areas present uncertainty and risk and have had an adverse effect on us and may have a material adverse effect on us in the future.

Table of Contents

The integrated senior health campuses managed by Trilogy Management Services, LLC, or TMS, account for a significant portion of our ~~annual base rent may be concentrated~~revenues and/or operating income. Adverse developments in ~~a small number of tenants. Therefore, non-renewals, terminations~~TMS’s business or ~~lease defaults by any of these significant tenants~~financial condition could ~~reduce our net income and~~ have a ~~negative~~material adverse effect on ~~our ability to pay distributions to our stockholders.~~us.

As of ~~August 13,~~November 15, 2021, ~~rental payments by~~TMS managed all of the day-to-day operations for our ~~tenant, RC Tier Properties, LLC, accounted for approximately 11.1%~~integrated senior health campuses pursuant to long-term management agreements. These integrated senior health campuses represent a substantial portion of our ~~total property portfolio’s annualized base rent or annualized NOI. The success~~portfolio, based on their gross book value, and account for a significant portion of our ~~investments materially depends~~revenues and/or NOI. Although we have various rights as the owner of these integrated senior health campuses under our management agreements, we rely on TMS’s personnel, expertise, technical resources and information systems, proprietary information, good faith and judgment to manage our integrated senior health campuses operations efficiently and effectively, and to identify and manage development opportunities for new integrated senior health campuses. We also rely on TMS to provide accurate campus-level financial results for our integrated senior health campuses in a timely manner and to otherwise operate our integrated senior health campuses in compliance with the terms of our management agreements and all applicable laws and regulations. We depend on TMS’s ability to attract and retain skilled personnel to provide these services. A shortage of nurses or other trained personnel or general inflationary pressures may force TMS to enhance its pay and benefits package to compete effectively for such personnel, but it may not be able to offset these added costs by increasing the rates charged to residents. As such, any adverse developments in TMS’s business or financial condition, including its ability to retain key personnel, could impair its ability to manage our integrated senior health campuses efficiently and effectively and could have a material adverse effect on us. In addition, if TMS experiences any significant financial, legal, accounting or regulatory difficulties due to a weak economy, industry downturn or otherwise, such difficulties could result in, among other adverse events, acceleration of its indebtedness, impairment of its continued access to capital, the enforcement of default remedies by its counterparties, or the commencement of insolvency proceedings by or against it under the United States Bankruptcy Code. Any one or a combination of these risks could have a material adverse effect on us.

In the event that our management agreements with TMS are terminated or not renewed, we may be unable to replace TMS with another suitable manager, or, if we were successful in locating such a manager, that it would manage the integrated senior health campuses effectively or that any such transition would be completed timely, which may have a material adverse effect on us.

We continually monitor and assess our contractual rights and remedies under our management agreements with TMS. When determining whether to pursue any existing or future rights or remedies under those agreements, including termination rights, we consider numerous factors, including legal, contractual, regulatory, business and other relevant considerations. In the event that we exercise our rights to terminate management agreements with TMS for any reason or such agreements are not renewed upon expiration of their terms, we would attempt to reposition the ~~financial stability~~affected integrated senior health campuses with another manager. Although we believe that many qualified national and regional operators would be interested in managing our integrated senior health campuses, we cannot provide any assurance that we would be able to locate another suitable manager or, if we were successful in locating such a manager, that it would manage the integrated senior health campuses effectively or that any such transition would be completed timely. Any such transition would likely result in disruption of the ~~tenants leasing~~operation of such facilities, including matters relating to staffing and reporting. Moreover, the ~~properties~~transition to a replacement manager may require approval by the applicable regulatory authorities and, in most cases, one or more of our lenders including the mortgage lenders for the integrated senior health campuses, and we ~~own. Therefore,~~cannot provide any assurance that such approvals would be granted on a ~~non-renewal after~~timely basis, if at all. Any inability to replace, or delay in replacing TMS as the ~~expiration~~manager of integrated senior health campuses could have a ~~lease term, termination, default or other failure~~material adverse effect on us.

Risks Related to meet rental obligations by significant tenants, such as RC Tier Properties, LLC, would significantly lower our net income. These events could cause us to reduce the amount of distributions to our stockholders.Investments in Real Estate

A high concentration of our properties in a particular geographic area would magnify the effects of downturns in that geographic area.

We have a concentration of properties in particular geographic areas; therefore, any adverse situation that disproportionately effects one of those areas would have a magnified adverse effect on our portfolio. As of ~~August 13,~~November 15, 2021, our properties locateded in ~~Missouri and Michigan~~Indiana accounted for approximately ~~12.1% and 10.4%, respectively,~~30.7% of our total property portfolio’s annualized base rent or annualized NOI. Accordingly, there is a geographic concentration of risk subject to fluctuations in ~~each~~such state’s economy.

Most of our costs, such as operating and general and administrative expenses, interest expense, and real estate acquisition and construction costs, are subject to inflation.

A significant portion of our operating expenses is sensitive to inflation. These include expenses for property-related costs such as insurance, utilities and repairs and maintenance. Property taxes are also impacted by inflationary changes as taxes are typically regularly reassessed in most states based on changes in the fair value of our properties. We also have ground lease expenses in certain of our properties. Ground lease costs are contractual, but in some cases, lease payments reset every few years based on changes on consumer price indexes.

Table of Contents

Operating expenses on our non-RIDEA properties, with the exception of ground lease rental expenses, are typically recoverable through our lease arrangements, which allow us to pass through substantially all expenses associated with property taxes, insurance, utilities, repairs and maintenance, and other operating expenses (including increases thereto) to our tenants. As of September 30, 2021, the majority of our existing leases were either triple net leases or leases that allow us to recover operating expenses, and also provided for the recapture of capital expenditures. Our remaining leases are generally gross leases, which provide for recoveries of operating expenses above the operating expenses from the initial year within each lease. During inflationary periods, we expect to recover increases in operating expenses from our triple net leases and our gross leases. As a result, we do not believe that inflation would result in a significant adverse effect on our net operating income, results of operations, and operating cash flows at the property level. For our RIDEA properties, increases in operating expenses, including labor, that are caused by inflationary pressures will generally be passed through to the us and may adversely impact our net operating income, results of operations and operating cash flows.

Effective upon the Merger and the AHI Acquisition on October 1, 2021, our general and administrative expenses consist primarily of compensation costs, as well as professional and legal fees. Annually, our employee compensation is adjusted to reflect merit increases; however, to maintain our ability to successfully compete for the best talent, rising inflation rates may require us to provide compensation increases beyond historical annual merit increases, which may significantly increase our compensation costs. Similarly, professional and legal fees are also subject to the impact of inflation and expected to increase proportionately with increasing market prices for such services. Consequently, inflation is expected to increase our general and administrative expenses over time and may adversely impact our results of operations and operating cash flows.

Also, during inflationary periods, interest rates have historically increased, which would have a direct effect on the interest expense of our borrowings. Our exposure to increases in interest rates is limited to our variable-rate borrowings, which consist of borrowings under the Credit Facilities and variable-rate mortgage loans payable. As of September 30, 2021, our outstanding debt and GAHR III outstanding debt aggregated $2.4 billion, of which 31.2% was unhedged variable-rate debt. Therefore, a significant increase in inflation rates would have a material adverse impact on our financing costs and interest expense.

We have long term lease agreements with our tenants that contain effective annual rent escalations that were either fixed or indexed based on a consumer price index or other index. We believe our annual lease expirations allow us to reset these leases to market rents upon renewal or re-leasing and that annual rent escalations within our long-term leases are generally sufficient to offset the effect of inflation on non-recoverable costs, such as general and administrative expenses and interest expense. However, it is possible that during higher inflationary periods the impact of inflation will not be adequately offset by the resetting of rents from our renewal and re-leasing activities or our annual rent escalations. As a result, during inflationary periods in which the inflation rate exceeds the annual rent escalation percentages within our lease contracts, we may not adequately mitigate the impact of inflation, which may adversely affect to our business, financial condition, results of operations, and cash flows.

Additionally, inflationary pricing may have a negative effect on the real estate acquisitions and construction costs necessary to complete our development and redevelopment projects, including, but not limited to, costs of construction materials, labor, and services from third-party contractors and suppliers. Higher acquisition and construction costs could adversely impact our net investments in real estate and expected yields in our development and redevelopment projects, which may make otherwise lucrative investment opportunities less profitable to us. As a result, our financial condition, results of operations, and cash flows, we well as our ability to pay dividends, could be adversely affected over time.

Risks Related to Debt Financing

Changes in banks’ inter-bank lending rate reporting practices or the method pursuant to which LIBOR is determined may adversely affect the value of the financial obligations to be held or issued by us that are linked to LIBOR.

LIBOR and other indices which are deemed “benchmarks” are the subject of recent national, international and other regulatory guidance and proposals for reform. Some of these reforms are already effective while others are still to be implemented. These reforms may cause such “benchmarks” to perform differently than in the past, or have other consequences which cannot be predicted. As published by the Federal Reserve Bank of New York, it currently appears that, over time, United States dollar LIBOR may be replaced by SOFR. In March 2021, the FCA confirmed its intention to cease publishing one-week and two-month LIBOR after December 31, 2021 and all remaining LIBOR after June 30, 2023. At this time, it is not known whether or when SOFR or other alternative reference rates will attain market traction as replacements for LIBOR. Market participants are still considering how various types of financial instruments and securitization vehicles should react to a discontinuation of LIBOR. It is possible that not all of our assets and liabilities will transition away from LIBOR at the same time, or to the same alternative reference rate, in each case increasing the difficulty of hedging. The process of transition involves operational risks. It is also possible that no transition will occur for many financial instruments. At this time, it is not possible to predict the effect of any such changes, any establishment of alternative reference rates or any other reforms to

Table of Contents

LIBOR that may be implemented. Uncertainty as to the nature of such potential changes, alternative reference rates or other reforms may adversely affect the market for or value of any securities on which the interest or dividend is determined by reference to LIBOR, loans, derivatives and other financial obligations or on our overall financial condition or results of operations. More generally, any of the above changes or any other consequential changes to LIBOR or any other “benchmark” as a result of international, national or other proposals for reform or other initiatives, or any further uncertainty in relation to the timing and manner of implementation of such changes, could have a material adverse effect on the value of financial assets and liabilities based on or linked to a “benchmark.”

~~Table of Contents~~

Risks Related to the Merger

~~Failure to complete the Merger could negatively impact our future business and financial results.~~

If the Merger is not completed, the ongoing business of our company could be materially adversely affected and we will be subject to a variety of risks associated with the failure to complete the Merger, including the following:

•our being required, under certain circumstances in which the Merger Agreement is terminated, to pay to GAHR III a termination fee of $23,028,000 and reimbursement of expenses incurred by GAHR III in connection with the Merger of up to $4,000,000;

•~~our having to bear certain costs incurred by us relating to the Merger, such as legal, accounting, financial advisor, filing, printing and mailing fees; and~~

•~~the diversion of our management’s focus and resources from operational matters and other strategic opportunities while working to implement the Merger.~~

~~If the Merger is not completed, these risks could materially affect our business and financial results.~~

The pendency of the Merger, including as a result of the restrictions on the operation of our and GAHR III’s business during the period between signing the Merger Agreement and the completion of the Merger, could adversely affect our business and operations, the business and operations of GAHR III, or both.

In connection with the pending Merger, some of our business partners or vendors and those of GAHR III may delay or defer decisions, which could negatively impact the revenues, earnings, cash flows and expenses of our company or GAHR III, regardless of whether the Merger is completed. In addition, due to operating covenants in the Merger Agreement, we and GAHR III may be unable, during the pendency of the Merger, to pursue certain strategic transactions, undertake certain significant capital projects, undertake certain significant financing transactions and otherwise pursue other actions that are not in the ordinary course of business, even if such actions would prove beneficial.

~~In certain circumstances, either we or GAHR III may terminate the Merger Agreement.~~

Either we or GAHR III may terminate the Merger Agreement if the REIT Merger has not been consummated by 11:59 p.m. New York time on March 23, 2022. Also, the Merger Agreement may be terminated in certain circumstances if a final and non-appealable order is entered prohibiting the transactions contemplated by the Merger Agreement, upon a material uncured breach by the other party that would cause the closing conditions not to be satisfied, or upon the failure to obtain receipt of approvals of the GAHR III stockholders or our stockholders. In addition, (i) at any time prior to the time GAHR III stockholders approve the Merger and the amendments to the GAHR III charter that are required to consummate the Merger, GAHR III has the right to terminate the Merger Agreement in order to accept a Superior Proposal (as defined in the Merger Agreement), and (ii) at any time prior to the time our stockholders approve the Merger and the amendments to our charter that are required to consummate the Merger, we have the right to terminate the Merger Agreement in order to accept a Superior Proposal. Finally, (i) at any time prior to the time our stockholders approve the Merger and the amendments to our charter that are required to consummate the Merger, GAHR III has the right to terminate the Merger Agreement upon a GAHR IV Adverse Recommendation Change (as defined in the Merger Agreement) or if we have materially violated any of our obligations regarding the solicitation of and response to Competing Proposals (as defined in the Merger Agreement), and (ii) at any time prior to the time GAHR III stockholders approve the Merger and the amendments to the GAHR III charter that are required to consummate the Merger, we have the right to terminate the Merger Agreement upon a GAHR III Adverse Recommendation Change (as defined in the Merger Agreement) or if GAHR III shall have materially violated any of its obligations regarding the solicitation of and response to Competing Proposals.

~~We and GAHR III each expect to incur substantial expenses related to the Merger.~~

We and GAHR III each expect to incur substantial expenses in connection with completing the Merger and integrating our properties and operations. While we and GAHR III each have assumed that a certain level of transaction expenses would be incurred, there are a number of factors beyond the control of each company that could affect the total amount or the timing of such expenses. Many of the expenses that will be incurred, by their nature, are difficult to estimate accurately at the present time. As a result, the transaction expenses associated with the Merger could, particularly in the near term, exceed the savings that we expect to achieve from the elimination of duplicative expenses and the realization of economies of scale and cost savings following the completion of the Merger.

~~Table of Contents~~

The ownership position of our stockholders and the stockholders of GAHR III ~~will be~~is diluted by the REIT Merger.

The REIT Merger ~~will dilute~~diluted the ownership percentage of our stockholders and ~~result~~resulted in GAHR III stockholders having an ownership stake in the Combined Company that is smaller than their ~~current~~prior stake in GAHR III. Based on the number of shares of our common stock and GAHR III common stock outstanding on ~~July 9,~~September 30, 2021, our stockholders, on the one hand, and former GAHR III stockholders, on the other hand, ~~will own~~owned approximately 31.3% and 68.7%, respectively, of the issued and outstanding shares of our common stock following the REIT ~~Merger.~~Merger on October 1, 2021. Consequently, each of our stockholders and each GAHR III stockholder, as a general matter, ~~will have~~has less influence over the management and policies of the Combined Company following the Merger than ~~currently~~previously exercisable over our management and policies and the management and policies of GAHR III, as applicable.

If and when the Combined Company completes a liquidity event, the market value ascribed to the shares of common stock of the Combined Company upon the liquidity event may be significantly lower than the current estimated per share NAV after the consummation of ~~GAHR III common stock or our common stock, as applicable, considered by~~ the ~~board of directors of GAHR III and our board in approving and recommending the REIT~~ Merger.

In approving and recommending the REIT Merger, the board of directors of GAHR III, the special committee of the board of directors of GAHR III, our board and our special committee considered, among other things, the most recent estimated per share NAV of GAHR III common stock and our common stock as determined by the board of directors of GAHR III and our board, respectively, with the assistance of their respective third-party valuation experts. The estimated per share NAV of our common stock ~~may~~was not be immediately determined following the consummation of the Merger. In the event that the Combined Company completes a liquidity event after consummation of the Merger, such as a listing of its shares on a national securities exchange, a merger in which stockholders of the Combined Company receive securities that are listed on a national securities exchange, or a sale of the Combined Company for cash, the market value of the shares of the Combined Company upon consummation of such liquidity event may be significantly lower than the current estimated ~~values considered by the board of directors of GAHR III, the special committee of the board of directors of GAHR III, our board and our special committee and the estimated~~ per share NAV of our common stock that may be reflected on the account statements of stockholders of the Combined Company after consummation of the Merger. For example, if the shares of the Combined Company are listed on a national securities exchange at some point after the consummation of the Merger, the trading price of the shares may be significantly lower than the most recent estimated per share NAV of our common stock of $9.22 as of September 30, 2020.

As a result of the AHI Acquisition, the Combined Company is newly self-managed.

As a result of the AHI Acquisition and the Merger, the Combined Company is a self-managed REIT. The Combined Company will no longer bear the costs of the various fees and expense reimbursements previously paid to the former external advisors of GAHR III and our company and their affiliates; however, the Combined Company’s expenses will include the compensation and benefits of the Combined Company’s officers, employees and consultants, as well as overhead previously paid by the former external advisors of GAHR III and our company and their affiliates. The Combined Company’s employees will provide services historically provided by the external advisors and their affiliates. The Combined Company will be subject to potential liabilities that are commonly faced by employers, such as workers’ disability and compensation claims, potential labor disputes, and other employee-related liabilities and grievances, and the Combined Company will bear the cost of the establishment and maintenance of any employee compensation plans. In addition, the Combined Company has not previously operated as a self-managed REIT and may encounter unforeseen costs, expenses and difficulties associated with providing these services on a self-advised basis. If the Combined Company incurs unexpected expenses as a result of its self-management, its results of operations could be lower than they otherwise would have been.

If the REIT Merger does not qualify as a tax-free reorganization, there may be adverse tax consequences.

The REIT Merger is intended to qualify as a tax-free reorganization within the meaning of Section 368(a) of the Code. The closing of the REIT Merger iswas conditioned on the receipt by us and GAHR III of an opinion of counsel to the effect that the REIT Merger will qualify as a tax-free reorganization within the meaning of Section 368(a) of the Code. However, these legal opinions will not be binding on the IRS or on the courts. If, for any reason, the REIT Merger were to fail to qualify as a tax-free reorganization, then each GAHR III stockholder generally would recognize gain or loss, as applicable, equal to the difference between (1) the merger consideration (i.e. the fair market value of the shares of our Class I common stock) received by such GAHR III stockholder in the REIT Merger; and (2) such GAHR III stockholder’s adjusted tax basis in its GAHR III common stock.

5458

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

~~Recent Sales of Unregistered Securities~~

~~None.~~

~~Purchase of Equity Securities by the Issuer and Affiliated Purchasers~~

Our share repurchase plan allows for repurchases of shares of our common stock by us when certain criteria are met. Share repurchases will be made at the sole discretion of our board. All share repurchases are subject to a one-year holding period, except for repurchases made in connection with a stockholder’s death or “qualifying disability,” as defined in our share repurchase plan. Funds for the repurchase of shares of our common stock will come exclusively from the cumulative proceeds we receive from the sale of shares of our common stock pursuant to our DRIP Offerings.

On March 31, 2020, our board suspended our share repurchase plan with respect to all repurchase requests other than repurchases resulting from the death or qualifying disability of stockholders, beginning with share repurchase requests submitted for repurchase during the second quarter of 2020. Shares of our common stock repurchased in connection with a stockholder’s death or qualifying disability were repurchased at a price no less than 100% of the price paid to acquire the shares of our common stock from us. In connection with our special committee’s strategic alternative review process and in order to facilitate a strategic transaction, on March 18, 2021, our board approved the suspension of our share repurchase plan with respect to all repurchase requests received by us after February 28, 2021, including repurchases resulting from the death or qualifying disability of stockholders.

~~During the three months ended June 30, 2021, we repurchased shares of our common stock as follows:~~

Period
Total Number of
Shares Purchased
Average Price
Paid per Share
Total Number of Shares
Purchased As Part of
Publicly Announced
Plan or Program Maximum Approximate
Dollar Value
of Shares that May
Yet Be Purchased
Under the
Plans or Programs
April 1, 2021 to April 30, 2021 117,228 $ 9.89 117,228 (1)
May 1, 2021 to May 31, 2021 — $ — — (1)
June 1, 2021 to June 30, 2021 — $ — — (1)
Total 117,228 $ 9.89 117,228

~~___________~~

~~(1)A description of the maximum number of shares that may be purchased under our share repurchase plan is included in the narrative preceding this table.~~None

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

5559

Table of Contents

Item 6. Exhibits.

The following exhibits are included, or incorporated by reference, in this Quarterly Report on Form 10-Q for the period ended ~~June~~September 30, 2021 (and are numbered in accordance with Item 601 of Regulation S-K).


2.1			Agreement and Plan of Merger, dated June 23, 2021, by and among Griffin-American Healthcare REIT IV, Inc., Griffin-American Healthcare REIT IV Holdings, LP, Continental Merger Sub, LLC, Griffin-American Healthcare REIT III, Inc. and Griffin-American Healthcare REIT III Holdings, LP (included as Exhibit 2.1 to our Current Report on Form 8-K (File No. 000-55775) filed June 24, 2021 and incorporated herein by reference).

3.1			~~Third~~Fourth Articles of Amendment and Restatement of Griffin-American Healthcare REIT IV, Inc., dated ~~December 28, 2015~~October 1, 2021 (included as Exhibit 3.1 to ~~Pre-effective Amendment No. 2 to~~ our ~~Registration Statement~~ Current Report on Form ~~S-11~~8-K (File No. ~~333-205960)~~000-55775) filed ~~January 5, 2016~~October 1, 2021 and incorporated herein by reference)

3.2			~~Articles Supplementary~~Bylaws of ~~Griffin-American~~American Healthcare REIT, ~~IV,~~ Inc. ~~filed May 25, 2016~~ (included as Exhibit 3.1 to our Current Report on Form 8-K ~~(File No. 333-205960)filed May 26, 2016 and incorporated herein by reference)~~

~~3.3~~			~~Second Amended and Restated Bylaws of Griffin-American Healthcare REIT IV, Inc. (included as Exhibit 3.2 to Pre-effective Amendment No. 2 to our Registration Statement on Form S-11~~ (File No. ~~333-205960)~~000-55775) filed ~~January~~October 5, ~~2016~~2021 and incorporated herein by reference)

4.1			Amended and Restated Distribution Reinvestment Plan of Griffin-American Healthcare REIT IV, Inc. (included as Exhibit 4.6 to our Registration Statement on Form S-3 (File No. 333-229301) filed January 18, 2019 and incorporated herein by reference)

10.1			~~Amendment to Advisory~~Form of Indemnification Agreement ~~dated June 23, 2021, by and among Griffin-American Healthcare REIT IV, Inc., Griffin-American Healthcare REIT IV Holdings, LP and Griffin-American Healthcare REIT IV Advisor, LLC~~ (included as Exhibit 10.1 to our Current Report on Form 8-K (File No. 000-55775) filed ~~June 24,~~October 1, 2021 and incorporated herein by reference)

10.2			Second Amended and Restated Agreement of Limited Partnership of American Healthcare REIT Holdings, L P , dated October 1, 2021 (included as Exhibit 10.1 to the Company’s Current Form on 8-K (File No. 000-55775) filed October 5, 2021 and incorporated by reference )

10.3			Amended and Restated Share Repurchase Plan (included as Exhibit 10.2 to our Current Report on Form 8-K (File No. 000-55775) filed October 5, 2021 and incorporated herein by reference)

10.4			Registration Rights Agreement, dated October 1, 2021, by and between Griffin-American Healthcare REIT III, Inc. and Griffin-American Healthcare REIT III Holdings, LP (i ncluded as Exhibit 10.1 to Griffin-American Healthcare REIT III, Inc’s Current Report on Form 8-K (File No. 000-55434) filed October 1, 2021 and incorporated herein by reference )

10.5*			Second Amendment to Credit Agreement by and among Griffin-American Healthcare REIT IV Holdings, L P , Griffin-American Healthcare REIT IV, Inc., Subsidiary Guarantors, Lenders and Bank of America, N.A., dated October 1, 2021

10.6			Credit Agreement dated as of January 25, 2019, among Griffin-American Healthcare REIT III Holdings, LP, Griffin-American Healthcare REIT III, Inc. and certain subsidiaries, certain lender parties, Bank of America, N.A., KeyBank, National Association, Citizens Bank, National Association, Merrill Lynch, Pierce, Fenner & Smith Incorporated and KeyBanc Capital Markets (included as Exhibit 10.1 to Griffin-American Healthcare REIT III, Inc’s Current Report on Form 8-K (File No. 000-55434) filed January 31, 2019 and incorporated herein by reference)

10.7			First Amendment to Credit Agreement by and among Griffin-American Healthcare REIT III Holdings, LP, Griffin-American Healthcare REIT III, Inc., Subsidiary Guarantors, Lenders and Bank of America, N.A., dated July 28, 2020 (included as Exhibit 10.1 to Griffin-American Healthcare REIT III, Inc.’s Current Report on Form 8-K (File No. 000-55434) filed August 3, 2020 and incorporated herein by reference)

10.8*			Second Amendment to Credit Agreement by and among Griffin-American Healthcare REIT III Holdings, LP, Griffin-American Healthcare REIT III, Inc., Subsidiary Guarantors, Lenders and Bank of America, N.A., dated October 1, 2021

10.9			First Amended and Restated Senior Secured Credit Agreement dated as of September 5, 2019, among Trilogy RER, LLC, and certain subsidiaries of Trilogy RER, LLC, Trilogy OpCo, LLC and Trilogy Pro Services, LLC, KeyBank National Association and the other lenders which are parties thereto from time to time, CIT Bank, N.A., Regions Bank, KeyBanc Capital Markets, Inc., Regions Capital Markets, Bank of America, N.A. and The Huntington National Bank (included as Exhibit 10.1 to Griffin-American Healthcare REIT III, Inc.’s Current Report on Form 8-K (File No. 000-55434) filed September 11, 2019 and incorporated herein by reference)

10.10			Unconditional Guaranty of Payment dated as of September 5, 2019, by Trilogy Investors, LLC, Trilogy Healthcare Holdings, Inc., Trilogy Pro Services, LLC and Trilogy OpCo, LLC for the benefit of KeyBank National Association and the other lenders which are parties thereto from time to time, CIT Bank, N.A., Regions Bank, KeyBanc Capital Markets, Inc., Regions Capital Markets, Bank of America, N.A. and The Huntington National Bank (included as Exhibit 10.2 to Griffin-American Healthcare REIT III, Inc.’s Current Report on Form 8-K (File No. 000-55434) filed September 11, 2019 and incorporated herein by reference)

10.11			Offer Letter, dated October 1, 2021, between Griffin-American Healthcare REIT III, Inc. and Jeffrey T. Hanson (included as Exhibit 10.2 to Griffin-American Healthcare REIT III, Inc.’s Current Report on Form 8-K (File No. 000-55434) filed October 1, 2021 and incorporated herein by reference )

Table of Contents


10.12			Offer Letter, dated October 1, 2021, between Griffin-American Healthcare REIT III, Inc. and Danny Prosky (included as Exhibit 10.3 to Griffin-American Healthcare REIT III, Inc.’s Current Report on Form 8-K (File No. 000-55434) filed October 1, 2021 and incorporated herein by reference )

10.13			Offer Letter, dated October 1, 2021, between Griffin-American Healthcare REIT III, Inc. and Mathieu B. Streiff (included as Exhibit 10.4 to Griffin-American Healthcare REIT III, Inc.’s Current Report on Form 8-K (File No. 000-55434) filed October 1, 2021 and incorporated herein by reference )

10.14			Offer Letter, dated October 1, 2021, between Griffin-American Healthcare REIT III, Inc. and Brian S. Peay (included as Exhibit 10.5 to Griffin-American Healthcare REIT III, Inc.’s Current Report on Form 8-K (File No. 000-55434) filed October 1, 2021 and incorporated herein by reference )

31.1*			Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*			Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1**			Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002

32.2**			Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*			Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL Document

101.SCH*			Inline XBRL Taxonomy Extension Schema Document

101.CAL*			Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*			Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*			Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*			Inline XBRL Taxonomy Extension Presentation Linkbase Document

104*			Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

___________


*			Filed herewith.
**			Furnished herewith. In accordance with Item 601(b)(32) of Regulation S-K, this Exhibit is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

5661

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

American Healthcare REIT, Inc. (f/k/a Griffin-American Healthcare REIT IV, Inc.)

(Registrant)

~~August 13,~~November 15, 2021

By:

/s/ JD~~EFFREY~~ANNY ~~T. H~~P~~ANSON~~ROSKY

Date

~~Jeffrey T. Hanson~~Danny Prosky

Chief Executive Officer and ~~Chairman of the Board of Directors~~President

(Principal Executive Officer)

~~August 13,~~November 15, 2021

By:

/s/ BRIAN S. PEAY

Date

Brian S. Peay

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

5762


	June 30, 2021		December 31, 2020
Balance Sheet Data:
Total assets	$	1,862,179,000	$	1,882,584,000
Total liabilities	$	1,325,497,000	$	1,329,832,000


Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased As Part of Publicly Announced Plan or Program	Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
April 1, 2021 to April 30, 2021	117,228	$	9.89	117,228	(1)
May 1, 2021 to May 31, 2021	—	$	—	—	(1)
June 1, 2021 to June 30, 2021	—	$	—	—	(1)
Total	117,228	$	9.89	117,228